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Objectives: To evaluate the influence of pharmacist interventions on drug and dosage 
prescribing in pediatric settings. 
 
 
Method: Demographic, clinical, and prescribing data and parents’ measurement data 
were evaluated by pre- and post studies including time series studies and control groups. 
The data was evaluated against Australian Therapeutic Guidelines. Educational 
intervention strategies were designed and administered and a post-intervention evaluation 
was conducted. Group comparisons were made using χ2 and Student’s t-test statistics. 
Time series analysis involved multiple linear regression analysis. 
 
 
Results: The major study involved antibiotics and analgesic drugs and dosages in 
appendectomy in children. Significant improvements occurred in the selection and 
dosages of prophylactic antibiotics (p<0.001) and in subsequent ward antibiotic 
treatments (p<0.001) also showed marked conformity with the guidelines. Other pediatric 
studies involved liquid medication dosing and prescribing accuracy for paracetamol in a 
developing country where a simple intervention produced very marked improvements 
(p<0.001). An intervention in severe community-acquired pneumonia showed an 
improvement in the prescription of appropriate drugs (p<0.001) and appropriate dosages 
of paracetamol (p<0.001) according to the guidelines. In drug utilisation evaluation of 
ceftriaxone, flucloxacillin and Liquigesic Co®, there was a significant improvement in 
the dosage prescribing of ceftriaxone and flucloxacillin and no change in Liquigesic Co® 
following the intervention. Of the total, 38/218 (17%) of the patients received appropriate 
post-operative antibiotic dosages, 286/368 (78%) of the analgesic prescriptions and 
31/218 (14%) of the patients on postoperative antibiotic choice and dosage that were 




Conclusion: This study has identified deficiencies related to the prescribing of antibiotics 
and analgesics in children. There was a varied level of improvement in the drug dosage 
prescribing of pediatricians following the pharmacist educational intervention. Locally 
developed guidelines are more likely to be accepted and followed than those developed 
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1.1 History of antibiotic resistance 
The astonishing effects of antibiotics, the occurrence of resistance, and the considerable 
resources spent on antibiotics globally are convincing reasons for concern about ensuring 
adequate and proper use of these powerful agents. Antibiotics are the largest of any 
therapeutic group of drugs, often accounting for 15%-30% of total drug expenditure. 
Antibiotics represent agents with the most potential impact on mortality, along with 
vaccines, oral rehydration solutions, and contraceptives[1]. 
 
 
Antibiotics are given to humans for treatment and prophylaxis of infectious diseases, 80-
90% of antimicrobial drugs are used in outpatients and the remainder in hospitals. 
Antibiotics appear to be used not only in excess but also inappropriately and this accounts 
for 20-50% of all antibiotic use [2, 3]. The Center for Disease Control and Prevention in 
the USA has estimated that some 50 million of the 150 million prescriptions for 
antibiotics written for outpatients every year are unnecessary[4].  
 
 
In the United States, expenditure for prescription drugs were $33 billion in 1987, 
approximately 75% of which were in the outpatient setting. Such substantial expenditure 
may be acceptable if medical outcomes or quality of life significantly improve. The 
consequence of antibiotic overuse and misuse include increased risk of adverse side 
effects, higher cost and higher rate of antimicrobial resistance of community pathogens. 
What distinguishes antimicrobial agents from other drugs is that each antimicrobial agent 
used may have a potential significant effect on the world microbial ecology. Antibiotics 
affect both pathogens and the normal flora. In theory any antibiotic can select resistant 
strains as long as the local concentration of the drug exceeds the minimal inhibitory 
concentration (MIC) for the susceptible bacterial population but is below the MIC for the 
resistant clone. To what extent disturbances occur depends on the spectrum of the agent, 
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dose, and route of administration, pharmacokinetic and pharmacodynamic properties, and 
in vivo inactivation of the agent[2].  
 
 
Incomplete absorption of orally administered drugs may influence the intestinal 
microflora, and secretion of an antimicrobial agent by the eccrine glands may interfere 
with the normal flora at different habitats. As a consequence, antibiotic-resistant 
microorganisms may increase in numbers, and they also might serve as reservoirs for 
resistance genes. Since resistance is genetically linked, one antibiotic may select for 
resistance to one or more structurally unrelated antibiotics. Some antimicrobial agents are 
more selective for resistance than others. Besides selective antibiotic pressure, 
transferable resistance is the major determinant of resistance development[2]. 
 
 
Antibiotic usage and resistance rates vary from one country to another[5-7]. Countries 
with the highest per capita antibiotic consumption have the highest resistance rates. 
Countries with high total outpatient antibiotics sales have a higher prevalence of 
Haemophilus influenzae  β-lactamase positive strains, than those with low total usage. It 
is not only the amount of antibiotics used that selects for resistance, but also the number 
of individuals receiving the drug, and the population density[2]. Giving 1000 doses of an 
antibiotic to one individual will have considerably less ecological effect on resistance 
emergence than giving those same 1000 doses to 1000 individuals[8]. A study by Levy 
[9] suggests that a combination of antibiotic use and population density correlates more 




Since the discovery of the sulphonamides and penicillin in the 1920s and 1930s, 
physicians around the globe have had a growing armamentarium of antimicrobial agents 
with which to fight infectious diseases that threaten the health of the human race. 
Although antibiotics have saved millions of lives, their extensive and often indiscriminate 
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use has created its own set of problems. Ever-increasing antibiotic resistance among 
bacteria presents a continuing challenge for physicians[10]. 
 
 
Antibiotic resistance first became challenging shortly after penicillin gained extensive use 
in the 1940s[11]. Even though β-lactamase was described as early as 1940, its 
significance emerged only after penicillin was introduced as a treatment for severe 
staphylococcal infections[12]. Within a decade, most hospital acquired Staphylococcus 
aureus isolates produced β-lactamase and were resistant to penicillin[13]. Nowadays, 
more than 95% of Staphylococcus aureus isolates globally are resistant to penicillin, 
ampicillin, and the anti-Pseudomonas penicillins[14]. An initial response to this 
resistance, was the development of methicillin, a semisynthetic penicillin. By the late 
1980’s, methicillin-resistant Staphylococcus aureus had become prevalent in many 
hospitals and are difficult to treat[10, 15]. 
 
 
Antibiotic resistance amongst hospital-acquired gram-negative bacteria has been a long-
standing and well-recognised problem; resistance has been seen in multiple genera, 
including Escherichia, Enterobacter, Klebsiella, Proteus, Salmonella, and Serratia[15]. 
The majority of these strains are resistant to all β-lactam antibiotics except cephamycins 
and carbapenems[10, 16]. 
 
 
During the 90’s, vancomycin-resistant enterococci have emerged as a problematic cause 
of nosocomial infection. Until recently, vancomycin was a dependable drug for the 
treatment of infections caused by multidrug-resistant enterococci, but in the mid-80s, 
vancomycin resistance began to emerge. The National Nosocomial Infection Survey of 
the Centre for Disease Control and Prevention reported in 1996, that between nosocomial 
isolates of enterococci, vancomycin resistance had increased more than 20-fold from 
1989 to 1995[17]. Of even greater concern is the chance that enterococci can serve as a 
pool for the transfer of resistance genes to other organisms[10, 18]. 
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Community-acquired pathogens were slower to build up significant levels of resistance. 
In the early 1960s, transferable resistance was first described in Shigella species[19]. This 
resistance restricts the number of dependable antimicrobial agents accessible for the 
treatment of individual patients and poses a considerable community health problem[15]. 
An endemic of enteritis caused by Shigella dysenteriae that was resistant to all oral 
antimicrobial agents available in that country occurred, in Burundi in 1990[10, 20]. 
 
 
Neisseria gonorrhoeae is an additional community-acquired pathogen that has undergone 
significant changes in antibiotic resistance. For a number of years, penicillin was the drug 
of choice to treat gonorrheae, but in 1976, the plasmid-mediated β-lactamase of 
Escherichia coli was found in Neisseria gonorrhoeae isolates in Africa and Asia[21]. 
Currently, in excess of 90% of Neisseria gonorrhoeae isolates in the Philippines and 
Thailand produce β-lactamase[10, 22]. 
 
 
Streptococcus pneumoniae is very important in pediatrics. The development of antibiotic 
resistance was first reported in animal models in 1940s [23] and subjectively reported 
among patients in the 1970s[24], penicillin resistant pneumococci are rapidly rising in 
prevalence in the United States and are a most important problem globally[10]. 
 
 
1.2 Resistance development due to excessive antimicrobial use 
A study by Baquero et al. was one of the first to report a correlation between antibiotic 
use and bacterial resistance in the community[25]. They found that both individual 
antibiotic use and total antimicrobial consumption in the community were strongly 





Resistance to pneumococcal antibiotics is increasing worldwide. The nasopharyngeal 
bacterial population is an important reservoir of infection, carriage and spread of 
pathogenic bacteria including antibiotic-resistant clones. Several randomised prospective 
studies have shown an association between the use of β-lactam antibiotics and the 
carriage of penicillin-resistant organisms[2, 26, 27]. 
 
 
A critical threshold of approximately 200-prescriptions/1000 inhabitants/year has been 
suggested to trigger the dispersion of erythromycin resistance[28]. In Slovenia the 
number of prescriptions/1000 inhabitants/year is <150, and resistance of Streptococcus 
pneumoniae is below 10%. The twofold increase in macrolide consumption noted in a 6-
year period was associated with a nearly linear increase in macrolide resistance, first in 
Streptococcus pyogens then in upper respiratory Streptococcus pneumoniae isolates and 
lastly in invasive strains in Streptococcus pneumoniae[2, 29]. 
 
 
Baquero examined the development of macrolide resistance in Streptococcus pneumoniae 
during the late 1980s and early 1990s, and found that the increasing resistance was due to 
wider use of the newer long-acting macrolides[2, 30]. 
 
 
Antimicrobial resistance rates are higher in paediatric populations in day-care centres and 
among isolates from the middle ear, nasopharynx or respiratory tract[31-33]. The higher 
resistance rate is possibly associated with a higher frequency of antibiotic treatment in 
children than in adults, and extensive child-to-child transmission in some settings, such as 
day-care centres and nursery schools[2]. 
 
 
Using antibiotics with poor activity or administering them at an inappropriate dosing 
level, dosing frequency, or for a prolonged duration increases the opportunity for 
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selection of resistant strains[2]. Guillemot et al.[34] found that children treated with low 
daily doses of an oral β-lactam had an increased risk of penicillin resistant streptococcus 
pneumoniae carriage compared with children who had recommended doses[2].  
 
 
A study by Nasrin et al.[27] showed higher penicillin resistance of Streptococcus 
pneumoniae in children who had taken β-lactam antibiotic for more than 14 days 
compared with a group taking no antibiotics or taking them for less than 7 days in the 6 
months before nasal swabbing. Cohen et al.[35] demonstrated an increase in the MIC of 
Streptococcus pyogenes in 8 of 79 children with streptococcal tonsillopharyngitis treated 
with a low dose of azithromycin, with a bacteriological failure on day 14. The strains of 
Streptococcus pyogenes, which were susceptible to azithromycin before the treatment, 
might have gained resistance due to low antibiotic doses[2]. 
 
 
During a 7-year period, in a French hospital, the change of both the more prevalent 
bacterial species and their susceptibility patterns to antibiotics was due to an increase in 
the consumption of third-generation cephalosporins and aminoglycosides[36]. The 
increased use of these agents in the hospital was notable by a marked increase in 
seriously ill patients without an increase in admissions. There was a significant 
correlation between increase in antibiotic use and decrease in susceptibility. The most 
remarkable event was the significant relationship between third generation cephalosporin 
use and the increasing numbers of Acinetobacter calcoaceticus, Pseudomonas aeruginosa 
and Serratia marcescens isolates[37]. 
 
 
In the Netherlands the correlation between antibiotic consumption and antibiotic 
resistance rates was studied in 976 human isolates of coagulase negative 
Staphylococci[38]. A significant correlation was found between percentage of methicillin 
resistance and the prescription of flucloxacillin for prophylactic, and cephalosporins for 




A study in a Danish University hospital on the susceptibilities to antimicrobial agents of 
coagulase negative Staphylococci isolates from blood cultures, cerebrospinal fluids and 
peritoneal effluents found a great diversity in antibiotic resistance between the wards[39]. 
When comparing the consumption of antibiotics with antibiotic susceptibilities among 
coagulase negative Staphylococci, a significant association of multiple antibiotic 
resistance was seen with broad spectrum β-lactams such as third generation 
cephalosporins and carbapenems, quinolones such as ciprofloxacin and total antibiotic 
consumption on a ward[37]. 
 
 
Johansen et al [40] studied the correlation between aminoglycoside consumption patterns 
and the occurrence of aminoglycoside-resistant bacteria from 12 countries and found that 
there was a wide variation in the national aminoglycoside consumption patterns. They 
found a striking correlation of gentamicin resistance and national gentamicin 
consumption. In addition, there was a clear association between bacterial resistance 
inside and outside the hospital and the total amount of aminoglycoside, particularly 
gentamicin, consumption in hospitals. In a study by Courcol et al. [36]there was a 
significant correlation found between the increase in aminoglycoside use and decrease in 
susceptibility of A.calcoaceticus for gentamicin, tobramycin and amikacin[37]. 
 
 
The development of new classes of antibiotic agents has slowed significantly. During the 
past four decades, following the introduction of penicillin, over 20 structural classes of 
antimicrobial agents were discovered through natural product screens[12]. On the 
contrary, since the early 80s, few vital new agents have been marketed based upon using 
this method. Accordingly, the cost of developing and bringing new antibiotics to market 
is enormous[41]. It has led to concerns that antibiotics may not be available to treat 
multiresistant organisms as they emerge, due to cost and difficulty in producing new 
classes of antibiotic agents. The appearance of resistance in Streptococcus pneumoniae, 
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an organism accountable for general pediatric infections such as sinusitis, otitis media, 
and pneumonia and the leading cause of bacterial meningitis in children, has noticeably 
heightened alertness about antibiotic resistance. We have already begun to see the 
appearance of organisms, such as enterococci and Staphylococcus aureus that are 
resistant to, or have the possibility to be resistant to, all existing antibiotics[10]. 
 
 
The extent of bacteria resistant to general antimicrobial agents, predominantly multidrug-
resistant pneumococci, has lead to a new interest in antimicrobial prescribing patterns and 
the endorsement of cautious antimicrobial use. The five major indications for outpatient 
antimicrobial prescribing are all upper respiratory infections, and children are given an 
inconsistent number of these prescriptions[42]. Many of the prescriptions are needless, 
being given for viral infections such as the common cold[43]. Reducing improper 




1.3 Reversing the rise of resistance by reducing the antimicrobial use 
In 1970s, the first intervention to decrease bacterial resistance in the community occurred 
in Japan where decreased erythromycin consumption led to a decreased level of 
erythromycin-resistant Streptococcus pyogenes. In Japan, macrolides accounted for 22% 
of the antibiotics used and 62% of Streptococcus pyogenes isolates were resistant to 
erythromycin in 1974. By 1988, macrolides accounted for only 8% of antibiotic use and 
the Streptococcus pyogenes isolates resistant to erythromycin fell to 2%[46].  
 
 
In Finland, a recommendation was made to decrease the use of macrolides in infections 
caused by Group A Streptococci due to an increase of the macrolide resistance in 
Streptococcus pyogenes[46]. This recommendation reduced to half the usage of 
macrolides from 2.44 DDD/1000 inhabitants/day to 1.38 in 1992 and 1.44 DDD/1000 
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inhabitants/day in 1996 respectively. The resistance of Streptococcus pyogenes to 
macrolides decreased from 19% to 9%[37]. Similarly in Iceland during the period 1993-
1997, the prevalence of penicillin-nonsusceptible pneumococcal carriage in children 
attending day-care centres reduced from 20 to 13%[47, 48]. 
 
 
In South Africa, invasive Gram-negative isolates from blood and cerebrospinal fluid were 
monitored for 1 year before and after the first-line aminoglycoside in a paediatric 
department was changed from gentamicin to amikacin[49, 50]. In the neonatal unit, an 
outbreak of amikacin resistant, gentamicin susceptible Serratia spp. occurred and abated 
spontaneously. In the year after the change in aminoglycoside usage, the resistance to 
amikacin of noscomial Gram-negative infections increased from 7.6 to 27.7% (p<0.001) 
and the resistance to gentamicin decreased from 71.2 to 60.2% (p=0.07). The observed 




1.4 Australian antibiotic resistance patterns 
In 1967, the first clinically important isolate of a penicillin-resistant pneumococcus was 
reported from Australia[50]. Though, penicillin resistance was not the most important 
medical problem in this country, it caused major problems elsewhere, mostly in Papua 
New Guinea and South Africa. In the late 70s and the 80s, rates of resistance increased in 
Western countries, mainly in Spain. A study from United States found 25% of persistent 
Streptococcus pneumoniae isolates were penicillin-resistant. Resistance rates are 
generally higher in children, and the circulation of resistance varies within countries and 
inhabitant groups[51-55]. In 1989, a nation-wide study in Australia of over 1800 isolates 
of Streptococcus pneumoniae, found that only 1% were penicillin resistant[56], a lower 
rate than in most other Western countries. Though, in aboriginal communities had 




Staphylococcus aureus is one of the most frequent causes of nosocomial infection in 
Australia and also globally. It is accountable for postoperative wound infection, 
intravascular line-associated sepsis, infection of prosthetic devices and a variety of other 
general problems. Multiple resistant Staphylococcus aureus (MRSA) has been well-
known among the strains of Staphylococcus aureus coupled with hospital acquired 
infection in Australia, mainly on the eastern seaboard, occurring mainly in teaching 
hospitals and institutions providing composite tertiary-level care. Efforts to avoid cross-
infection with MRSA in Australian hospitals have been mostly unsatisfactory, apart from 
reports of intermittent accomplishment in single units where rigorous intervention and 
supervision had been instituted. As a result, antibiotic treatment is the basis of 
management, and vigilance of changes in resistance patterns is a necessary element of 
recommendations for therapy[58]. 
 
 
1.5 Factors contributing to overuse of antibiotics 
Achieving more thoughtful prescribing of antibiotics requires (a) perception of the factors 
that encourage overuse and the barriers to modify and (b) the execution of efficient 
strategies for altering conduct[59]. 
 
 
Results of a decisive study in the United States identified four major factors encourage 
the overuse of antibiotics: lack of appropriate education, prior experience, patients’ 
expectations, and economics. Lack of education applies to both prescribers and patients. 
Surveys of primary care physicians show that several have imprecise knowledge about 
the necessity for antibiotics in patients, and many family physicians do not follow 




Lack of knowledge amongst patients and past experience contribute to increased demand 
for antibiotics[59]. Whether genuine or professed, patients’ expectations for antibiotics 
have an effect on physicians’ prescribing behaviour[61]. Years of prescribing or 
receiving antibiotics for viral respiratory infections have formed a sequence of supply and 
demand, reinforcing behaviours that are harmful in an era of rising antibiotic resistance. 
Breaking this cycle requires educating the public that past practices are no longer 
appropriate and persuade doctors that a patient’s fulfilment is based more on 
communication than on prescription[59, 62]. 
 
 
Diagnostic ambiguity can also contribute to inappropriate antibiotic use. Intermittent 
diagnostic uncertainty is unavoidable. There is the possibility that a clinician will 
prescribe an antibiotic “just in case” an infection is bacterial. Suitable clinical assessment 
combined with good communication and mutual decision making, may reduce the risk of 
patients’ discontent, or other undesirable outcome[59, 63]. 
 
 
Improper use of antibiotics has resulted in enormous wastage of hospital resources, and to 
overcome this problem a variety of strategies have been adopted. Whether concentrating 
at antibiotics or other drugs, provisional regulations such as prescribing from a formulary 
and/or automatic stop policies have often worked[64-66], but may not be suitable in all 
hospitals as doctors generally perceive obligatory controls as impinging on clinical 
independence. Educational strategies including the use of guidelines, handbooks, and 
seminars have also been widely reported[67-70]. On the other hand, the efficacy of such 
accomplishments have not been publicized constantly and when documented, their 
impact on prescribing behaviour is often minimal and momentary[68, 70-72]. Methods 
that are efficient frequently integrate other facilitative manoeuvres like feedback 





Education is generally resorted to as a means of changing prescribing practices, but when 
used single-handedly is not fully successful[72, 76-78]. Intervention programmes that are 
successful habitually integrate added enabling/reinforcing elements[70, 72]. The use of 
feedback as a means of enhancing prescribing behaviour has previously been reported but 
its effectiveness has not been constantly acknowledged[78-80].  
 
 
1.6 Drug Utilisation Evaluation in Children 
Several studies have evaluated antibiotic usage evaluation in children[81-84] and in 
appendicitis in children[85-87]. None of the studies have considered antibiotic dosage 
prescribing and the impact of pharmacist educational intervention in appendicitis in 
children in Australia or elsewhere. Both of these are important in respect to the quality 
use of medicines. 
 
 
In a study by Lesar et al[88] the most common types of medication prescribing errors 
detected among the 696 dosing errors, were overdoses 291 (41.8%) and underdoses 115 
(16.5%); prescribing medications to which the patient was allergic 90 (12.9%); and errors 
involving the prescribing of inappropriate dosage forms 81 (11.6%). The most common 
medications involved were antimicrobials 276 (17.5%), gastrointestinal agents 122 
(7.3%), and non-narcotic analgesics and antipyretics 46 (6.6%). Many of these were 
clinically significant 557 (80%), fatal 43 (6.2%) and 96 (13.8%) were rated as serious. 
Hence an evaluation of dosages should be included in all pediatric interventions.  
 
 
Other factors usually associated with errors included presence of a history of allergy to 
prescribed medication class 84 (12.1%), incorrect dosage calculations 77 (11.1%), 
atypical and critical dosage frequency 75 (10.8%), need to specify special dose forms for 
brand names, 43 (6.2%) and generic names 36 (5.2%), and the presence of duplicative 




The use of dosage calculations 17 of 96 (17.7%) serious errors and decimal point 
placement, allergy history, and unusual or atypical dose frequency 11 of 96 total serious 
errors were the most common related factors for errors rated as potentially serious[88]. 
 
 
Other workers includes Potts & Phelan[89], Koren & Haslam[90] and Baldwin[91] have 
demonstrated significant deficiency in the ability of prescribers to correctly calculate 
drug dosages. Steps to reduce the likelihood of such errors reaching the patient include 
requiring a double check of all calculations by another individual, increasing the use of 
standardised drug preparations and dosing, and using dosing tables. The integration of 
pharmacists on medical teams and patient care units provides an effective method of 
promoting appropriate medication use[92]. 
 
 
Folli et al[93] identified physician ordering errors, using a pharmacy-based review in two 
pediatric hospitals. They found that pediatric patients younger than two years and 
pediatric intensive care unit patients were particularly susceptible to errors, most of them 
were dosing errors[92].  
 
 
Of 10788 medication orders written for 1020 patients, 616 (5.7%) orders involved an 
error at anyone of drug ordering, transcribing, dispensing, administering, or monitoring. 
There were 5 (0.8%) preventable adverse drug events, 115 (18.6%) potential adverse 
drug events, and 486 (80.5%) errors with relatively little potential for harm. A total of 
320 (31%) patients experienced a medication error; 118 (12%) patients experienced two 
or more errors. The majority of errors occurred at the ordering stage (77.8%), followed 
by administering (12.8%) and transcribing (5.8%). The most frequent type of medication 




In a prospective multicentre study on medication errors in two pediatric teaching 
hospitals, it was found that errors occurred at a rate of 5.7 errors per 100 orders, with 
most of these errors occurring at the ordering stage (79%). Many of them involved 
incorrect dosing (34%)[94]. Importantly, although this overall error rate was similar to 
that found in a previous study by Bates et al[95] on adult inpatients using similar 
methods, errors with the potential to cause harm were three times more likely to occur in 
pediatric inpatients compared with adults.  
 
 
Medication errors and adverse drug events are serious problems in pediatrics. The 
relatively higher rates of potentially harmful errors in hospitalised children compared 
with adults probably occurs primarily because dosing is more complex in pediatrics and 
underscore the need for safer systems in this setting. However, until recently, the 
incidence of pediatric medication errors has received relatively little scrutiny compared 
with adults, and even less has been done to assess their preventability[92]. 
 
 
1.7 Drug Audit 
It has been recognized long ago that there is a need for drug audit to assess and improve 
the quality of medical care[96, 97]. According to the World Health Organization (WHO) 
drugs are not frequently used to their full potential, nor according to usually accepted 
criteria[98]. Differences in drug consumption patterns between similar populations in 
developed countries and the mortality and/or morbidity following inappropriate use of 
drug/s, adverse reactions, and antimicrobial resistance have often been attributed to 
physicians. Physicians regulate drug consumption, so their prescribing habits are 




Pharmacists today frequently provide an important service of drug usage 
review/evaluation (DUR/DUE). The outcomes of these assessments often lead to 
improvements in cost-effective prescribing and, better utilisation of limited resources. 
This service is in high demand as organisations are searching for methods of reducing 
their costs. A typical drug evaluation process generally entails an in-depth analysis of an 
agreed specific therapeutic group. The method of analysis generally involves a 
pharmacist screening the literature and clinical data, developing and gaining agreement 
on practice guidelines in conjunction with other related departments, and evaluates the 
collected data against it. The results of the review will be presented to the prescribers and 
methods to modify prescribing behaviour sought and then evaluated[100]. 
 
 
1.8 Strategies to modify prescribing behaviour 
Strategies to alter prescribing behaviour have been developed around the world two 
decades ago. These methods include[101-103]: 
• persuasive and educational programs including peer review meetings, drug 
bulletins, lectures[104], guidelines[105, 106], and feedback of prescribing trends 
based on drug audits; 
• professional advice of specialists such as microbiologists, pharmacologists and 
pharmacists; 
• restrictive methods such as required approval by a clinical specialist prior to use, 
formularies[107], and automatic ‘stop’ orders. 
 
 
Four studies conducted in the early 80’s have suggested that educational measures can 
increase the optimal prescribing of drugs. Soumerai and Avorn (1983)[108] reported that 
optimal prescribing of target drugs was increased when physicians were “detailed’ by 
clinical pharmacists. Ray et al (1985)[109] and Schaffner et al (1983)[110] found that 
clinical pharmacists who visited physicians to give drug information had a modest effect 
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on increasing the optimal prescribing of target drugs after a single visit, however multiple 
intervention strategies are more effective than a single strategy[111]. 
 
 
1.9 Hospital Quality Assurance Activities  
Drug utilisation review (DUR) is a quality assurance (QA) approach for the facility per 
se, and it involves the setting of criteria and standards, an assessment phase using a set of 
screening criteria and a follow-up correctional phase with the prescriber. It comprises of 
all aspects of drug treatment from the time a patient presents to a prescriber, to the final 
outcome of the therapy[112]. 
 
 
The goals of drug usage review were explained by Knapp et al (1975)[113] as the 
encouragement of optimal drug use and the provision of high quality drug therapy as 
cost-effectively as possible[114]. 
 
 
1.10 Objectives of quality assurance activities 
The objectives of this activity are to achieve quality drug use and patient care by ensuring 
appropriate, safe and cost-effective drug therapy. The outcomes of drug use are improved 
by[115]: 
 
o determining drug usage and prescribing patterns; 
o developing criteria and standards which explain optimal drug use; 
o promoting rational therapy through education and by the provision of drug 
information and advice; 
o carrying out regular drug use audits to evaluate the appropriateness of drug use, 
and characterize inappropriateness; 
o minimizing the risk of adverse drug events caused by inappropriate drug use 
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o promoting economical drug use by reducing drug wastage, and unnecessary drug 
and drug related expenditure; 




1.11 Selecting drugs and drug-use processes for evaluation 
Drug or drug-use processes should be selected for evaluation for one or more of the 
following reasons[116]: 
♠ The drug is known or suspected to interact with another drug, food, or to cause 
adverse reactions in a way that presents a significant health risk. 
♠ The drug is used in the treatment of patients who are at high risk for adverse 
reactions. 
♠ The drug-use process affects a large number of patients or the drug, which is 
frequently prescribed. 
♠ The drug or drug-use process is a critical component of care for a specific disease, 
condition, or procedure. 
♠ The drug is potentially toxic or causes adverse reactions at usual doses. 
♠ The drug is very effective when used in a specific way. 
♠ The drug is under consideration for formulary retention, addition, or deletion. 
♠ The drug or drug-use process is one for which suboptimal use would have a 
negative effect on patient outcomes or system costs. 
♠ The medication is expensive 
 
 
Data sources commonly available within the hospitals are patient demographics, clinical 
and administrative data. The demographic data available such as age, sex, disease, 
average length of stay etc; clinical data such as patient charts, admission records, adverse 
drug reaction reports, microbiology/infection control data etc and finally administrative 
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data such as drug purchasing, drug utilisation, equipment purchasing, utilisation and cost 
per adjusted hospital bed day data etc[116].  
 
 
Table 1. 1 Benefits of DUE programs 
Benefits of DUE programs[117] 
Area of practice Perceived benefits 
Hospital and government administrators Cost savings 
 Potential to justify expenditure/identify 
efficiencies 
 Embraces the concept of Total Quality 
Management 
 In some countries, hospitals require a 
formal DUE program in place to achieve 
accreditation 
Hospital pharmacists Extends opportunities for pharmaceutical 
care 
 Provides a leadership role within a 
multidisciplinary team 
 Contributes to cost justification of clinical 
pharmacy services 
Other health professionals Increase potential to prevent adverse drug 
reactions or iatrogenic disease 
 Recognizes the ‘added value’ applied by 
pharmacists to the drug use process 
 Education 




1.12 Intervention strategies 
Two decades ago studies were undertaken to assess strategies that could improve the 
therapeutic use of drugs in society. Much of this work has been aimed towards assessing 
educational and directive strategies. In early 1980’s, the psychological aspects of 
modifying behaviour were explored[99]. Strategies to influence prescribing and improve 
drug use may take a number of forms[99, 115, 118, 119]: 
♣ (Re-) educative strategies are those where a relatively unbiased presentation of 
fact is intended to provide an impetus for change. 
♣ Persuasive strategies which attempt to bring a change partially through reasoning, 
urging and inducement. 
♣ Facilitative strategies recruit the services of others to assist in changing the 
behaviour of an individual or group. 
♣ Power strategies involve the use of coercion of one type or an other to obtain 
compliance with a desired action. 
♣ Combined strategies, which use two or more of the above simultaneously. 
 
 
1.12.1 Re-educative strategies 
A re-educative strategy “is one whereby the relatively unbiased presentation of fact is 
intended to provide a rational justification for action. It assumes that humans are rational 
beings capable of discerning fact and adjusting their behaviour accordingly when facts 
are presented to them. The prefix ‘re’ in re-educative is used because this strategy may 
involve the unlearning or unfreezing of something prior to the learning of the new 
attitude or behaviour”[118]. 
 
 
The following should be considered when employing re-educative strategies[99]: 
♥ Re-educative strategies often take time to work and may require additional 
resources to sustain the desired effect, so time should not be a pressing factor 
♥ They are useful in creating an initial awareness of a problem 
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♥ Active opposition, factual ambiguity and an inability to assess the information 
presented reduce the effectiveness of re-education. 
♥ They can be effective in linking causes with symptoms and offering solutions 
♥ When used alone, re-education is not capable of affecting large-scale change in 
the short term particularly if motivation to change is low. 
♥ They can be used after change is affected to reduce dissonance, which, if 
unchecked, could gradually reverse the change. 
♥ If the degree of resistance is high, re-educative programs should begin well in 
advance of the change. 




Re-educative strategies can be used to influence prescribing by increasing awareness. 
Drug bulletins, newsletters and journals also use re-educative techniques[99].  
 
 
1.12.2 Persuasive strategies 
Persuasive strategies are strategies, which attempt to bring about change partially through 
bias in the manner in which a message is structured and presented. They attempt to create 
a change by reasoning, urging, and inducement. Persuasive strategies can be based on 
rational appeal and can reflect fact accurately[120]. Most advertising and interpersonal 
communication is persuasive in nature[99]. 
 
 
The following should be considered when employing persuasive strategies[99]: 
♠ The greater the need of a persuasive strategy, occurs when the degree of 
commitment to change in lower 
♠ Persuasive strategies are implemented when a problem is not recognised, or when 
a recommendation is not perceived as potentially effective. 
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♠ Since it requires time to implement, if change is desired quickly, power strategies 
may be more appropriate. 
♠ Persuasive strategies are potentially very effective in countering resistance to 
change as they allow for the use of two-way discussion with feedback. However, 
the presentation of many recommendations may be counterproductive and, 




Persuasive strategies applied to prescribing practice must often use data based on 
authoritative sources. The use of promotional material quoting articles from respected 
journals, or written by authoritative workers is well known and the promotion of drugs by 
pharmaceutical companies relies heavily on this approach[99].  
 
 
1.12.3 Facilitative strategies 
Facilitative strategies involve the use of another person to assist an individual change his 
or her behaviour. The use of facilitative strategies ‘assume that the target group: (a) 
recognizes a problem; (b) is in general agreement that remedial action is necessary; (c) is 
open to external assistance and willing to engage in self-help’[118]. 
 
 
The following should be considered when employing facilitative strategies[99]: 
♦ The target group must be aware of the change agent’s existence. 
♦ Change is more likely to occur if the change agent is located within the 
organization. 
♦ Developing a trust relationship between the change agent and target group 
influences the willingness to accept change 
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♦ The level of resistance to change must be very minimal, since the greater the 
resistance the less effective facilitative strategies will be. Facilitative strategies assume 
that target groups recognise a problem and are open to external assistance. 
♦ Time requirements can be considerable, so that if time and willingness to change 
are limited, facilitative strategies are not appropriate. 
♦ Follow-up assistance must be provided by the change agent according to the 
ability of the target groups 
♦ Different subgroups may require different facilitative strategies. Therefore, the 
approach should be modified to meet specific needs 
♦ Little success will be seen when the change attempts to alter firmly held attitudes 
or entrenched behaviour 
♦ The greater the magnitude and complexity of change, the most important it is to 
use facilitative strategies. 
 
 
Facilitative strategies have considerable potential for influencing prescribing. Personal 
contact between individuals allows for two-way discussion and feedback, and can 
engender commitment to change. Facilitative strategies also offer an adaptive alternative, 
which is readily responsive to changing needs[99].  
 
 
1.12.4 Power strategies 
Power strategies “involve the use of coercion to obtain the targets compliance”[118]. The 
exertion of power is based on the dependency of the target group on the change agent for 
the achievement of goals. The ability to use power strategies is high when goals 
controlled by the change agent are important motivational objectives of the target group. 





The following should be considered when employing power strategies[99]: 
♠ Power strategies generally result in compliance, but require continuous 
surveillance because of a lower degree of commitment.  
♠ The greater need of a power strategy is when the target group feels a lower 
perception of need for change. 
♠ Power strategies are very important where the target group is unwilling to 
implement change, or where immediate action is necessary. 
♠ Power strategies will be ineffective if the skills are absent or assistance by the 
change agent is not given and the target group doesn’t have the resources and 
skills to implement the desired change. 
♠ Power strategies can be used to overcome high levels of resistance. They are most 
commonly used after a decision has been made and requires implementation, 
while education and persuasion are more often used as a means of influencing 
future decisions. 
♠ The greater the power required by the change agent, the greater the magnitude of 
change. Therefore, if a major change is contemplated, it may be preferable to 
undertake it in different stages. 
♠ Change may force a target group to compromise for a moderate change by 
threatening drastic change. In fact, the moderate change may have been the 
original goal that was desired. 
 
 
Influencing prescribing through power strategies is practised at both national and local 
levels. Government regulatory control has a major impact on national drug usage 
patterns. This can be exercised through restrictions on the release and use of drugs and 
controls on prescribing applied to subsidized pharmaceutical benefits schemes. At a local 
level drug formularies and prescribing restrictions have been enforced within some 
hospitals. Prescribing can be restricted to certain groups of prescribers, individual drugs 
can be restricted by deleting them as stock lines, or use of a drug may require prior 




1.12.5 Combined strategies 
Combined strategies use two or more of the preceding strategies simultaneously and/or 
sequentially. Most interventions are of the combined type[99].  
 
 
There are many strategies that have been effective in improving drug use. Mainly their 




1.13 Selection criteria of a strategy 
Ideally, the selection of a strategy should be guided by the following requirements[112]:  
♠ Acceptability to the hospital and prescribers. It should be neither disruptive to 
hospital routine, nor impair the care or health outcomes of patients 
♠  Efficiency in the improvements in drug use can outweigh the resources and 
efforts required achieving and sustaining them 
♠ Specificity in impact on drugs and prescribers. The strategy should neither restrict 
the use of alternative, appropriate drugs, nor penalise prescribers who comply 
with therapeutic standards and hospital requirements 
♠ The educational benefits for staff, particularly inexperienced prescribers should be 
considered. This aspect is sound in teaching hospitals 
♠ Sharing of guidelines and policies to related hospitals which have proven 




The success of strategies will depend mainly on certain features of hospitals. The 
availability of staff and resources dedicated to improving drug use is important. 
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Pharmacologists, pharmacists and microbiologists have been frequently associated with 
successful DUR programs in hospitals[112]. 
 
 
1.14 Drug Bulletins 
In 1958, Kallet and Aaron first released the Medical Letter on Drugs and Therapeutics, a 
biweekly newsletter for physicians and other health personnel[121]. According to 
guidelines released by the World Health Organization, hospital drug bulletins are 
publications whose content is intended to optimise drug treatment in the interests of both 
the patient and the society, which the hospital serves. The information in drug bulletins 
should be precise, specific to the needs of the target group, independent of the 
pharmaceutical industry, presented attractively, and distributed efficiently and punctually 
to the relevant staff in the hospital[122, 123]. 
 
 
Plumridge et al[103] concluded that bulletins are useful in increasing an awareness of 
specific prescribing problems and can achieve changes in prescribing patterns. According 
to the WHO drugs are frequently not used to their full potential, nor according to 
generally accepted criteria. Drug bulletins or newsletters are produced by many hospitals 
on the assumption that they improve the quality of drug treatment with a subsequent 
decrease in costs[104, 122]. 
 
 
May and colleagues in the USA[124, 125] demonstrated that information in drug 
bulletins had a short-term effect on prescribing patterns. Since 1960, Moir and associates 
have employed regular feedback of drug usage data to prescribers in hospitals. Drug 
usage surveys conducted at the Pharmacy Department, Fremantle Hospital are in 
consistent with the observations made by the WHO recommendation. “However good the 
surveillance systems, they will not contribute directly to safer and more effective therapy 
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In the vibrant field of drug therapy the need to be current is essential. There are many 
ways to gather drug information, but prescribers generally prefer and use printed 
information sources such as journals and bulletins. Two decades ago several studies have 
been completed, with conflicting results, to assess the effects of printed drug information 
on prescribing behaviour[104, 108, 110, 127-129]. In general, it has been concluded that 
printed material alone may change knowledge but it rarely has a direct effect on 
prescribing behaviour without the addition of multiple strategies[122, 130-132].  
 
 
Drug bulletins are mainly directed at transmitting information about treatment aspects 
such as efficacy, adverse effects, and cost. Such information is not the only factor 
influencing drug choice and prescribing behaviour: the value attached to the treatment 
aspects is also important[132-135]. 
 
 
1.15 The Pharmacist Role 
Pharmacists should play a central role in the overall operation of DUE programs in 
addition to assisting in the performance of individual reviews. Suggested roles and 
responsibilities include[115]: 
o Preparation of submissions for program justification; 
o Program development, supervision and coordination; 
o Education of hospital staff about DUE in conceptual and practical terms; 
o Recommendation and promotion of the goals and objectives of DUE; 
o Development/review of audit criteria, guidelines, study protocols and other 
educational material; 
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o Development of data collection instruments, field testing, data collection, analysis 
and report writing; 
o Documentation of program outcome, effectiveness and cost benefit; 
o Prospective/concurrent monitoring of drug usage; 
o Participating as a member of hospital committees concerned with quality 
assurance in general and drug usage evaluation in particular; 
o Presentation of DUE results at meetings and conferences. 
 
 
Pharmacists should monitor quality assurance activities in all practice settings and assist 
in established guidelines to discourage unnecessary drug use. Pharmacists should also 
become directly involved in aiding physicians in the decision to use drug therapy by 
documenting important drug related information in medical charts, by participating in 
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Review of prescribed Antibiotic and Analgesic dosage and the impact of 
intervention at a pediatric teaching hospital in Western Australia 
 
2.1 Introduction 
Paediatric and neonatal therapeutics and toxicology deals with an immature subject in a 
continuous state of development of body and organ function. It is well recognised that 
children cannot be viewed as "little adults" with respect to either drug effects or drug 
disposition [1]. Children and adults respond to drugs differently. There are important 
differences in the absorption, distribution, metabolism, and excretion of drugs during 
infancy and childhood. Children's body systems are less developed; their gastrointestinal 
transit time varies, and their body composition changes with development [2]. Children 
often require and tolerate proportionally greater daily doses of many drugs to achieve 
similar pharmacodynamic effects as adults, whereas newborn and infants may require 
more or less of a drug for a comparable effect [1]. 
 
 
Prescribing medication to a child requires careful consideration. In comparison to an 
adult, there are both subtle and marked differences in the pharmacokinetic action of drugs 
in the developing child. Many current medications have not been tested in children, so 
rational prescribing poses many challenges [2]. 
 
 
A significant increase in the knowledge base in paediatric clinical pharmacology has 
occurred over the past two decades and has largely been the result of important scientific 
and sociological advances pertaining to paediatric therapeutics. Although the data on 
drug disposition in infants and children have increased considerably over the past few 
years, pharmacokinetic, pharmacodynamic interactions, particularly the effects dependent 




Errors in calculating drug doses have long been recognised as a cause of morbidity and 
mortality. In infants and small children such errors are more likely to be life threatening. 
It could be argued that such errors may stem from many factors such as poor medical 
knowledge, excessive workload, and fatigue [4]. 
 
 
Antibiotics are one of the most commonly used treatments around the world [5]. 
Antibiotics differ from other drugs in at least two respects. First, the main action of 
antibiotics is only to inhibit or to kill microorganisms. They are unlikely to heal or to 
reverse the damage already inflicted by the infecting organisms. Second, misuse of 
antibiotics not only causes morbidity and mortality due to side effects and financial loss, 
but it may also induce antibiotic resistance [6].  
 
 
Antibiotic resistance is a very important worldwide problem. Strategies for reducing the 
inappropriate use of antibiotics are being explored in order to minimise the development 
of antibiotic resistance and to maximise the efficiency of antibiotic use. A number of 
measures have been taken to influence the use of antibiotics in the hospital setting. 
Restrictive or administrative approaches may work in the short term, but by themselves 
may meet resistance from the prescribers. An educational strategy seems to be a useful 




Drug usage evaluation is one of the important services provided by pharmacists today in 
hospitals. The outcomes of these evaluations are designed to lead to improvements in 
prescribing, to better utilisation of limited resources and improved patient care. This 
service is in high demand as organisations are searching for methods of improving patient 
care and reducing their costs. A typical drug evaluation process generally entails an in-
depth analysis of an agreed specific group of drugs. The method of analysis involves a 
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pharmacist screening the literature and clinical data, developing and evaluating the 
collected data against practice guidelines in conjunction with other related stakeholders. 
The results of the review will then be presented to the prescribers and strategies used 
where appropriate modification of their prescribing behaviour is sought. 
 
 
This chapter describes a series of studies, which were carried out as a preliminary to the 
development of a major study. These consist of study one; a pilot study to survey the 
frequency of drugs prescribed across the hospital during a 24-hour period, study two; to 
identify the level of appropriateness of prescribing antibiotic and paracetamol-compound 
analgesic dosages by retrospectively reviewing the medical records for a period of four 
weeks and study three; to evaluate the impact of an educational intervention programme 
on physicians prescribing of flucloxacillin, ceftriaxone and Liquigesic Co® dosages. The 
series of studies were conducted at Princess Margaret Hospital for Children (PMH), 




The initial study was conducted prospectively over a single 24-hour period on all patients 
admitted in PMH. Since the entire data collection to cover 250-bed hospital is not 
possible in one day, some patients prescribing data were collected on the following day. 
The drugs prescribed during the previous 24-hour period are only recorded. Other drugs, 
which are prescribed outside the 24-hour period, were not collected in the form. The time 
of prescription written on the medical record is taken into account.  
 
 
The second study was a retrospective study carried out in December 1999. A list of 
patients admitted at PMH for the month of October 1999 was obtained from the Clinical 
Coding (CC) department. A request was sent to the Patient Information and Management 
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The third study was carried out in three stages. Initially, a pre-intervention study (Group 
1) was conducted to evaluate the level of appropriate dose prescribing of flucloxacillin, 
ceftriaxone and Liquigesic Co® by retrospectively reviewing the medical records. An 
intervention strategy was then planned and implemented. Subsequently, a post-
intervention study (Group 2) was carried out by prospectively reviewing the medication 
charts in the wards to evaluate the level of impact of the intervention programme on 
physician’s prescribing.  
 
 
The pre-intervention study was conducted for a period of six weeks in January and 
February 2000 and the post-intervention study for the same period in June and July 2000. 
The PIMS and CC Departments supplied the list of patient medical records available 
during January and February 2000 and the data was transcribed only from the patients 
prescribed any of flucloxacillin, ceftriaxone and Liquigesic Co®. 
 
 
2.2.1 Data collected 
In study-1, the name of each drug and number of times prescribed to a patient on that day 
was entered into a prepared form. In studies -2 and -3, a coded form was prepared to 
transcribe the data from the medical records. Data recorded included patient details (age, 
weight, sex, date of admission and date of discharge), clinical details (principal diagnosis, 
principal procedure and other procedures) and medication details (drug name, dose, 




In study-2, prescribing data related to all antibiotics and paracetamol and paracetamol 
with codeine analgesics were collected whereas in study three only data for flucloxacillin, 
ceftriaxone, and Liquigesic Co® drugs were collected.  
 
 
2.2.2 Inclusion and exclusion criteria 
In study-1, all prescriptions written from 4th October at 8.00 a.m. until 8.00 a.m. 5th 
October were included in the study and others were excluded. For study-2, all medical 
records where no antibiotics or analgesics were prescribed or the data was incomplete 
were excluded. Patients prescribed flucloxacillin, ceftriaxone and Liquigesic Co® in 
study-3 were included in the study. 
 
 
2.2.3 Data analysis 
The drugs prescribed were categorised according to the British National Formulary [8]. 
The prescribed dosage was evaluated against Australian Therapeutic Guidelines (ATG) 
for Antibiotics [9] [10] and for Analgesics [11]. Liquigesic Co® was evaluated according to 
the PMH in-house guidelines of 0.8 ml/kg/6-hourly (19.2 mg/kg of paracetamol and 
0.8mg/kg of codeine). Each 5 ml of Liquigesic Co® contains 120 mg of paracetamol and 
5 mg of codeine. 
 
 
An appropriate dose was classified as one prescribed within ±25% of the recommended 
dose. The permitted dosage error of ±25% was based on the common variability allowed 
in dosage forms and bioequivalency studies. Statistical evaluations were performed using 
χ2 analysis for patient categorical and other non-parametric data. The influence of the 
intervention was analysed by analysis of variance. The sample size was based on current 
prescribing being 60% appropriate, and if increased to 80% by the intervention at α =0.05 




2.2.4 Intervention programme 
The intervention strategy involved (i) releasing a newsletter to the relevant key 
prescribing medical and other appropriate staff in the hospital on 6th June 2000; (ii) 
personal discussion held with the appropriate key staff; (iii) the chief pharmacist gave a 
presentation to all prescribers and clinical pharmacists subsequently followed up on the 
wards regularly; (iv) this included a review and analysis of the prescribing data collected 
in the pre-intervention study along with current recommendations for ceftriaxone, 
flucloxacillin and Liquigesic Co® dosages. 
 
 
2.2.5 Ethical issues 
As this study involved an analysis of patient’s prescription data, ethical issues arise in 
relation to confidentiality and release of data. A unique non-patient identifiable code was 
allocated to each medical record to enable re-identification if necessary. Any coded data 
to leave the hospital was kept secure in accordance with National Health and Medical 
Research Council guidelines{Grandis JR, 1992 #57} and only group data released from 
the research. Informed consent was not obtained, because the study was classified as a 
quality audit. The PMH and Curtin University of Technology Ethics Committees 





One hundred and thirty nine different drugs were prescribed during the selected 24-hour 
period. A total of 537 drugs were prescribed, which on average is 3.6 drugs per patient. 
Of the total prescriptions, 25.5% were antibiotics, 22% analgesics, and 11% antifungals 




It was evident from Table 2.1 that antibiotics and analgesics made up almost half of the 
prescribed medication. Antifungals a sub-group of antibiotics increased the total to in 
excess of 50% with laxatives the next most frequent group. This gives clear evidence that 
there is only a relatively small use of other drug treatments. The “Other Groups” category 
did include a range of treatment for serious pathologies such as cancer, and the need for 
pulmonary surfactants and antihypertensives. A total of 537drugs were prescribed, which 
was on average was 3.6 drugs per patient (Appendix 2.1). 
 
 
As antibiotics and analgesics made up approximately 50% of total prescribing, these 
groups were then targeted for further evaluation. It was noteworthy that within the group 



















Table 2. 1 Classification of drug groups 
Classification of drug groups and their percentages prescribed over 24 hours 
S.No Group Total number of 
patients on this group of 
drugs 
Percentage of this 
group in the total drugs 
prescribed 
1 Antibiotics 137 25.5 
2 Analgesics 118 22.0 
3 Antifungal 29 5.4 
4 Laxative 29 5.4 
5 Drugs used to treat 
nausea and vertigo 
19 3.5 
6 Supplements 15 2.8 
7 Anti-epileptic 14 2.6 
8 Anti-inflammatory 13 2.4 
9 Bronchodilators 12 2.2 
10 Diuretics 12 2.2 
11 Drugs used for 
glucocorticoid therapy 
12 2.2 
12 Anxiolytics and 
neuroleptics 
11 2 
13 Anti-histamine 11 2 
14 Anti-hypertensive 10 1.9 
15 Vitamins 9 1.7 
16 Anti-muscarinic 7 1.3 
18 Local anaesthetic 7 1.3 
19 Antiviral 7 1.3 
20 Other groups 65 12.1 





There were 2000 medical records available for the month of October 1999. Of these, 355 
(17.7%) were selected at random for review. Prescribing data was incomplete in 8, no 
medication chart was available in 11, no drugs were prescribed in 78, no drugs were 
administered in 2 (drugs prescribed as PRN but not administered) and no antibiotics 
and/or analgesics were prescribed in 63 patient records. Of the initial 355, 193 (54%) 
medical records were analysed for antibiotic and oral analgesic dosage prescribing 
appropriateness. Ninety one females and one hundred and two males were included in 
this study (Table 2.2). 
 
 
Fourteen different antibiotics and four paracetamol-compounded analgesics were 
prescribed. Of these, cotrimoxazole, erythromycin, gentamicin, roxithromycin and 
tobramycin were prescribed according to the guidelines at appropriate dosages. Whereas 
the other antibiotics and analgesics showed variable levels of lack of conformity with 
current guidelines (Tables 2.3&2.4). The level of their appropriateness data is provided in 
Appendices 2 & 3. Flucloxacillin, ceftriaxone and Liquigesic Co® were selected for 


















Female 3 21 6 46 15 91 
Male 3 24 12 50 13 102 






Table 2. 3 Number of patients prescribed appropriate and inappropriate doses of 
antibiotics 




Total % of appropriate dose 
prescribing 
Amoxicillin 13 (92)* 15 (134) 28 
(226) 
46.4 
Augmentin® 1 (6) 5 (36) 6 (44) 16.7 
Cefotaxime 21 (116) 2 (19) 23 
(135) 
91.3 
Ceftazidime 3 (22) 1 (5) 4 (27) 75.0 
Ceftriaxone 16 (32) 14 (48) 30 
(80) 
53.3 
Cephalexin 10 (120) 9 (140) 19 
(260) 
52.6 
Cotrimoxazole 1 (5) - 1 (5) 100.0 
Erythromycin 6 (75) - 6 (75) 100.0 
Flucloxacillin 20 (142) 26 (346) 46 
(488) 
43.5 
Gentamicin 8 (12) - 8 (12) 100.0 
Metronidazole 3 (16) 16 (110) 19 
(126) 
15.8 
Penicillin 10 (108) 4 (45) 14 
(153) 
71.4 
Roxithromycin 4 (26) - 4 (26) 100.0 
Tobramycin 1 (1) - 1 (1) 100.0 





Table 2. 4 Number of patients prescribed appropriate and inappropriate doses of 
analgesics 




Total % of appropriate dose 
prescribing 
Liquigesic® 41 (95)* 11 (22) 52 
(117) 
78.8 
Panadeine® 6 (11) 5 (14) 11 (25) 54.5 
Panadeine 
Forte® 
16 (54) 7 (23) 23 (77) 69.5 
Paracetamol 103 (294) 49 (119) 152 
(413) 
67.7 
*Sum of doses in the parenthesis 
 
2.3.3 Study-3 
Overall, the patients’ ages ranged from six days to 17 years in Group 1 and ten days to 17 
years in Group 2. One hundred and forty five females and 202 males in Group 1 and one 
hundred and five females and 161 males in Group 2 were included (Table 2.5). No 
significant difference was found between the distributions of genders between the two 
groups (p = 0.712). The mean age of the patients in Group 1 was 6.13 years and 6.29 
years in Group 2 with no significant difference (p = 0.638).  
 
 
In Group 1, 86 patients had been prescribed ceftriaxone, 157 flucloxacillin and 241 
Liquigesic Co® doses. Seventy-six patients were prescribed ceftriaxone, 96 flucloxacillin 
and 192 Liquigesic Co® doses in Group 2. There was a significant improvement in the 
appropriate dose prescribing of ceftriaxone and flucloxacillin following the intervention 
(p = 0.001). No significant difference was found in the dose prescribing of Liquigesic 
Co® (p = 0.535) (Table 2.6). The level of dose prescribing appropriateness in Group 1 
and Group 2 in study three is summarised in the Appendix 2.4. 
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Table 2. 5 Patient group statistics 
Group 1 Group 2 Patient group 
Male Female Male Female 
Neonate (<30 days) 2 2 - 1 
Infant (1month -1year) 9 12 19 9 
Toddler (1 –2 years) 26 13 14 15 
Children (3- 12 years) 140 102 112 68 
Teenager (13-17 years) 25 16 16 12 
Total 202 145 161 105 
 
 
Table 2. 6 Comparison data of drug dosage prescribing between Group 1&2 
Drug code Dose 
appropriateness
Group 1 Group 2 P 
Ceftriaxone Appropriate 50 (58.1%) 68 (89.5%) 
 Inappropriate 36 (41.9%) 8 (10.5%) 
 Total 86 76 
 
0.001 
Flucloxacillin Appropriate 108 (68.8%) 87 (90.6%) 
 Inappropriate 49 (31.2%) 9 (9.4%) 
 Total 157 96 
 
0.001 
Liquigesic Appropriate 178 (73.8%) 142 (74%) 
 Inappropriate 63 (26.2%) 50 (26%) 







In Study-1, antibiotics comprised 25.5% (137/537) of the total prescriptions, of these 
cephalosporins constituted 18.9% (26/137). While studies have indicated that antibiotic 
purchases comprise 19-35% of total pharmacy drug budgets[13-15], it is the cephalosporins, 
which currently account for the highest antibiotic cost in hospitals[16, 17]. In Study-2, 
43.8% of the total prescribed antibiotics dosages did not conform with the guidelines. 
Studies have shown that as many as 60% or more of the patients who are prescribed 
antibiotics in the hospital receive therapy, which is deemed “inappropriate [18-20].” 
 
 
To enhance and provide an agreed basis for the rational use of drugs, most hospitals have 
developed and implemented drug policies[21]. However, development alone is not 
sufficient to ensure the quality of drug use[22]. Herman & Rodowskas[23] have suggested 
that programs meant to improve the quality of patient care and thus drug usage, can 
succeed only if practitioners adopt a positive attitude towards such programs. It has also 
been reported that attitude was the strongest predictor of whether or not pharmacists 
performed clinical pharmacy activities[24]. The attitudes of pharmacists and physicians to 
drug policies is likely to be one of the important factors that may affect compliance with, 
and hence the ultimate effectiveness of such policies[25].  
 
 
The results of four studies carried out in the early 1980’s suggested that educational 
measures can reduce less than optimal prescribing of drugs[26-29]. Avorn and Soumerai[26] 
reported that suboptimal prescribing of target drugs was reduced when physicians were 
detailed by clinical pharmacists. Schaffner et al.[27] and Ray et al.[28] found that clinical 
pharmacist drug educators who visited physicians had only a modest effect on reducing 
the use of target drugs[30]. In the intervention (Study-3), the appropriate dosage 
prescribing of ceftriaxone was increased from 58.1% to 89.4% (p<0.001) and 
flucloxacillin from 68.7% to 90.6% (p<0.001). This shows that the intervention, which 
included clinical pharmacist involvement in the education of prescribers, has resulted in a 




Several low (5 in Study-2 and 26 in Study-3 were more than 51% below the 
recommended dose) and high (8 in Study-2 and 3 in Study-3 were more than 51% above 
the recommended dose) antibiotic dosages were prescribed. Both overdose and underdose 
prescribing of antibiotics are inappropriate practices; overdose prescribing potentially is 
associated with increased side effects, and unnecessary expenditure, whereas underdose 
prescribing potentially leads to treatment failure and possibly resistant organisms[21]. 
 
 
In Study-2, the appropriateness of paracetamol with codeine analgesic (Liquigesic Co®) 
dosage was found to be 69.7%. Patients on low analgesic dosage (1 in Study-2 and 7 in 
Study-3 were more than 51% below the recommended dose) may suffer from preventable 
pain, complications leading to a longer duration of hospital stay and increased costs. 
While patients on high dosage of paracetamol / paracetamol with codeine analgesic (3 in 
Study-2 were more than 51% above the recommended dose) may potentially suffer from 
toxicity effects.  
 
 
In this study, Liquigesic Co® dosage appropriateness did not show any significant 
improvement following the intervention (p = 0.535). This shows that the intervention, 
which was the same methodology as for antibiotics, showed success for antibiotics and 
had no effect on analgesic prescribing. On further investigation it was found that 
prescribers were using a monograph, which is not endorsed by the hospital and also did 
not match with the current guidelines for dosages of analgesics. 
 
 
The overall proportion of antibiotic dosage prescribing adherence to ATG was 65% in the 
pre-intervention group in Study-3. This is similar to the other Australian DUE studies 
which show a 50-71% adherence [22, 31-34]. In the post-intervention group, the level was 
increased to 90.1%. When implementing educational strategies, time should not be a 
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pressing factor, as they often take time to work and may require additional resources to 
sustain the desired effect. This type of strategy is useful in creating initial awareness of a 
problem, when the prescribers lack knowledge of the problem. Re-educative strategies 
can be effective by offering solutions or recommendations to the problem. These 
strategies are not capable of affecting large-scale change in a short time scale when used 
alone if the motivation to change is low[35]. 
 
 
Pharmacists have an important role in monitoring drug utilisation in all practice settings 
and should encourage the use of existing hospital guidelines and discourage suboptimal 
drug prescribing. Pharmacists should also become directly involved in aiding physicians 
in the decision to use drug therapy by documenting important drug related information in 
medical charts, by participating in patient care rounds, and by providing in-service 
education to the medical staff[36].  
 
 
This study has evaluated the influence of a comprehensive intervention strategy on a 
short-term basis. Clinical pharmacists regularly identify the need to maintain high levels 
of appropriate prescribing. Clearly this needs to include educational strategies at selected 
time intervals as prescribing occurs over the whole 24 hours and seven day a week 
whereas clinical pharmacists are in many settings available for 7.5 hours per day and five 




This study has identified that since antibiotics and analgesics constitute around 50% of 
medications prescribed to children, attention should be placed on their appropriateness. 
Improvement in the prescribing of antibiotic dosages for ceftriaxone and flucloxacillin 
was achieved with a multifaceted educational program. This did not occur with 
Liquigesic Co® but identified another source that influenced that prescribing. It is 
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important for pharmacists to be constantly vigilant regarding prescribing and evaluate 
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 Liquigesic Analgesic (compound) 27 
 Panadeine Analgesic (compound) 2 
 Panadeine Forte Analgesic (compound) 9 
 Aspirin Analgesic (NSAID) 3 
 Paracetamol Analgesic (NSAID) 56 
 Morphine Analgesic (opiod) 21 
 
 Beclomethasone dipropionate Anti-asthamatic 7 
 
 Amoxycillin Anti-bacterial 20 
 Ampicillin Anti-bacterial 1 
 Augmentin Anti-bacterial 6 
 Bactrim (sulfamethoxazole + trimethoprim) Anti-bacterial 16 
 Cefotaxime Anti-bacterial 9 
 Ceftriaxone Anti-bacterial 9 
 Cephalexin Anti-bacterial 7 
 Cephalothin Anti-bacterial 1 
 Chloramphenicol Anti-bacterial 4 
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 Ciprofloxacin Anti-bacterial 3 
 Cotrimoxazole Anti-bacterial 2 
 Erythromycin Anti-bacterial 1 
 Flucoxacillin Anti-bacterial 8 
 Gentamicin Anti-bacterial 15 
 Metronidazole Anti-bacterial 11 
 Penicillin Anti-bacterial 5 
 Rulide Anti-bacterial 1 
 Tobramycin Anti-bacterial 7 
 Vancomycin Anti-bacterial 4 
 
 Heparin Anti-coagulant 3 
 
 Zoloft Anti-depressant 1 
 
 Actrapid Anti-diabetic 4 
 Humulin Anti-diabetic 1 
 
 Carbamazepine Anti-epileptic 2 
 Clobazam Anti-epileptic 1 
 Epilim Anti-epileptic 4 
 Phenobarbitone Anti-epileptic 6 
 Vigabatrin Anti-epileptic 1 
 
 Canesten Cream Anti-fungal 1 
 Daktarin Anti-fungal 1 
 Econazole Anti-fungal 3 
 Fluconazole Anti-fungal 12 
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 Flucytosine Anti-fungal 1 
 Itraconazole Anti-fungal 1 
 Nilstat Anti-fungal 8 
 Nystatin Anti-fungal 2 
 
 Benadryl Anti-histamine 1 
 Hydroxyzine Anti-histamine 1 
 Loratidine Anti-histamine 3 
 Promethazine Anti-histamine 6 
 
 Atenolol Anti-hypertensive 2 
 Captopril Anti-hypertensive 2 
 Catapress Anti-hypertensive 1 
 Diltiazem Anti-hypertensive 1 
 Enalapril Anti-hypertensive 1 
 Nifedipine Anti-hypertensive 3 
 
 Dexamethasone Anti-inflammatory 6 
 Ibuprofen Anti-inflammatory 4 
 Indomethacin Anti-inflammatory 1 
 Naprosyn Anti-inflammatory 1 
 Sofradex Anti-inflammatory 1 
 
 6-Mercaptopurine Anti-metabolite 2 
 Methotrexate Anti-metabolite 2 
 Thioguanine Anti-metabolite 1 
 
 Atropine Anti-muscarinic 3 
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 Atrovent Anti-muscarinic 1 
 Benztroprine Anti-muscarinic 1 
 Oxybutynin Anti-muscarinic 1 
 Sucralfate Anti-muscarinic 1 
 
 Mycophenolate Anti-proliferative immunosuppresant 1 
 
 Tazocin Antibiotic 2 
 Timentin Antibiotic 5 
 
 Haloperidol Anti-psychotic 1 
 
 Omeprazole Anti-secretory 1 
 
 Rifampicin Anti-tubercular 1 
 
 Cimetidine Anti-ulcer 1 
 Ranitidine Anti-ulcer 2 
 
 Acyclovir Anti-viral 2 
 CMV-Ig Anti-viral 2 
 Fanciclovir Anti-viral 1 
 Ganciclovir Anti-viral 1 
 Valacyclovir Anti-viral 1 
 
 Diazepam Anxiolytic 9 
 Midazolam Anxiolytic and neuroleptic 2 
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 Aminophylline Bronchodilator 3 
 Salbutamol Bronchodilator 9 
    
 Caffeine CNS stimulant 2 
 Ritalin CNS stimulant 1 
 
 Betadine drops Dis-infectant 1 
 Chlorhexidine Dis-infectant 1 
 
 Frusemide Diuretic 8 
 Hydrochlorthiazide Diuretic 2 
 Spironolactone Diuretic 2 
 
 Bonjela Drug acting on oropharynx 3 
 G-CSF Drug used to treat neutropenia 2 
 Gaviscon Drug used for gastroesophageal reflux 1 
 Hydrocortisone Drug used for glucocorticoid therapy 3 
 Prednisolone Drug used for glucocorticoid therapy 9 
 Prochloroperazine Drug used for nausea and vertigo 1 
 Tilade (nedocromil) Drug used for prophylaxis of asthma 1 
 Metoclopromide Drug used for the relief of nausea 5 
 Ondansetron Drug used to treat nausea and vertigo 13 
 Nitrofurantoin Drug used to treat urinary tract infection 1 
 
 Potassium Chloride Electrolyte 2 
 Sodium Chloride Electrolyte 3 
 
 Dermazole Cream Emollient 1 
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 Chloral Hydrate Hypnotic 3 
 Nitrazepam Hypnotic 1 
 Temazepam Hypnotic 1 
 
 Azathioprine Immunosuppressant 1 
 Cyclosporin Immunosuppressant 1 
 Tacrolimus Immunosuppressant 2 
 
 Coloxyl Laxative 8 
 Lactulose Laxative 1 
 Magnesium asparate Supplement (magnesium) 2 
 Microlax Laxative 6 
 Parachoc Laxative 8 
 Senna Laxative 1 
 Sorbitol Laxative 2 
 Phosphate Enema Laxative 1 
 
 Bupivacine Local anaesthetic 1 
 Emla Local anaesthetic 6 
 
 Pancuronium Muscle relaxant 1 
 Suxamethonium Muscle relaxant 3 
 
 Permethrin Parasiticidal preparation 2 
 
 Calcium Carbonate Phosphate binding agent 2 
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 Survanta Pulmonary surfactant 3 
 
 Calcium gluconate Supplement (calcium) 1 
 Calcium Supplement (calcium) 2 
 Carnitine Supplement (carnitine) 1 
 Erythropeotin Supplement (erythropoietin) 1 
 Ferrous gluconate Supplement (ferrous) 1 
 Folate Supplement (folic acid) 1 
 Pancrease Supplement (pancrease) 1 
 Phosphate Sandoz Supplement (phosphorous) 4 
 Sodium Bicarbonate Supplement (bicarbonate) 2 
 
 Calcitriol Vitamin-D 2 
 Vitamin- A+D Vitamins 1 
 Vitamin-C Vitamins 1 
 Vitamin-E Vitamins 3 




Appendix 2. 2 Profile of dose prescribing of antibiotics in Study two 













Total Percentage of 
appropriateness 
Amoxycillin 2 (4)*  12 (129)  1 (1) 13 (92) 28 (226) 46.4 
Augmentin   2 (15) 3 (23)  1 (6) 6 (44) 16.67 
Cefotaxime   1 (14) 1 (5)  21 (116) 23 (135) 91.3 
Ceftazidime    1 (5)  3 (22) 4 (27) 75 
Ceftriaxone 11 (40) 1 (6)  1 (2)  16 (32) 30 (80) 53.3 
Cephalexin 8 (100) 1 (40)    10 (120) 19 (260) 52.6 
Cotrimoxazole      1 (5) 1 (5) 100 
Erythromycin      6 (75) 6 (75) 100 
Flucloxacillin 15 (176) 2 (11) 9 (159)   20 (142) 46 (488) 43.47 
Gentamicin      8 (12) 8 (12) 100 
Metronidazole 9 (92) 1 (3) 5 (12) 1 (3)  3 (16) 19 (126) 15.8 
Penicillin 4 (45)     10 (108) 14 (153) 71.4 
Roxithromycin      4 (26) 4 (26) 100 
Tobramycin      1 (1) 1 (1) 100 
*Sum of doses in the parenthesis 
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Appendix 2. 3 Profile of dose prescribing of oral analgesics in Study two 













Total Percentage of 
appropriateness
Liquigesic® 10 (20)*  1 (2)   41 (95) 52 (117) 78.8 
Panadeine® 4 (8)  1 (6)   6 (11) 11 (25) 54.5 
Panadeine 
forte® 
6 (16)  1 (7)   16 (54) 23 (77) 69.5 
Paracetamol 32 (93) 1 (1) 13 (21) 2 (2) 1 (2) 103 (294) 152 (413) 67.7 












Appendix 2. 4 Profile of level of dose prescribing appropriateness in Group 1 and Group 2 in Study three 
Group 1 Group 2 Level of appropriateness 
Ceftriaxone Flucloxacillin Liquigesic® Ceftriaxone Flucloxacillin Liquigesic® 
26-50% low dose 32 (60)* 25 (152) 54 (129) 7 (19) 2 (7) 49 (128) 
51-75% low dose 2 (9) 24 (93) 7 (112)  4 (15)  
76-100% low dose     1 (4)  
26-50% high dose 1 (5)  1 (168) 1 (1)  1 (2) 
51-75% high dose 1 (1)    1 (1)  
76-100% high dose     1 (5)  
Appropriate 50 (126) 108 (705) 179 (1028) 68 (191) 87 (779) 142 (454) 
Total 86 (201) 157 (950) 241 (1480) 76 (211) 96 (811) 192 (584) 





Impact On Surgeons Antibiotic and Analgesic Prescribing Following The 
Implementation Of Hospital Treatment Guidelines In Pediatric Appendectomy 
Procedures in Australia 
 
3.1 Introduction 
Appendectomy is the surgical removal of the appendix. Surgeons have been successfully 
performing appendectomies for more than 100 years, and it is now the most common 
type of emergency surgery. Approximately 60,000 US children are operated annually for 
the presumptive diagnosis of appendicitis[1]. About 10% to 30% of these have normal 
pathology and 30% to 45% have ruptured appendices, at least one third of all patients do 
not achieve optimal timing for the surgical intervention[2]. Fitz stated, “The vital 
importance of early recognition of perforative peritonitis is unmistakable…its eventual 
treatment by laparotomy indispensable[3].” In McBurney’s treatise he proposes, “In the 
early stage no accurate diagnosis can be made as to whether the appendix is perforated or 




The hallmark of the diagnosis of acute appendicitis is a compatible history and physical 
examination. Signs and symptoms of right lower quadrant tenderness and pain are 
anticipated for the vast majority of patients examined for acute appendicitis. However, 
the absence of right lower quadrant symptoms, it is very reliable for eliminating the 
diagnosis and therefore for avoiding surgery[5].  
 
 
Despite technologic advances, the diagnosis of appendicitis is still based primarily on the 
patient’s history and a physical examination. Prompt diagnosis and surgical referral may 
reduce the risk of perforation and prevent complications. The mortality rate in non-
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perforated appendicitis is less than 1 percent, but it may be as high as 5 percent or more 




3.1.1 Appendectomy in Western Australia 
Appendectomy is one of the most common surgical procedures in Australian children. An 
increase in the incidence of appendicitis was reported during the early part of the 20th 
century, but a decline has been reported since about 1930[7]. 
 
 
Western Australia occupies one third of the Australian continent. It is sparsely populated. 
Seventy-three percent of the total population of 1.9 million reside in the capital city of 
Perth [7]. According to a study conducted by Donnelly et al, of the 59,749 
appendectomies performed in WA during 1981-1997, 33,352 (58%) were performed on 
female patients and 26,397 (42%) on males. They found that a marked decline occurred 
in the rate of appendectomy during the study period; it was more marked in females than 
males which is consistent with trends reported from European countries [7-9]. Of the 
30,934 appendectomies performed in WA during 1988-1997, 18,961 (61.3%) were acute 
emergency admissions, 3820 (12.3%) were other emergency admissions, 2192 (7.1%) 
were incidental procedures and 5961 (19.3%) were recorded as other appendectomy 
admissions [7].  
 
 
Depending on the nature of the appendicitis, which can manifest with perforation, 
peritonitis, phlegmon, or abscess, treatment usually incorporates a combination of 




3.1.2 Misuse of antibiotic prophylaxis during surgery 
Antibiotic use has soared in recent years. Furthermore, antibiotics appear to be used both 
in excess and inappropriately. The Center for Disease Control and Prevention in the USA 
has estimated that some 50 million of the 150 million prescriptions for antibiotics written 
for outpatients every year are unnecessary. A similar type of study, an evaluation of 
antibiotic use at Hacettepe University Hospital in Turkey in 1994 revealed that antibiotics 
were being used inappropriately in 23% of patients[10, 11]. 
 
 
Inappropriate antibiotic use has been shown to have implications for the cost-
effectiveness of patient care. A study from Naples, Italy, examined surgeons’ compliance 
with published international guidelines for surgical prophylaxis and evaluated the cost of 
the surgical prophylaxis against what it would have been had the guidelines been 
followed[12]. The first observation was that the duration of prophylaxis use was longer 
than recommended. Two hundred and twenty patients who underwent clean surgical 
procedures, for which prophylaxis was not generally recommended, received prophylaxis 
lasting from 1.1±0.3 days to 4.6±2.8 days. Similarly, 440 patients who underwent clean-
contaminated surgical procedures, for which single-dose prophylaxis was indicated, 
received prophylaxis lasting from 3.6±2.4 days to 5.2±3.7 days. They found that 84% and 
90.5% of patients’ who underwent clean and clean-contaminated surgical procedures, 
received non-standard antibiotics. Third-generation cephalosporins were the most popular 
prophylactic agents for both clean and clean-contaminated surgery, even though these 
agents are not recommended in the guidelines. A study by Akalin, stated that if the 
recommendations regarding choice of antibiotic and timing of prophylaxis had been 
followed, approximately 10% of the actual cost would have been saved[11]. Gorecki et al 
supports the above statement with savings of $18,533 per patient due to excessive 




3.1.3 Principles of prophylaxis 
Since infectious complications in surgical patients are responsible for prolonged wound 
healing, disability, deformity, prolonged hospitalisation, increased overall cost of hospital 
care and even death, and since the patients quality of life can be affected or even 
permanently altered by them, including very high human and economic costs, it is 
important to prevent them as far as possible. This can be done by improving the patients 
ability to overcome the microbial invasion, by improving the patients general conditions, 
by judicial surgical procedures and by using antibiotic prophylaxis[14]. 
 
 
Antibiotic prophylaxis for abdominal procedures has been used since antibiotics became 
available in the 1940s[15]. Since then, numerous investigations have attempted to define 
the optimal antibiotic, number of doses, risk factors, and cost-effectiveness of 
prophylaxis in this field of surgery.  
 
 
Following the initial studies by Burke[16] in the 1960s, the basic principles of surgical 
prophylaxis established in that period are now widely accepted. Bacterial contamination 
of surgical wounds potentially occurs in every operation. The origin of the contamination 
may be exogenous or endogenous. Both may coexist, are usually minor, and are more 
likely to occur during than after a surgical procedure[17].  
 
 
The objective of antibiotic prophylaxis in surgery is to prevent wound infection, in 
particular deep abscess, caused by intraoperative bacterial contamination. Success 
depends on the ability of the patients local and systemic defence mechanisms to resist the 





The likelihood of a wound becoming infected depends largely on the size of the bacterial 
inoculum, since infection only occurs when pathogens invade the tissues in a sufficient 
number to overcome the natural defences of the body. The surgeon can enhance host 
resistance by ensuring an adequate supply of blood and avoiding tissue haematomas and 
the entry of foreign materials to the surgical site. In this situation, the role of prophylactic 
measures is to reduce the number of ‘invaders’ as far as possible[17]. The key elements of 
surgical antibiotic prophylaxis are indications, choice of antibiotic, dosage, route of 
administration and timing. 
 
 
The prophylactic use of antimicrobial agents is recommended for the prevention of a 
variety of post-operative infections[18], which represent 25% of all nosocomial infections 
in hospitals [19]. Since antibiotics were discovered, no single preventive measure 
contributed more to the decrease in post-operative wound infection than prophylaxis[20]. 
However, its appropriate application is a source of concern as it currently accounts for up 
to 30-50% of antimicrobial prescriptions in hospitals. Inappropriate antimicrobial 
prophylaxis adds to the pressure on microbial ecology within the hospital, and increases 
the risk of antimicrobial resistance. It contributes to the development of multiple 
antibiotic resistances, including resistance to newer agents, and antimicrobial resistance is 
associated with poor clinical outcome and increased treatment costs[21, 22]. 
 
 
The principles of surgical prophylaxis have been defined over the years: administration 
just prior to surgery, maintenance of sufficient tissue drug levels for the duration of the 
procedure and for not more than 24hrs, and the antimicrobial agent given is active against 
those organisms most likely to be encountered in the particular surgical field[23]. 
Antibiotic “prophylaxis” initiated after the operation is useless[13]. The timing of 
antibiotic administration relative to the time of surgery is the most crucial factor in the 




3.1.4 Determinants of the need for prophylaxis 
The decision to administer antibiotic prophylaxis during a given surgical procedure can 
readily be linked to the traditional classification of surgical procedures (Table 3.1)[24]. 
Prophylaxis is required usually for clean-contaminated procedures, and always for 
contaminated procedures. Aggressive therapy is obviously essential in the case of dirty-
infected procedures[14].  
 
Table 3. 1 Traditional classification of surgical procedure 
Category Infection 
risk (%) 




Clean 1.5-4.2 Non-traumatic; no inflammation 
encountered; no break in technique; 
respiratory, alimentary, genitourinary 






<10 Gastrointestinal or respiratory tract 
entered without significant spillage; 
appendectomy, oropharynx or vagina 
entered, urinary or biliary tract entered in 




Contaminated 10-20 Major lapse in technique; gross spillage 
from gastrointestinal tract; fresh 
traumatic wound; infection of entry in 





20-40 Acute bacterial inflammation without 
pus; transection of clean tissue to enable 
collection of pus; traumatic wound with 
retained devitalised tissue; foreign 







Prophylactic antibiotics are effective in a wide range of surgical procedures and have 
contributed substantially to reducing postoperative wound infections rates. Moreover, 
financial savings may be associated with their use since wound infections are among the 
most expensive nosocomial infections. However, use of broad-spectrum antibiotics 
potentially contribute to the appearance of multi-resistant organisms, including strains 
resistant to newer agents, and antimicrobial resistance is associated with poor clinical 
outcomes and increased treatment costs[25]. The decision to prescribe antimicrobials has 
to be carefully balanced between immediate benefits and possible adverse effects as well 
as unfavourable medium-term impact on patient or hospital ecology[22]. 
 
 
3.1.5 Cost of intra-abdominal infections 
Surgical site infection in the postoperative period can be very costly. The cost of surgical 




Postoperative wound infections account for approximately 25% of all hospital-acquired 
infections and are the most expensive type of hospital-acquired infection[27]. 
Postoperative wound infections affect at least 920,000 of the 23 million patients who 
undergo surgery each year in the USA[11].  
 
 
Despite considerable progress in the areas of prevention, diagnosis, and therapy, 
postoperative infections continue to be associated with considerable morbidity and 
mortality. Surgical patients can develop several postoperative infections; wound 
infections – representing more than 19% of all postoperative infections. These 
complications add 10-20% additional costs to the total hospital bill[28]. In the USA, for 
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any given type of operation, the development of a wound infection, will approximately 
double the cost of hospitalisation. These infections lead to 80,000 deaths and are 
associated with an annual treatment cost of US$ 2 billion. These data are similar in Italy, 
where nosocomial infections occur in 500,000 out of 8,000,000 hospital admissions per 
year and where the hospital antibacterial expenditure was about ITL 580 billion in 1997, 
which is 22% of the total drug expenditure[11, 29]. 
 
 
3.1.6 Need for surgical prophylaxis 
The economic consequences of hospital-acquired infections are well known and have 
changed little during the past few years. In the USA in 1995, hospital-acquired infections 
account for approximately 2 million patients per year[11], with an increased hospital stay 
by an average of seven days, at a cost of $2434 per patient[26]. A similar study in the UK 
showed an increased stay of 8.2 days at a cost of £1041[30]. A recent report from the 
Public Health Laboratory Service identified a 2.5 fold greater cost for patients developing 




The effect of postoperative infections in prolonging the length of hospital stay and 
thereby increasingly the direct cost of patient care is especially noticeable for patients 
undergoing cardiothoracic, orthopaedic and gastrointestinal operations. The indirect costs 
can be very high in these patients, and are an important consideration in assessing the 
consequences of postoperative infection[11]. 
 
 
Postoperative infection is the major common avoidable cause of both morbidity and 
mortality in surgical procedures. Advances in overcoming this problem have transformed 
surgery from an activity associated with frequent infection and death into a discipline 




Given the high morbidity and mortality rates and high costs associated with the treatment 
of surgical infections, prophylaxis is the much preferred management option. The 
prophylaxis of surgical-site infections is based on four principles: preoperative patient 




3.1.7 Effects of inappropriate antimicrobial use 
Overuse or “inappropriate” use of antimicrobials is often cited as a risk factor for the 
emergence of antibiotic resistant bacteria. The use of vancomycin, of third generation 
cephalosporins and of antimicrobials with anaerobic activity has been cited as a risk 
factor for development of vancomycin resistant enterococcus[33, 34]. Third generation 
cephalosporins have been implicated as a risk factor for the development of multi-
resistant Gram-negative bacilli[35, 36]. Most studies suggest that a correlation between 
antibiotic use and resistance rates have described the experience of single institutions[37]. 
 
 
Antibiotic use in common practice is excessive[38, 39]. Effects of antibiotics other than 
bactericidal are common and include drug interactions, toxic or allergic reactions, and 
release of endotoxins from enteric bacteria. Beyond these issues and excessive hospital 




3.1.8 Guidelines for improved quality of surgical prophylaxis 
There are at least three reasons to promote the rational use of antibiotics: to improve the 
quality of patient care, to delay the development of antibiotic resistance, and to increase 
the cost-effective use of antibiotics. With regard to the quality of care, inappropriate 
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hospitalisation, medical treatments and/or surgical intervention clearly represent poor-
quality medical care. In addition, large variations in practice patterns have implications 
for quality of care, as does variation in the way a treatment is applied[11, 40]. 
 
 
The current pediatric surgery environment demands the provision of quality health care at 
an affordable cost. Both payers and regulators are committed to lowering cost through 
initiation of best practice strategies that include practice guidelines, clinical pathways, 
and standards of care[13, 41]. 
 
 
Several studies have indicated that the implementation of guidelines can yield significant 
improvements in antibiotic use and hence quality of patient care[11]. In a study by Akalin, 
when compared with the previous practice, compliance with newer guidelines increased 
after their implementation, from 32% to 79%. The proportion of cases managed by 
single-dose prophylaxis also increased from 34% to 80%, there was a decrease in 
prophylactic antibiotic consumption from 0.75 to 0.53 DDD/patient. After intervention, 
only 16% of total antibiotic use was for prophylactic use, compared with 31% before 
intervention. The incidence of prophylaxis lasting more than 24 hours decreased from 
21% to 8%[11]. 
 
 
The control of variation through quality processes such as pathway development, 
refinement of guidelines, and feedback of providers may improve the care of children 
with appendicitis[42]. By evaluating comparative data, physicians and hospitals may be 
able to identify and adopt best practices, improve outcomes, and perhaps decrease 
resource utilisation and the cost of care[43]. National databases have become an 




The best approach is the development of formal clinical practice guidelines (CPGs) to 
guide patient care prospectively within a select population. The development of CPGs is 
part of a larger trend toward evidence-based medicine and quality of care. A clinical 
practice guideline is defined as a systematically developed, evidence or consensus based, 
or both, multidisciplinary plan of care for a specific patient population that serves as a 
guide for clinical decision-making and as a method to ensure that all aspects of the care 
process are carried out in a timely fashion to best meet the patient’s needs[45].  
 
 
According to a survey by Chen et al. on current practice patterns in the treatment of 
appendicitis in children, a majority of surgeons (59%) base their clinical practices on 
individual surgeon’s preferences. Another 24% of respondents used informal guidelines 
based on a consensus of surgeons in the practice group. Surprisingly, only 17% of 




Reduction in funds appropriated for health care forces physicians all over the world to 
take into consideration therapeutic costs[46]. Restricting antibiotic overuse is even more 
justified because expenses towards antibacterial agents constitute a major item in a 
budget of many hospitals[13]. 
 
 
Perioperative antimicrobial prophylaxis (PAP) accounts for more than one of every three 
antibiotic prescriptions in hospitals, and the dollar value of antibiotics used for this 
purpose is significant and an aggregate expenditure of several billion dollars per year 
results in the United States. The benefits that PAP produces are of substantial economic 
importance, because of the cost of postoperative infections. Hospitals in the United States 
usually recover a small net gain for surgical procedures; this profit is lost when the 
patient develops a postoperative infection[47]. PAP “may account for a substantial 
portion of hospital pharmacy antibiotic use that is regarded as inappropriate,”[48] so it 
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deserves attempts to improve usage. However, even if there was no cost rationale for its 




The purpose of this study is to evaluate drug use in appendectomy procedures in pediatric 
patients. This will be achieved by (i) determining drug usage and prescribing patterns for 
antibiotics in appendectomy patients (ii) identifying and establishing criteria and 
standards which describe appropriate use of these drugs (iii) promoting rational therapy 
by implementing treatment guidelines through education programs administered by 
targeted interventions (iv) evaluating the outcomes of the intervention and analysing the 
implications of any identified inappropriate drug use. 
 
 
The uniqueness of this study is evaluating both drug usage and dosage prescribing 
appropriateness in pediatric appendectomy patients and implementing multifaceted 




3.2.1 Setting and patient population 
The study was conducted at Princess Margaret Hospital for Children (PMH) (test-1&2), 
Subiaco, Western Australia a 250-bed pediatric teaching hospital. The control groups 
were identified at Fremantle Hospital (FH) (control-1&2), Fremantle, Western Australia 
and Royal Children’s Hospital (RCH) (control-3&4), Melbourne, Victoria. FH is a 350-





A pre-intervention retrospective study (Group 1) of appendectomy procedures was 
carried out from April 2000 to August 2001 at PMH, FH and RCH. The Patient 
Information and Management Services Department supplied the patient medical records 
in each case. Post-intervention (Group 2) studies were conducted from December 2001 to 
April 2002 and data was collected retrospectively at all the hospitals. All pediatric 
patients undergoing treatment at PMH and RCH and patients under 18 years of age at FH 
were eligible to be included in this study. 
 
 
3.2.2 Data collected 
The data related to antibiotic prescribing were entered from the medical records into a 
coded prepared form. Patient details included age, weight, sex, date of admission, date of 
discharge, clinical details such as principal diagnosis and principal procedure, medication 
details including drug name, dose, frequency, route and number of doses administered. 
 
 
3.2.3 Inclusion criteria 
All pediatric patients undergoing treatment at PMH and RCH and patients under 18 years 




An intervention strategy involved (i) releasing a newsletter to the relevant key prescribing 
medical and other appropriate staff in the PMH hospital on 5th December 2001 detailing 
current recommendations for the prophylaxis and treatment of appendectomy (ii) Chief 
Pharmacist and the surgical ward pharmacist held personal discussions with the 
appropriate staff (iii) a senior pharmacist gave a presentation to surgeons and subsequent 
regular follow-up by clinical pharmacists regarding antibiotic treatments, this included a 
review and analysis of the prescribing data collected in the Group 1 study for analgesics 
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and with current recommendations of antibiotics for prophylaxis and treatment in 
appendectomy procedures (iv) any infections developed by patients due to inappropriate 
antimicrobial cover was discussed with the microbiologist and the recommendations 
made by him/her were presented to the physicians (v) this was re-inforced by the hospital 
clinical pharmacists (vi) guideline posters were displayed in the wards and operating 
theatres (vii) the principal goal was to achieve compliance with the developed guidelines 
in the hospital. 
 
 
3.2.5 Ethical issues 
As this study involved an analysis of patient records, ethical issues arise in relation to 
confidentiality and release of data. A unique non-patient identifiable code was allocated 
to each record to enable re-identification of the record if necessary. The key to the code 
was held by the Chief Pharmacist, which does not leave the hospital. Any coded data to 
leave the hospital was kept secure in accord with National Health and Medical Research 
Council [50] guidelines and only group data released from the research. 
 
 
3.2.6 Patient groups 
Patients were categorised into five groups based on their age. Patients of less than 30 
days of age were neonates, one month to one-year infants, one to two years’ toddlers, 




An appropriate dose was classified as one prescribed within ±25% of the recommended 
dose. The designated dosage error of ±25% was based around common variability 
allowed in dosage forms and bio-equivalency studies. An appropriate choice of the drugs 
/ combination of drugs were those prescribed as recommended in the Australian 
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Therapeutic Guidelines. Theatre antibiotics were the antibiotics prescribed in the theatre 
as a prophylactic cover. Ward antibiotics were the antibiotics prescribed postoperatively 
in the ward. Total antibiotic choice was the choice of the drugs / combination of drugs 
prescribed according to the guidelines in the theatre and ward combined. Theatre dosage 
was the dosage of theatre antibiotics. Ward dosage was the dosage of the ward 
antibiotics. Total dosage was the dosage of all the antibiotics prescribed in the theatre and 
ward together. Total appropriateness was the level of appropriateness of a combination of 
the choice and dosage of antibiotics prescribed in the theatre and ward in accordance with 




3.2.8 Statistical Evaluation 
The study design was a pre-post time series incorporating control groups. Group 2 data 
was used to evaluate the antibiotic prescribing compared with a Group 1 population 
undergoing the same procedure. Populations were matched for number of patients 
included in each group, age and length of stay were tested using independent sample t-
tests. Differences in the choice, dosage of antibiotic, and gender were evaluated using χ2 
analysis. One was added to the fields where zero was the result in a cell and analysed 
using χ2 analysis. Bonferroni method was used to control the alpha level for multiple 
comparisons. Multiple regression analysis is used to evaluate the post-intervention group 
following the release of guidelines. Based on α=0.05 and β=0.2 and a 20% change in 
prescribing appropriateness estimated approximately from 60-80% require a sample of 80 
patients in each group to achieve statistical significance. Control groups were analysed 





This study was approved by (i) Curtin University of Technology, Division of Health 
Sciences (ii) Cutin University of Technology, Human Research Ethics Committee (iii) 
Princess Margaret Hospital for Children, Head, Department of General Pediatric Surgery 
(iv) King Edward Memorial and Princess Margaret Hospitals Ethics Committee (v) 
Fremantle Hospital, Head, Department of Surgery (vi) Fremantle Hospital Ethics 
Committee (vii) Royal Children Hospital, Head, Department of General Pediatric Surgery 
(viii) Royal Women and Royal Children Hospitals Ethics Committee 
 
 
3.3.0 Data analysis 
The data was evaluated against Australian National Therapeutic Guidelines for antibiotics 
(ANTG)[51] and hospital in-house guidelines for appendectomy procedure, which was 
written in detail according to the ANTG. Physicians’ prescribing of analgesic dosages 
was evaluated against Australian National Therapeutic Guidelines (ANTG) for 
paracetamol[52]. The stated dosage is: paracetamol - 15 mg/kg/dose orally, every 4 to 6 
hours, to a maximum of 90 mg/kg/day. Analgesic and antibiotic dosage was calculated 
according to the product of the weight of the patient and the recommended dose per 













Table 3. 2 PMH in-house antibiotic guidelines for appendectomy procedure 
Post-operative treatment Category Prophylaxis (at 
the time of 
induction) 
Inflamed appendix Peritoneal soiling / 
peritonitis detected 




Ticarcillin / Clavulanic acid 
(Timentin®) 50mg/kg (as 
Ticarcillin) (maximum dose 




mg/kg (as Ticarcillin) 
(maximum dose 3g) 
four times daily for 










Ceftriaxone 50 mg/kg 
(maximum dose 1g) as a 
single dose with 
Metronidazole 12.5 mg/kg 
IV (maximum dose 500 
mg) as single dose given 6 
hours post-operatively 
Ceftriaxone 50 mg/kg 
(maximum dose 1g) 
once daily with 
Metronidazole 12.5 
mg/kg IV (maximum 
dose 500mg) twice 








600 mg) with 
Gentamicin 7 
mg/kg IV single 
dose 
Clindamycin 10 mg/kg IV 
(maximum dose 600 mg) 2 
doses given 6 hours apart 
starting 6 hours post-
operatively with 
Gentamicin 7mg/kg IV 
single dose (if Gentamicin 
has been given as 
prophylaxis at induction 
then no further dose is 
required) 
Clindamycin 10 
mg/kg IV (maximum 
dose 600 mg) four 
times daily with 
Gentamicin 7 mg/kg 





3.4.1 Patient demographic comparisons 
3.4.1.1 Patient group comparisons 
A total of 207 patients in test-1&2 groups, 125 in control-1&2 and 224 in control-3&4 
groups were included in this study (Table 3.3). No significant difference was found 
between the gender and mean age of patients in each test and control groups (p > 0.05) 
(Table 3.4&3.5). There was a significant difference in the mean age of patients between 
test-1 & control-1 (p < 0.001) and test-2 & control-2 groups (p < 0.001) and no difference 
was found between test-1 & control-3 (p = 0.196) and test-2 & control-4 groups (p = 
0.138) (Table 3.6). 
 
Table 3. 3 Patient group comparisons in the test and control groups 
Groups Test-1 Test-2 
 Male Female Total Male Female Total 
Infant - - - 1 - 1 
Toddler 1 - 1 2 - 2 
Children 38 32 70 45 31 76 
Teenager 18 13 31 14 12 26 
Total 57 45 102 62 43 105 
 Control-1 Control-2 
Children 11 12 23 4 4 8 
Teenager 31 45 76 11 7 18 
Total 42 57 99 15 11 26 
 Control-3 Control-4 
Toddler - - - 2 2 4 
Children 45 32 77 53 29 82 
Teenager 28 14 42 9 10 19 




3.4.1.2 Gender comparisons 




Test-1 57 45 
Test-2 42 43 
0.645 
Control-1 42 57 
Control-2 15 11 
0.164 
Control-3 73 46 




3.4.1.3 Mean age comparisons 
Table 3. 5 Mean age of patients in each group 
Type Number Mean (years) P value 
Test-1 102 10.72 
Test-2 105 11.04 
0.437 
Control-1 99 14.01 
Control-2 26 14.40 
0.556 




Age in years 









Table 3. 6 Comparison of mean age of patients between test and control groups 
Type Number Mean (years) P value 
Test-1 102 10.72 
Control-1 99 14.01 
0.000 
Test-2 102 10.72 
Control-2 26 14.40 
0.000 
Test-1 102 10.72 
Control-3 119 11.30 
0.196 





Age in years 




3.4.2 Diagnoses and Histopathology  
3.4.2.1 Principal diagnosis  
The principal diagnosis of all the patients is summarized in the Tables 3.7-
3.9.Appendicitis was diagnosed in 56% of patients in test-1&2, 40% in control-1&2 and 
60% in controls-3&4 groups and acute appendicitis in 21% of patients in test-1&2, 57% 













Table 3. 7 Principal diagnosis of appendectomy patients in test-1&2 hospitals 
Test-1* Test-2* Diagnosis 
Female Male Female Male 
Total 
Appendicitis 32 35 23 27 117 
Acute appendicitis 5 10 11 18 44 
Appendicitis with peritonitis 1 2 - 1 4 
Gangrenous appendicitis - 1 1 2 4 
Perforated appendicitis 3 6 2 3 14 
Acute suppurative appendicitis 4 3 - 6 13 
Acute and gangrenous appendicitis - - 1 - 1 
Acute inflamed appendix - - 4 2 6 
Acute perforated appendicitis - - 1 1 2 
Gangrenous and perforated appendicitis - - - 2 2 
Total 45 57 43 62 207 
*Number of patients 
 
 
Table 3. 8 Principal diagnosis of appendectomy patients in control-1&2 hospitals 
Control-1* Control-2* Diagnosis 
Female Male Female Male 
Total 
Appendicitis 22 12 7 9 50 
Acute appendicitis 35 30 2 5 72 
Acute and perforated appendicitis - - 1 - 1 
Acute suppurative appendicitis - - 1 1 2 
Total 57 42 11 15 125 





Table 3. 9 Principal diagnosis of appendectomy patients in control-3&4 hospitals 
Control-3* Control-4* Diagnosis 
Female Male Female Male 
Total 
Appendicitis 29 42 25 27 123 
Acute appendicitis 6 14 6 11 37 
Appendicitis with peritonitis 1 - - 1 2 
Gangrenous appendicitis 1 1 1 4 7 
Perforated appendicitis 5 13 4 7 29 
Acute suppurative appendicitis 1 - - 4 5 
Acute and gangrenous appendicitis - - - 1 1 
Acute suppurative and perforated - 1 - - 1 
Acute perforated appendicitis 1 2 - 1 4 
Gangrenous and perforated appendicitis 1 - - 1 2 
Appendix with faecolith 1 - - 1 2 
Acute inflamed appendix - - 1 - 1 
Chronic appendicitis - - - 2 2 
Other complications - - 4 4 8 
Total 46 73 41 64 224 
*Number of patients 
 
 
3.4.2.2 Histopathology descriptions 
It was found that 14% of the patients in test-1&2 & control-3&4 and 10% in control-1&2 
groups who were diagnosed as appendicitis were found to have a normal appendix. The 






Table 3. 10 Histopathology descriptions of test-1&2 groups 
Test-1* Test-2* Appendix pathology 
Female Male Female Male 
Total
Normal appendix 6 8 8 7 29 
Suppurative appendicitis - 2 4 11 17 
Appendix with perforation 1 1 1 - 3 
Gangrenous appendicitis 1 1 2 - 4 
Appendix with pin worms 3 2 3 - 8 
Appendix with faecolith 1 - - - 1 
Acute appendicitis 19 27 7 5 58 
Acute appendicitis with peritonitis 3 1 - - 4 
Gangrenous appendix with peritonitis 1 2 - - 3 
Suppurative appendicitis with peritonitis 7 7 - - 14 
Acute appendicitis with pin worms 1 - - - 1 
Gangrenous appendicitis with perforation and 
peritonitis 
- 1 - - 1 
Acute and gangrenous appendicitis - 1 2 5 8 
Peritonitis appendicitis with pin worms - 1 - - 1 
Gangrenous appendicitis with perforation - - 2 2 4 
Gangrenous and suppurative appendicitis with 
peritonitis 
1 - - - 1 
Acute inflammation and perforation 1 - - - 1 
Acute inflammation with peritonitis - - - 1 1 
Acute appendicitis with perforation 1 - - 1 2 
Acute inflamed appendicitis - - - 2 2 
Acute suppurative appendicitis - - 7 18 25 
Minor changes of uncertain significance - - 1 2 3 
Data not available - 2 6 8 16 
Total 45 57 43 62 207 
*Number of patients 
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Table 3. 11 Histopathology descriptions of control-1&2 groups 
Control-1* Control-2* Appendix pathology 
Female Male Female Male 
Total
Normal appendix 10 2 - - 12 
Acute and gangrenous appendicitis - 1 - - 1 
Acute appendix - 2 - - 2 
Appendix with acute inflammation 1 2 - - 3 
Appendix with acute inflammation and pin 
worms 
1 - - - 1 
Acute suppurative appendicitis with 
perforation 
- 1 - - 1 
Acute suppurative appendicitis 40 28 2 - 70 
Appendix with faecolith - 1 - - 1 
Appendix with pin worms - 1 - - 1 
Gangrenous appendicitis - 3 - - 3 
Perforated appendix 1 - - - 1 
Data not available - 1 13 11 25 
Total 42 57 15 11 124 












Table 3. 12 Histopathology descriptions of control-3&4 groups 
Control-3* Control-4* Appendix pathology 
Female Male Female Male 
Total
Normal appendix 6 5 12 8 31 
Acute appendicitis with inflammation 1 1 - - 2 
Acute appendicitis with perforation 2 3 1 - 6 
Acute appendicitis 4 20 6 9 39 
Acute appendix with pin worms 1 - - - 1 
Acute inflammation 3 3 - - 6 
Acute inflammation and necrosis - 2 - - 2 
Acute inflammation and perforation 3 1 - - 4 
Acute suppurative appendicitis 8 6 6 19 39 
Gangrenous and suppurative appendicitis - 1 - - 1 
Gangrenous appendicitis with perforation 3 12 3 4 22 
Gangrenous appendicitis 5 6 6 8 25 
Necrosis & perforation 4 - - - 4 
Suppurative appendicitis with perforation 3 2 - 1 6 
Suppurative appendicitis 3 7 - 6 16 
Acute suppurative appendicitis with 
perforation 
- - 1 - 1 
Appendix with pin worms and mild 
inflammation 
- - 2 1 3 
Appendix with mild inflammation - - 1 1 2 
Suppurative appendicitis with acute 
inflammation 
- - 1 - 1 
Suppurative appendicitis with pin worms - - - 1 1 
Data not available 1 3 2 6 12 
Total 46 73 41 64 224 
*Number of patients 
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3.4.3 Theatre and ward antibiotics 
3.4.3.1 Theatre antibiotic choices 
Six different types of inappropriate prophylactic antibiotic regimens were prescribed in 
test-1, which was reduced to three inappropriate regimens in test-2, 7 to 2 from control-1 
to control-2, and 5 in both control-3&4 groups. Prophylactic antibiotic administration in 
test and control groups is summarized in the Tables 3.13-3.15.  
 
 
Table 3. 13 Prophylactic antibiotic administration in test-1&2 hospitals 
Drug/s prescribed Test-1* Test-2* 
Metronidazole 24 6 
Ceftriaxone 4 6 
Cefotaxime 3 - 
Metronidazole + Ceftriaxone 44 - 
Metronidazole + Cefotaxime 8 - 
Metronidazole + Cephamandole 1 - 
Cefotetan - 68 
Timentin - 7 
No prophylaxis 18 18 
Total 102 105 










Table 3. 14 Prophylactic antibiotic administration in control-1&2 hospitals 
Drug/s prescribed Control-1* Control-2* 
Cefotetan 14 7 
Metronidazole 2 4 
Cephalothin 1 - 
Amoxicillin 1 - 
Ceftriaxone 2 - 
Cephazolin 5 1 
Cefotetan + Metronidazole 13 3 
Metronidazole + Cephazolin 15 - 
Cephazolin + Metronidazole 1 5 
Cefotaxime + Metronidazole 1 - 
Metronidazole + Ceftriaxone 26 - 
Metronidazole + Amoxicillin + Gentamicin 1 1 
Cefotetan + Cefotaxime + Metronidazole 1 - 
Cephazolin + Amoxicillin + Gentamicin + 
Metronidazole 
1 - 
No prophylaxis 14 5 
Total 99 26 












Table 3. 15 Prophylactic antibiotic administration in control-3&4 hospitals 
Drug/s prescribed Control-3* Control-4* 
Amoxicillin 1 1 
Gentamicin 6 - 
Cephazolin 8 14 
Metronidazole 7 10 
Metronidazole + Cephazolin + Gentamicin 3 3 
Amoxycillin + Gentamicin + Metronidazole 7 2 
Cephazolin + Metronidazole 50 47 
Gentamicin + Metronidazole 2 1 
Amoxycillin + Metronidazole 2 2 
Amoxycillin + Metronidazole + Cephazolin 1 - 
Ampicillin + Gentamicin + Metronidazole - 4 
Benzylpenicillin + Metronidazole + Gentamicin - 2 
Amoxicillin + Gentamicin - 1 
No prophylaxis 32 18 
Total 119 105 
*Number of patients 
 
 
3.4.3.2 Theatre antibiotic choice comparisons 
The number of patients receiving appropriate theatre antibiotics choice based on 
guidelines in test-1 was nil, control-1 46, and control-3 63. There was a significant 
improvement in the prescribing of appropriate theatre antibiotics in test-2 group patients 
following the intervention (p < 0.001), and neither of the control pairs (control-2 and 4) 














Test-1  84 18 102 
Test-2 72 15 18 105 
Total 72 99 36 207 
P value 0.000 
     
Control-1 46 39 14 99 
Control-2 16 5 5 26 
Total 62 43 19 124 
P value 0.187 
     
Control-3 63 24 32 119 
Control-4 56 29 20 105 
Total 119 53 52 224 
P value 0.248 
*Number of patients 
 
 
3.4.4 Comparison of prescribing of cephalosporin antibiotics before and after the 
release of health department circular in test-1 and control-1 groups 
During the pre-intervention study a Health Department circular was released to all 
hospitals in Western Australia on 8th March 2001. It proposed, “supply of third 
generation cephalosporins (particularly ceftriaxone) to operating theatres should cease 
wherever possible, and that their use for surgical prophylaxis in operating theatres and for 
the purpose of peri-operative antibiotic prophylaxis use should be avoided”. An 
evaluation of its effect in the pre-intervention period in test-1 was 35/77 (45.5%) patients 
were prescribed ceftriaxone prior to the circular and 13/25 (52%) following its release 
(p=0.367). In control-1 there were 23/72 (32%) patients prescribed it prior to the circular 
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and 6/27 (22.2%) following the its release (p=0.245). Both groups did not show any 
significant change (p>0.05) (Table 3.17). 
 
 
Table 3. 17 Comparison of prescribing of cephalosporin antibiotics before and after 
the release of health department circular Test-1 and Control-1 
Control-1 Test-1 Category 
Before After Before After
Number of patients on cefotaxime 1 1 9 2 
Number of patients on ceftriaxone 23 6 35 13 
Number of patients on appropriate prophylaxis 33 14 0 0 
Number of patients on inappropriate prophylaxis 28 10 65 19 
Number of patients on no antibiotic prophylaxis 11 3 12 6 
Total number of patients in the study 72 27 77 25 
% of patients on third generation cephalosporins 
among patients prescribed antibiotics 
39.3 29.1 67.6 78.9 
 
 
3.4.5 Comparison of patients on unnecessary prophylactic antibiotics between test 
and control groups 
The number of patients on unnecessary (not recommended) prophylactic antibiotic doses 
other than inappropriate antibiotics prescribed were 52 in test-1, 45 in control-1 and 13 in 
control-3 and changed to 0 in test-2, 4 in control-2, and 13 in control-4 groups (Table 
3.18). There was a significant improvement from test-1 and control-1 to test-2 and 






Table 3. 18 Comparison of patients on unnecessary prophylactic antibiotic doses 
Antibiotic Test-1 Test-2 Control-1 Control-2 Control-3 Control-4 
Ampicillin      4 
Amoxicillin   2 1 10 2 
Benzylpenicillin      2 
Cefotaxime   1    
Gentamicin   1  3 3 
Metronidazole 52  41 3   
Total* 52  45 4 13 13 
*Number of patients 
 
 
Table 3. 19 Prescribing pattern of unnecessary prophylactic antibiotic doses in the 
total doses 




















3.4.6 Theatre antibiotic doses 
The number of theatre antibiotic doses prescribed out of the total number of patients on 
theatre antibiotics was 137/84 (1.6) in test-1, 148/85 (1.7) in control-1, 163/87 (1.8) in 
control-3 changed to 87/87 (1) in test-2, 31/21 (1.4) in control-2 and 160/87 (1.8) in 
control-4 group following the intervention (Table 3.20). 
 
 
Table 3. 20 Number of theatre antibiotic doses out of number of patients on theatre 
antibiotics 












Test-1 137 84 1.6 
Test-2 87 87 1 
<0.001 
Control-1 148 85 1.7  
Control-2 31 21 1.4  
Control-3 163 87 1.8  




3.4.7 Ward antibiotic choice comparisons 
There was a significant improvement in the prescribing of appropriate ward antibiotic 
choices from 49/102 to 89/105 patients in test-1&2 (p < 0.001) and a non-significant 






Table 3. 21 Comparison of ward antibiotics between test and control groups 







Test-1 49 40 13 102 
Test-2 89 4 12 105 
Total 138 44 25 207 
P value 0.000 
     
Control-1 24 17 58 99 
Control-2 9 8 9 26 
Total 33 25 67 125 
P value 0.084 
     
Control-3 91 6 22 119 
Control-4 75 3 27 105 
Total 166 9 49 224 
P value 0.335 
*Number of patients 
 
 
3.4.8 Total antibiotic choice comparisons 
None of the patients were on appropriate total antibiotic choices in test-1, 8 in control-1 
and 43 in control-3 with a significant improvement as was evident in test-2 (p < 0.001) 







Table 3. 22 Comparison of total antibiotic choices between test and control groups 







Test-1  100 2 102 
Test-2 60 42 3 105 
Total 60 142 5 207 
P value 0.000 
     
Control-1 8 86 5 99 
Control-2 6 20  26 
Total 14 106 5 125 
P value 0.058 
     
Control-3 43 73 3 119 
Control-4 40 62 3 105 
Total 83 135 6 224 
P value 0.937 














3.4.9 Antibiotic dosage  
3.4.9.1 Individual theatre antibiotic dosage 
Individual theatre drug dosage appropriateness was summarized in Tables 3.23-3.25.  
 
 
Table 3. 23 Theatre antibiotic dosage appropriateness in Test-1&2 groups 
Drug name Test-1 Test-2 
Cefotaxime Appropriate 6 1 
 Inappropriate 5 - 
Ceftriaxone Appropriate 10 4 
 Inappropriate 39 1 
Metronidazole Appropriate 51 11 
 Inappropriate 25 1 
Cefotetan Appropriate - 67 
 Inappropriate - 3 
Timentin Appropriate - 12 
 Inappropriate - - 
Gentamicin Appropriate - 5 
 Inappropriate - 1 
Cephamandole Appropriate 1 - 
 Inappropriate - - 
Amoxycillin Appropriate - 1 






Table 3. 24 Theatre drugs dosage appropriateness in control-1&2 groups 
Drug name Control-1 Control-2 
Amoxycillin Appropriate 1 - 
 Inappropriate 2 1 
Cefotaxime Appropriate 2 - 
 Inappropriate  - 
Cefotetan Appropriate 6 6 
 Inappropriate 23 - 
Ceftriaxone Appropriate 27 - 
 Inappropriate 2 - 
Cephalothin Appropriate - - 
 Inappropriate 2 - 
Cephazolin Appropriate 19 6 
 Inappropriate 2 - 
Gentamicin Appropriate 2 1 
 Inappropriate - - 
Metronidazole Appropriate 59 13 














Table 3. 25 Theatre drugs dosage appropriateness in control-3&4 groups 
Drug name Control-3 Control-4 
Amoxycillin Appropriate 10 3 
 Inappropriate 1 4 
Cephazolin Appropriate 48 40 
 Inappropriate 14 22 
Gentamicin Appropriate 11 7 
 Inappropriate 7 6 
Metronidazole Appropriate 59 44 
 Inappropriate 13 25 
Ampicillin Appropriate - 2 
 Inappropriate - 1 
Benzylpenicillin Appropriate - 2 
 Inappropriate - - 
 
 
3.4.5.2 Total theatre antibiotic dosage comparisons 
Appropriate theatre antibiotic dosages were increased from 68/137 to 100/106 
prescriptions in the test groups (p < 0.001), and a significant diminution in the 
appropriateness of antibiotic dosage prescribing was seen in control groups 1&2 and 3&4 











Table 3. 26 Comparison of theatre antibiotic dosages between test and control 
groups 
Category Appropriate antibiotic dosage Inappropriate antibiotic dosage Total 
Test-1 68 69 137 
Test-2 100 6 106 
Total 168 75 243 
P value 0.000  
    
Control-1 118 38 156 
Control-2 30 1 31 
Total 148 39 187 
P value 0.020  
    
Control-3 128 35 163 
Control-4 99 58 157 
Total 227 93 320 















3.4.5.3 Individual ward antibiotic dosage 
Individual ward drug dosage appropriateness is summarised in Tables 3.27-3.29.  
 
Table 3. 27 Ward drugs dosage appropriateness in test-1&2 groups 
Drug name Test-1 Test-2 
Amoxycillin Appropriate 17 (40)* 12 (27) 
 Inappropriate 13 (33) 7 (21) 
Augmentin Appropriate 2 (2) 5 (6) 
 Inappropriate 4 (4) 2 (3) 
Cefotaxime Appropriate 40 (98) 6 (10) 
 Inappropriate 9 (18) - 
Ceftriaxone Appropriate 16 (16) 26 (29) 
 Inappropriate 87 (90) 1 (1) 
Gentamicin Appropriate 7 (7) 42 (42) 
 Inappropriate 20 (20) 1 (3) 
Metronidazole Appropriate 33 (120) 51 (100) 
 Inappropriate 60 (369) 33 (68) 
Timentin Appropriate - 226 (589) 
 Inappropriate - 10 (25) 
Cephalexin Appropriate - 3 (5) 
 Inappropriate 6 (11) - 
Cephalothin Appropriate - - 
 Inappropriate 3 (7) 1 (1) 
Cefotetan Appropriate - 3 (3) 
 Inappropriate - - 





Table 3. 28 Ward drugs dosage appropriateness in control-1&2 groups 
Drug name Control-1 Control-2 
Amoxycillin Appropriate - 4 (26)* 
 Inappropriate 17 (40) 2 (7) 
Augmentin Appropriate 1 (1) - 
 Inappropriate 9 (13) - 
Cefotetan Appropriate - 1 (6) 
 Inappropriate 4 (6) - 
Ceftriaxone Appropriate 41 (41) 6 (19) 
 Inappropriate 1 (1) - 
Cephalexin Appropriate 5 (8) - 
 Inappropriate 5 (12) - 
Cephazolin Appropriate 5 (10) 1 (4) 
 Inappropriate - 1 (2) 
Gentamicin Appropriate 13 (13) 2 (2) 
 Inappropriate - - 
Metronidazole Appropriate 74 (117) 13 (57) 
 Inappropriate 20 (38) 4 (22) 
Roxithromycin Appropriate - 1 (5) 
 Inappropriate - - 
Timentin Appropriate - 1 (4) 
 Inappropriate - - 









Table 3. 29 Ward drugs dosage appropriateness in control-3&4 groups 
Drug name Control-3 Control-4 
Amoxycillin Appropriate 37 (272)* 6 (56) 
 Inappropriate 18 (162) 8 (41) 
Cefotaxime Appropriate 4 (62) 3 (24) 
 Inappropriate - - 
Cephalexin Appropriate 14 (41) 5 (8) 
 Inappropriate 2 (4) - 
Cephazolin Appropriate 63 (525) 43 (412) 
 Inappropriate 32 (294) 20 (188) 
Gentamicin Appropriate 43 (137) 19 (78) 
 Inappropriate 13 (29) 7 (24) 
Metronidazole Appropriate 68 (371) 27 (199) 
 Inappropriate 95 (704) 60 (497) 
Penicillin Appropriate 2 (36) - 
 Inappropriate 1 (3) - 
Augmentin Appropriate 2 2 (3) 
 Inappropriate 12 - 
Flucloxacillin Appropriate 21 - 
 Inappropriate - - 
Ampicillin Appropriate - - 
 Inappropriate - 1 (3) 
Benzylpenicillin Appropriate - 7 (46) 
 Inappropriate - - 
Ceftazidime Appropriate - - 
 Inappropriate - 1 (35) 
Cephalothin Appropriate - 1 (3) 
 Inappropriate - - 
Clindamycin Appropriate - 1 (1) 
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 Inappropriate - - 
Timentin Appropriate - - 
 Inappropriate - 1 (14) 
*Sum of doses are in the parenthesis 
 
 
3.4.5.4 Total ward antibiotic dosage comparisons 
The frequency of appropriate ward antibiotic dosages significantly increased in the test 
groups from 492/947 (52%) to 970/1047 (92.6%) and no significant change was noticed 
in control-1&2 from 392/491 (79.8%) to 70/81 (86.4%) and a statistically marginal 
improvement in control-3&4 from 525/750 (70%) to 320/454 (70.5%) (Table 3.30). 
 
Table 3. 30 Comparison of ward antibiotic dosage between test and control groups 
Category No. of appropriate antibiotic 
dosages 
No. of inappropriate antibiotic 
dosages 
Total 
Test-1 492 455 947 
Test-2 970 77 1047 
Total 1462 532 1994 
P value 0.000  
    
Control-1 392 99 491 
Control-2 70 11 81 
Total 462 110 572 
P value 0.378  
    
Control-3 525 225 750 
Control-4 320 134 454 
Total 845 359 1204 




3.4.5.5 Total antibiotic dosage comparisons 
The total antibiotic dosages (theatre and ward antibiotic dosage together) were 
significantly improved in test-1&2 and significantly decreased in control-1&2 groups and 
no effect was noticed in control-3&4 groups (Table 3.31).  
 
 
Table 3. 31 Comparison of total antibiotic dosage between test and control groups 
Category No. of patients on 
appropriate total antibiotic 
dosage 
No. of patients on 
inappropriate total antibiotic 
dosage 
Total 
Test-1 - 89 89 
Test-2 60 43 103 
Total 60 132 192 
P value 0.000  
    
Control-1 9 85 94 
Control-2 7 19 26 
Total 16 104 120 
P value 0.033  
    
Control-3 14 102 116 
Control-4 4 99 103 
Total 18 201 219 
P value 0.084  
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3.4.6 Total appropriateness 
Patients achieving total appropriateness were 0/102 in test-1, 0/99 control-1 and 7/119 in 
control-3 changed to 46/105 in test-2 and 4/26 in control-2 and 1/105 in control-4. There 
was a statistical significant improvement was found in both test-1&2 and control-1&2 
groups (Table 3.32). 
 
 
Table 3. 32 Comparison of total appropriateness between test and control groups 
Category No. of patients on total 
appropriateness 
No. of patients on total 
inappropriateness 
Total 
Test-1  100 100 
Test-2 46 57 103 
Total 46 157 203 
P value 0.000  
    
Control-1  94 94 
Control-2 4 22 26 
Total 4 116 120 
P value 0.000  
    
Control-3 7 110 117 
Control-4 1 102 103 
Total 8 212 220 




3.4.7 Prescribing pattern of choice and dosage of antibiotics during the post-
intervention period 
There was no significant difference in the prescribing pattern of choice and dosage of 
theatre and ward antibiotic during the five month post-intervention study period in Test-
2. Bonferroni method was used to control the alpha level for multiple comparisons. The 
data was summarised in the Table 3.33. 
 
 
Table 3. 33 Monthly comparison of choice and dosage of theatre and ward antibiotic 
during the post-intervention period 








App 15 16 20 1 December 
01 Inapp 5 1  2 
App 14 17 16 4 January 02 
Inapp 3 2 1 3 
App 20 25 25 4 February 02 
Inapp 5   6 
App 12 21 13 3 March 02 
Inapp 3 1 2 2 
App 9 10 8 1 April 02 
Inapp 1  2 1 
P value 0.909 0.483 0.088 0.904 






3.4.8 Mean length of stay 
The mean length of stay was 3.34 days in test-1, 3.83 in test-2, 2.27 in control-1, 2.65 in 
control-2, 4.4 in control-3 and 4.2 days in control-4 groups. There was no significant 
difference in the mean length of stay between test-1&2 (p = 0.139), control-1&2 (p = 
0.102) and control-3&4 groups (p = 0.610) (Table 3.33). The mean length of stay 
between test-1&2 between perforated appendices 8.4 and 5.5 days (p = 0.289), 
gangrenous and/or perforated appendices 5.8 and 4.9 days (p = 0.518) and normal 
appendices 2.9 and 4.5 days (p = 0.121) is summarised in the Table 3.34. 
 
 
Table 3. 34 Total mean length of stay in days in each group 
Type Number Mean (days) P value 
Test-1 102 3.34 
Test-2 105 3.83 
0.139 
Control-1 99 2.27 
Control-2 26 2.65 
0.102 




Length of stay 
in days 













A significant different in the length of stay was found between patients identified as 
gangrenous and/or perforated and normal appendices in Test-1 (p = 0.025) and no 
significant difference in Test-2 (p = 0.733) was found. 
 
Table 3. 35 Comparison of mean of length of stay in different pathologies of 
appendix 
Category Groups Number Mean (days) P value
Test-1 14 2.9 Normal appendix 
Test-2 15 4.5 
0.121 
Test-1 5 8.4 Perforated appendix 
Test-2 6 5.5 
0.289 
Test-1 12 5.8 Gangrenous and/or perforated appendix 




3.4.9 Analgesic dosage 
3.4.9.1 Individual ward analgesic dosage  
Most of the patients were on paracetamol and/or paracetamol with codeine analgesics. 
Few patients were on ibuprofen alone or in combination with paracetamol and / or 











Table 3. 36 Analgesic dosage appropriateness in test and control groups 







Appropriate 63 (217)* 15 (65) 25 (97) 13 (54) 43 (112) 
Inappropriate 20 (80) 32 (97) 3 (10) 8 (31) - 
Test-2 
Appropriate 90 (511) 34 (111) 22 (90) 31 (111) 67 (222) 
Inappropriate 2 (2) 7 (17) 3 (11) 2 (6) 2 (3) 
Control-1 
Appropriate 57 (201) 13 (39) 19 (69) 27 (102) 9 (24) 
Inappropriate 14 (40) 6 (9) 4 (11) 2 (4) - 
Control-2 
Appropriate 21 (93) 6 (25) 2 (7) 5 (14) 5 (9) 
Inappropriate 2 (3) 1 (3) - 1 (5) - 
Control-3 
Appropriate 81 (849) - 1 (2) - 19 (62) 
Inappropriate 51 (527) - - - 1 (7) 
Control-4 
Appropriate 80 (765) - - - 28 (58) 
Inappropriate 33 (281) - - - 2 (2) 










3.4.9.2 Total ward analgesic dosage comparisons 
Analgesics dosage prescribing was significantly improved from 159/222 (71.6%) to 
244/260 (94%) doses following the intervention in test-1&2 (p < 0.001) and non-
significant from 125/151 (82.8%) to 38/42 (90.5%) in control-1&2 and 101/153 (66%) to 
108/143 (75.5%) in control-3&4 groups (p > 0.05) (Table 3.37). 
 
 




Test-1 159 63 
Test-2 244 16 
0.000 
Control-1 125 26 
Control-2 38 4 
0.205 
Control-3 101 52 




3.5.0 Microbiology results 
3.5.1 Number of patient’s culture results positive 
There were seven patients cultured positive with 7 different microorganisms in test-1 and 
17 with 33 in test-2, 9 with 12 in control-1, 1 with 1 in control-2, 21 with 29 in control-3 








Table 3. 38 Number of patients culture results positive 









3.5.2 Profile of organisms identified 













Gram-positive 2 11 1 - 2 6 
Gram-negative 1 9 2 1 15 13 
Anaerobe/s 3 10 1 - 6 8 
Mixed aerobes and 
anaerobes 
1 3 8 - 6 5 
Total* 7 33 12 1 29 32 




3.6.1 Patient demographics 
There was no significant difference between patient demographic statistics within each 
group. But there was a significant difference in the mean age of patients between Test-
1&2 and Control-1&2 groups, giving concerns of a varied population effect. And also, 
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there was a significant difference in the number of patients included between Control-
1&2 groups. These were the only possible comparable populations available in Western 
Australia. Hence, a second control group (control-3&4) was identified in Victoria, which 
had similar patient characteristics to Test-1&2 groups. 
 
 
Surgeons at PMH also practice at several other hospitals in Western Australia. This made 
it difficult to evaluate the impact of an intervention at PMH without a contaminated 
control group. Even though most of the surgeons at FH were different from PMH, the 
number of pediatric patients admitted for appendectomy surgery was much lower than 
PMH and they were more mature. This created a problem of insufficient and unmatched 
patient numbers. The investigators identified RCH located distant from PMH. This group 
would control for national influences on antibiotic prescribing during the study. 
 
 
3.6.2 Diagnosis and Histopathology 
The diagnosis of normal pathology in this study was 10 - 14%, which is in the similar to 
other studies of 10 - 30% [2]. Prompt treatment of appendicitis is important in preventing 
further morbidity and mortality; a margin of error in over diagnosis is acceptable. In this 
study, 13.8 – 20.6% of females (Test-1&2: 15.9%, Control-1&2: 13.8% and Control-
3&4: 20.6%) and 3.7 – 12.6% of males (Test-1&2: 12.6%, Control-1&2: 3.7% and 
Control-3&4: 9.48%) had appendix specimens removed, which were histologically 
normal. This supports the Harding findings that pain from females is more likely to be 
misdiagnosed than for males[53]. He reported that 62% of appendix specimens removed 
from females aged 11-20 were histologically normal, and although he accepted that pain 
from the ovary might mimic appendicitis, he believed there might be a large 
psychological element because of the important changes that occur in the lives of females 




The perforated appendix prevalence varied from 2 - 20% in this study (Test-1&2: 5.7%, 
Control-1&2: 2% and Control-3&4: 20.2%). This is in the lower end of the published 
studies, which are 30-45% [2]. The histopathological findings by a microbiologist (Test-
1&2: 14.1%, Control-1&2: 6.25% and Control-3&4: 32.5%) of gangrenous and/or 
perforated appendicitis was higher than actual diagnosis (Test-1&2: 11.1%, Control-1&2: 
0.8% and Control-3&4: 19.6%) by physicians in the test as well as in control groups in 
this study.  
 
 
Appendiceal rupture accounts for a majority of the complications of appendicitis. Factors 
that increase the rate of perforation are delayed presentation to medical care, age, and 
hidden location of appendix. Brief periods of in-hospital observation potentially improve 
the diagnostic accuracy. Appendicitis poses special difficulties in young children due to 
their being unable to relate a history, often have abdominal pain from other causes and 
may have more non-specific signs and symptoms[6]. These factors contribute to a 
perforation rate as high as 50% in children[55]. 
 
 
Koepsell [56] and Arnbjornsson [57] noted the incidence of perforation to be firmly 
related to the duration of the pre-admission stage of illness, but not to the length of the 
post-admission stage. White et al. [58] have suggested that hospital observation of 
children in whom the diagnosis of appendicitis is uncertain can improve the diagnostic 
accuracy of appendicitis and safely reduce the incidence of negative laparotomies without 
increasing perforation. Ravitch [59], on the other hand, argues for prompt surgery “on 
every child with abdominal pain in whom tenderness, preferably right lower quadrant, 
can be elicited…provided there is nothing in the history, in the physical examination, or 
in the laboratory studies that is incompatible with the diagnosis [60].” 
 
 
A delay in treatment of more than 36 hours after parents first noticed abdominal pain was 
associated with a 65% or greater incidence of perforation in children. This association 
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underlines the importance of a high index of suspicion of childhood appendicitis. Parents 
need to be educated regarding abdominal pain and its related diseases. This potentially 
reduces the number of perforations with prompt treatment for the patient [60]. 
 
 
Seventy years ago, the mortality rate for patients with perforated appendix was 10 to 20% 
[61, 62]; one death for every 940 children in 1960’s and it decreased to 0.1% in the 
1990’s [63]. In this study, none of the patients died due to appendicitis in the test and 
control groups. The risk of death from a perforated appendix has now decreased 
dramatically, but the morbidity rate remains high. 
 
 
3.6.3 Theatre and Ward antibiotics 
Some 84/102 patients were prescribed non-recommended antibiotic prophylaxis in the 
Test-1 group, of them, 52 patients were prescribed ceftriaxone or cefotaxime and 
metronidazole. Metronidazole’s activity is only against anaerobes, ceftriaxone and 
cefotaxime cover both Gram-positive and Gram-negative organisms, and each of the 
three drugs individually or in combination is considered an inappropriate choice for 




According to a study conducted by the Western Australian Drugs and Therapeutics 
Committee, the Health Department developed recommendations for prophylaxis in 
surgical procedures are cephalothin (with metronidazole) or cefotetan. They proposed, 
“supply of third generation cephalosporins (particularly ceftriaxone) to operating theatres 
should cease wherever possible, and that their use for surgical prophylaxis in operating 
theatres and for the purpose of peri-operative antibiotic prophylaxis use should be 
avoided”. The committee also stated that use of third generation cephalosporins in non-
approved indications significantly increased the probability of organisms to exhibit 
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multiple antibiotic resistance will emerge, particularly vancomycin-resistant enterococci. 
In this study, we found that 59/102 (57.8%) of the patients that were on prophylactic 
antibiotics in the test-1 group were on third generation cephalosporins.  
 
 
This circular issued in Western Australia during the pre-intervention phase did not show 
any impact on the prescribing behaviour of the surgeons evaluated in the pre-intervention 
group in PMH and FH, located in Western Australia. The number of patients on third 
generation cephalosporins (cefotaxime and ceftriaxone) among patients prescribed 
antibiotics for surgical prophylaxis was 23/72 (32%) before the release of the circular and 
changed to 6/27 (22%) after the circular in control-1 and 35/77 (45%) before and 13/25 
(52%) after in test-1 group patients (Table 3.17). However, following the introduction of 
local treatment guidelines and implementation of the educational intervention programme 
in this study, 6/87 (7%) of the patients on antibiotics were on the third generation 
cephalosporin (ceftriaxone) in test-2 and 0/21 and in control-2. However, there was no 
significant improvement in control-2 in the prescribing of appropriate theatre antibiotics. 
This supports that locally developed guidelines are more likely to be accepted and 
followed than those developed regionally or nationally without local input. 
 
 
The level of pre and post-operative non-recommended antibiotic combinations prescribed 
was common before the introduction of the intervention. These occurrences were 
significantly reduced following the intervention for the test group (Table 3.13). The 
number of prophylactic antibiotic doses prescribed was significantly reduced and equaled 
the number of patients in test-2 compared with the test-1 group. This was in accordance 
with the guidelines recommending a single dose of cefotetan as prophylaxis. This reduces 
the cost of antibiotics, administration costs, nursing, pharmacist and surgeon’s time and 




There was a significant reduction in the number of patients on unnecessary prophylactic 
antibiotic doses following the intervention in test-2 and also in the control-2 group. Due 
to the low sample size in control-2 and the p value (p=0.047) although slightly lower than 
0.05, it cannot be considered a clinically significant change. No significant change was 
observed in control-4 compared to control-3 group (Table 3.19). This shows clearly that 
the intervention had an impact on this aspect of the prescribing behaviour of surgeons. 
 
 
There was a significant improvement in the prescribing of post-operative and total 
antibiotic choices following the intervention in this study. The number of patients on 
appropriate total antibiotic dosage was improved from zero to 57% (60/105). Several 
studies have evaluated drug usage in children[64-69], and in pediatric appendectomy[70-
72], but none of the studies considered dosage prescribing appropriateness in children. 
Our study has identified that pharmacist intervention can influence drug dosage-
prescribing appropriateness of pediatricians in pediatric settings. This study is the first of 
its kind to be carried out in Australia or elsewhere to include dosages. 
 
 
The number of prophylactic antibiotic prescriptions on 26-50% below were 51/137, 26-
50% above the recommended dose were 18/137 in Test-1 which was decreased to 2/107 
on 26-50% below, 3/107 on 26-50% above, and one prescription on 76-100% above the 
recommended dose in Test-2. Sub-optimal dosing of antibiotics has two potential 
consequences: therapy failure and the possible emergence of resistance. High dosage can 
lead to unwanted side effects and unnecessary costs both to the patient and the society. 
The clinician has the ultimate responsibility to optimise the delivery of an appropriate 
antimicrobial agent to the site in concentrations that exceed those needed to inhibit the 
growth of the pathogen involved. Inappropriate use of antibiotics can lead to microbial 
resistance and may expose the patient to adverse effects. A continuously maintained 
bactericidal level of an antibacterial agent is particularly important for curing an infection 




3.6.4 Total appropriateness 
The total appropriateness of the prescribing was a combination of the following factors: 
(i) the surgeon prescribed an appropriate theatre antibiotic regimen (ii) an appropriate 
postoperative antibiotic regimen (iii) an appropriate theatre antibiotic dosage and (iv) an 
appropriate ward antibiotic dosage. In the pre-intervention test group (Test-1) none of the 
patients achieved total appropriateness, which changed to 22% in the post-intervention 
group (Test-2) following the extensive intervention undertaken (Table 3.32). It is a shared 
responsibility of the hospital including clinical pharmacists to maintain the local 
guidelines effectively in the long-term. 
 
 
3.6.5 Length of stay 
Patients in Test-1&2 stayed a day longer than Control-1&2, and a day less than Control-
3&4 groups, showing a significant difference. The mean length of stay for patients with 
normal appendices and acute appendicitis was 3.8 and 3.4 days, respectively. Patients 
with perforated appendicitis had a significantly longer hospital mean length of stay of 7.2 
days. A significant difference in the length of stay was found between patients identified 
as gangrenous and/or perforated and normal appendices in Test-1 and no significant 
difference in Test-2 was found showing probably that appropriate antibiotic 
administration reduced the hospital stay in patients identified as gangrenous and/or 
perforated appendices (Table 3.35). 
 
 
The mean length of stay of patients from Controls-1&2 was shorter and mean ages were 
higher than other groups. When a similar population (5.4 – 18 years) was compared 
across all the groups for mean length of stay there was a longer length of stay in the other 
groups compared to Controls-1&2. There was a significant difference between mean age 
Controls-1&2 and test groups (p < 0.001). When a normal population (0 – 18 years) is 
compared with a similar population as in Test-1&2 and Controls-3&4 for mean length of 
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stay and mean age showed no significant difference between them (p > 0.05) except in 
Control-4 where a significant change was just evident (p = 0.045). This is probably due to 
the different regimens of antibiotic prescriptions and varied patient conditions in the Test 
and Control groups. Some of this difference may relate to hospital policy or procedure 




The distribution of wound infections was not significantly affected by gender or age in 
this study. Intraoperative cultures were obtained for all patients in the study as a standard 
procedure at the hospital; one patient in each test group developed an infection and was 
readmitted to the hospital and another patient was readmitted due to pain. The infection 
results were irrespective of the diagnosis of the patient. Even though there was a 
difference in the pattern of antibiotic usage in the groups, no difference in the infection 
rate was found. The inappropriate antibiotics identified in the pre-intervention group 
however would be expected to be effective but were not an appropriate choice. The 
infection results were lower than reported by Hale et al. [73] on cultures obtained on 88 
patients, in whom a wound infection developed subsequently and the risk of a wound 
infection increased markedly with perforated appendicitis (6.4%) compared to the rate 
associated with normal appendices (1.8%) and acute appendicitis (1.4%), respectively. 
 
 
In this study, a small number of patients were identified with microorganisms 
(streptococcus sps 6.2%, mixed anaerobic 5.7%, aerobic 0.4%, E.coli 4.8%, 
pseudomonas 0.4% and mixed coliforms 0.4%) in perioperative samples in the test group, 
but according to the department of microbiology, those are not clinically significant. 
Those cultures were the reflection of the normal bowel flora. But, in a study by Hale et al 
[73], the spectrum of organisms identified from the cultures (no growth 23%, Escherichia 





This study found that most of the patients were prescribed paracetamol and/or 
paracetamol with codeine analgesics. Paracetamol is an analgesic widely used in children 
and does not induce nausea and vomiting. It has a good reputation for safety within the 
recommended dosage. The analgesic effect of paracetamol is directly related to its plasma 
concentration.[74] The addition of codeine gives a theoretical advantage of two 
analgesics with different mechanisms of action combined to enhance analgesia.[75] In a 
meta-analysis of 19 trials, De Craen et al.[76] found that the addition of codeine to 
paracetamol produced a 5% increase in analgesic effect. 
 
 
In this study, surgeons prescribed paracetamol 28/83 times 26-50% above and 35/83 
times 26-50% below the recommended dose in the test-1 group. It then decreased to 1/92 
times 26-50% above, 14/92 times 26-50% below and 1/92 times 50-75% below the 
recommended dose in test-2 group. High dosages of paracetamol potentially lead to 
toxicity and low dosages leads to preventable suffering of pain and potentially longer 
lengths of stay in the hospital.  
 
 
3.6.8 Intervention  
On the basis of this study, the majority of clinical and pharmacy departments have 
adopted drug utilisation programs which have resulted in the introduction of various 
strategies in an attempt to modify physician prescribing habits. These attempts can be 
generally classified as educational strategies.  
 
 
Girotti et al[77] reported on the introduction of a purely educational strategy in the form 
of an antibiotic handbook showed only a marginal improvement in the overall 
compliance with their recommendations on the surgical services. However, when they 
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introduced a control strategy through the use of a pre-printed physician order form in the 
perioperative period it resulted in a dramatic improvement in compliance with 
recommended antibiotic regimens. Employing a similar handbook, D’Eramo et al[78] 
reported a short-term improvement when their handbook was introduced into a hospital 
setting in an attempt to modify the patterns of physician drug use for empirical therapy. 
In this study, the compliance with the antibiotic guidelines was improved without any 
restrictions evident in the above studies. Clinical pharmacists in conjunction have 
developed the guidelines with clinical microbiologists and the division of surgical 
services. The multifaceted intervention consists of a newsletter, presentations, formal 
discussions, guidelines posters in ward and theatre and reminders by clinical pharmacists 
in the wards. Strategies, which involve all of the stakeholders, have been shown to the 
effective in other settings.[79, 80] 
 
 
One of the principal reasons for restrictive antibiotic policies is to preserve the 
effectiveness of a limited number of antibiotic drugs. The Malthusian prediction that 
antibiotic-resistant bacteria would develop more rapidly than the rate at which new 
antibiotic drugs could be manufactured has proved thus far to be untrue. In fact, the drug 
industry has outsmarted bacteria by producing new compounds at a much-faster rate than 
that at which bacteria have developed new mechanisms of resistance. Consequently, too 
many antibiotic drugs have been developed rather than too few, and this is an area where 
antibiotic guidelines have been useful. Where there are many antibiotic agents with 
similar names, overlapping properties and different dosage regimens and costs, it seems 
sensible to have restrictive antibiotic policies [81]. 
 
 
Review is an essential element of drug policies in hospitals, but as far as antibiotic agents 
are concerned such a review should include a reconciliation of the guidelines and usage 
with antibiotic resistance and cost. The application of antibiotic policies has resulted in 
improved practices and reduced costs. However, the advocates of such policies should be 
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Providing feedback to clinicians regarding their own antibiotic prescribing practices has 
been a successful technique for achieving behaviour change. Feedback can entail 
comparisons with peers or standards. As with practice guidelines, feedback may be most 
effective when the system is developed with local input, where clinicians accept the 
measures as important, fair, and relevant to their own practices.[79] 
 
 
The duration effect of the intervention during the five-month period of data collection 
following the implementation of intervention shows that there was no significant 
diminution of the effect of the intervention on the prescribing behaviour for theatre and 
ward antibiotic choices and theatre and ward antibiotic dosages. In a randomised 
controlled trial of academic detailing by Avorn and Soumerai[82], indicated that face-to-
face education of the practicing physician is an effective means of reducing less than 
optimal prescribing decisions and the differences in prescribing remained highly 
significant, with no sign of diminution in effect nine months after the start of the office-
based intervention.  
 
 
Ideally, the pharmacist should be involved in pursuing the above objectives through 
continually monitoring prescribing, providing information to new doctors and nurses and 
assisting in the process of drug use review. This will depend on improved communication 
with all newly arrived surgical and other related staff, and providing them with 





The introduction of local guidelines has resulted in improved practices. A multifaceted 
educational intervention by pharmacists can have a significant effect on surgeons 
prescribing. The choice and dosage of pre-operative and post-operative antibiotics and 
dosage of analgesics were significantly improved following a multifaceted intervention. 
Locally developed guidelines are more likely to be accepted and followed than those 
developed nationally without local input. There was no significant diminution of the 
effect of the intervention on the prescribing behaviour of surgeons during the five month 
post-intervention. Development of clinical practice guidelines should therefore be 
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Liquid Medication Dosing errors: A pre-post time series in India 
 
4.1 Introduction 
4.1.1 Medical errors 
Patient safety is a significant problem in health care. As we know medication-related 
problems are a significant cause of adverse medical events[1]. According to the Harvard 
Medical Practice Study, adverse drug events are more common than infectious 
complications in hospitals[2]. Most hospitals invest considerably more time and money in 
infection control than they do in improving medication safety[1]. It has been estimated 
that 44,000 to 98,000 people die each year as a result of medical errors. That is more than 
the number of people who die either from breast cancer, AIDS, or motor vehicle 
accidents in the U.S.A[3]. 
 
 
Adverse events are injuries arising from medical treatment. Not all adverse events are 
caused by errors; some result from differences among patients and their responses to 
treatment. However, about half of all adverse events are believed to be preventable[3]. In 
the past, an optimal therapeutic outcome has been defined as “the right drug, for the right 
patient, at the right time.” Currently an optimal therapeutic outcome also implies the 
absence of drug-related problems (DRPs). A DRP is defined as an event or circumstance 
involving patient’s drug treatment that actually or potentially interferes with the 
achievement of an optimal outcome. Unresolved DRPs may manifest as drug-related 
morbidity and, if left untreated, may eventually lead to drug related mortality[4].  
 
 
Information regarding the epidemiology and prevention of medication errors and adverse 
drug events (ADEs) in pediatric inpatient settings is scarce[5]. Children pose unique 
challenges to the system for ordering, dispensing, administering, and monitoring 
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medications. Kaushal et al[6] found that the errors with a potential for harm occurred most 
often in the youngest and most vulnerable patients. Drug dosages often must be 
calculated individually in children, leading to increased opportunities for error with a 
relatively high risk of 10-fold errors. Furthermore, weights can change rapidly and 
dramatically over time, especially in small infants, requiring frequent dosing re-
calculations. Medicine dispensing in children is complicated by the fact that stock 
solutions of medicines are often available only at adult concentrations and must be 
diluted for use in children. Children, particularly those who are young and critically ill, 
may be more prone to ADEs than adults because they have less physiologic reserve with 
which to buffer errors such as overdoses[7].  
 
 
Errors in the prescribing and management of drug therapy are common and have been 
identified as a major cause of adverse drug events. Understanding the many factors 
contributing to errors should assist in implementation of more effective error prevention 
strategies[8]. Leape et al[9] found lack of knowledge and lack of timely access to patient 
information to be the major root causes of medication prescribing errors. Many specific 
factors have been associated with prescribing errors including calculations of drug dose, 
errors in decimal points, medications with similar names, medication dosage forms, use 
of abbreviations, unusual routes of drug administration, uncommon dosage regimen 
frequencies, complicated dosage regimens, and poor patient history taking[8]. 
 
 
Poisoning in the small child is commonly equated with a toddler ingesting tablets 
belonging to someone else, generally a family member. The prospect of health 
professionals poisoning children is traumatic from various aspects, and perhaps this is 
one of the reasons this area has been sparsely researched[10]. 
 
 
In an anonymous written test conducted by Koren and Haslam to evaluate the 
performance in calculating pediatric drug dosages among neonatal and pediatric staff 
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found that on average 60% of them had calculation errors. About 6% of the errors were 
of tenfold magnitude, due to misplacing the decimal point[10]. Parents are an additional 
link between the prescribing physician, the pharmacist, and the patient, and medications 
are frequently administered to the child by parents without medical background. 
Moreover, there are only a few formulations available that are adapted for children[11]. 




In the United States, estimates of personal total expenditures for prescription medications 
in 1995 exceeded $77 billion{Grandis JR, 1992 #59}. Recent studies, indicate that the 
substantial costs associated with inappropriate drug use are likely to exceed the initial 
outlays for drug therapy. Johnson and Bootman[13] estimated the cost of drug-related 
morbidity and mortality in the ambulatory setting was $76.6 billion and that, with the 
provision of pharmaceutical care, this figure could be reduced to $45.6 billion[4]. 
 
 
It was estimated that approximately $3 billion was spent annually for drug therapy in 
nursing facilities, indicating that the estimated health care cost of drug-related morbidity 
and mortality exceeds the original outlay for drugs by $1 billion i.e., for every dollar 
spent on drugs, $1.33 is consumed in the treatment of drug related morbidity[4]. 
 
 
The total costs of preventable medical errors are in the range of $17 to $29 billion per 
year in hospitals in United States. Errors also are costly in terms of loss of trust in the 
health care system by patients and diminished satisfaction by both patients and health 
professionals. Patients who experience a long hospital stay or disability as a result of 
errors pay with physical and psychological discomfort. Health professionals pay with loss 
of morale and frustration at not being able to provide the best care possible. Society bears 
the cost of errors as well, in terms of lost worker productivity, reduced school attendance 




In a meta-analysis study Lazarou et al[15] estimated that 702,000 hospitalised patients 
experienced a serious adverse drug reaction (ADR) and 1,547,000 patients were admitted 
to hospitals due to ADRs in the United States. They calculated 106,000 deaths were 
caused by ADRs, which could account for 4.6% of the 2,286,000-recorded deaths from 
all causes during the study period. ADRs constituted the fourth leading cause of death in 
the United States, after hearth disease (743,460), cancer (529,904), stroke (150,108) 




Another meta-analysis study reported an overall incidence of 6.7% for serious adverse 
drug reactions. For every 1000 patients admitted to a hospital, approximately 3 will die 
and 1 will suffer serious long-term disability due to ADEs. The mean direct cost of an 
inpatient ADE ranges from $1900 to $5900[17]. 
 
 
According to the Harvard Medical Practice Study conducted on 30,000 inpatient 
hospitalisations found that ADEs were the most common type of adverse event 
experience by patients at several hospitals in New York State[2]. The study documented 
that at least 3.7% of all hospitalised patients developed a serious, disabling, and clinically 




The most common adverse events were complications of medication use. Thirty percent 
of patients with drug-related injuries died or were disabled for more than 6 months[19]. 
Most medication errors were dosing errors (28%), followed by route of administration, 
medical administration record and documentation, date, and frequency of administration 
errors. The most potential ADEs were due to dosing errors (34%), followed by frequency 
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and route errors. Physician ordering, followed by transcription and nurse administration 
were the most common stages for medication errors and potential ADEs. The most 
common drugs involved in medication errors and potential ADEs were anti-infective 
agents, analgesics and sedatives, electrolytes and fluids, and bronchodilators[6]. 
 
 
In response to the above findings, the Adverse Drug Event Prevention Study addressed 
medication errors and adverse drug events (ADEs) in hospitalised adults[9, 20]. It found 
that ADEs were occurring at a rate of 6.5 per 100 adult admissions and they were costly, 
and often had severe sequelae[20, 21]. Other studies largely confirmed these findings[15, 18].  
 
 
Medication errors are of two main types, prescribing errors and medication 
administration errors[22]. Approximately 3% of medication-error reports submitted in 
1999 to the United States Pharmacopeia national database described actual harm to 
patients. Nearly half of the errors recorded referred to doses not administered or drug 
products not given at the proper dose or in the correct quantity. “Performance deficit” 
was the most frequently cited cause of errors, often in combination with another cause. In 
the medication-use process, “administering” was identified most frequently (40%) and 
prescribing (11%) of the time of the medication-error reports[23]. 
 
 
Medication order writing constitutes 5% of the drug related errors. Of these, 28% to 56% 
are preventable. Prescription of the wrong drug or wrong dose is often due to lack of 
information regarding the drug or the patient[17]. A study by Leape et al[9] concluded that 
78% of errors leading of ADEs are due to system failures that could be corrected by 
improved information systems[17]. 
 
 
In a study by Bates et al[24] found that a large difference in length of stay and resource 
utilisation between preventable ADE and nonpreventable ADEs. Analgesics (30%) and 
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antibiotics (30%) accounted for the largest percentages of nonpreventable ADEs, 
followed by antineoplastic agents (8%) and sedatives (7%). The largest percentages of 
preventable ADEs were caused by analgesics (29%), sedatives (10%), antibiotics (9%), 
and antipsychotics (7%). Patients with long stay tend to be sicker and receive more 
medications and therefore had substantially greater rates of exposure per admission than 
other patients. They estimated an additional cost of $2595 to the hospital for preventable 
ADEs per patient. Thus, ADEs are costly, and interventions to reduce their frequency can 
be justified economically as well as to improve the quality of care[24]. 
 
 
In a case-control study performed by Evans et al[25] at a Hosptial in Salt Lake City, Utah, 
found an attributable increase in length of stay of 1.9 days and increased costs of $1939 
for ADEs per patient. 
 
 
Medication errors are quite frequent compared with accidental intoxications according to 
a survey of Poison Control Centres. Studies have shown that errors resulted in 4-11% of 
hospitalisations for intoxication in children. Seven hundred errors occurred with over-the-
counter drugs, which accounted for 63% of all the medications. 7.8% of 459 patients 
prescribed acetaminophen was misused. Wrong dosage was prescribed in 31.5% of 1082 
patients. The most frequent causes of error were parental prescribing (31.5%) and 
incorrect execution of the prescription (30%). The wrong dose often resulted from a 
wrong execution of the prescription, whereas drug errors were more frequently related to 
parental prescribing. In most of the cases of medication error (84.5%), the error was 




The study by Folli et al[5] demonstrated that pharmacy review of medication orders could 
prevent erroneous orders from being implemented at a rate of 14 to 18 per 1000 patient-
days. Fortescue et al[7] concluded in their study that the presence of clinical pharmacists 
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to monitor ordering might have prevented 58.3% of errors, whereas pharmacists 
monitoring transcribing and administering might have prevented an additional 19.6% and 
5.8% of errors. In all clinical pharmacists performing these functions could have resulted 
in a total medication error rate reduction of 81.3%. The high risk of medication errors 
highlights the importance of developing, testing, and implementing effective error-
prevention strategies in pediatrics[6]. 
 
 
4.1.2 Liquid medication dosing errors 
In 1975, the American Academy of Pediatrics Committee on Drugs described 
unacceptable levels of inaccuracies in administering liquid medication by household 
spoons.[26] When recommended 27 years ago the use of an oral dosing syringe, was then 
described as novel and innovative. Subsequently, a range of liquid medication dosing 
devices have been developed and become widely available, each of which has its 
advantages and disadvantages.[27] 
 
 
A study reported from poison control centers in the United States of America found two 
major causes of dosing errors using dispensing cups which were commonly provided 
attached to liquid medication: the assumption was made that the entire cup was the unit 
of measure; and secondly the misinterpretation that one cupful was the recommended 
dose.[28] Household measuring devices, such as teaspoons and tablespoons, were not 
recommended for measuring drugs because they are neither accurate nor consistent. The 
volume contained in a household teaspoon has been reported to range from 2.5 to 9.7 
ml.[26, 29, 30] Research has suggested that parents may be confused about differences 
among teaspoons, tablespoons, and dose cups.[11, 28, 31] Problems can also result from 
spillage and medication left in or on the measurement device rather than being 
administered to the child.[27, 32] After receiving reports of inappropriately marked plastic 
dosing cups, the Food and Drug Administration began a public education campaign in 
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1994 to increase health professional and consumer awareness of dosing hazards with 
liquid medicines.[33]  
 
 
When the oral dosing syringe was introduced in 1975, 75% of parents used a household 
teaspoon or other measuring device when dosing liquid medication.[29] A study from 




Optimal administration of liquid mediations to children requires the delivery system to be 
effective, safe, and acceptable to the parent. It also needs to be able to deliver the dose 
correctly to the child once measured. However, traditional techniques for administering 
pediatric oral liquid medications are not optimal because of the variability of the volume 




Oral dosing syringes are considered the best device for the delivery of liquid 
medication.[27] Oral syringes can accurately measure liquids and may reduce drug dosage 
errors if the syringe is marked correctly and parents are trained.[32, 35] Its advantages 
include accuracy, expediency, availability in various sizes, and relatively low expense. 
The syringe permits the user to direct the delivery of the medication to the side of the 
mouth of an infant or small child, thus minimizing spillage. It also reduces the risk of 
possible gagging and aspiration of medication.[37]  
 
 
Although a range of methods have been used to study medication administration errors, 
the observation-based method developed 40 years ago by Barker and McConnell[38] is 
generally accepted as the most reliable[39, 40]. In this approach, a researcher accompanies 
nurses preparing and administering drugs, records details of all doses administered, and 
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compares this information with the doses prescribed[22]. This approach can also be 
applied to measure the efficiency of parents administering a liquid medication dose. Less 
is known about the level of liquid medication dosing errors in India, the second largest 
populated country in the world. So the authors designed this study to evaluate the 
accuracy with which parents administered a paracetamol suspension prescribed for 
pyrexia because of the frequent diagnosis and use of liquid medication for this condition. 
This study was intended to determine whether parents could administer the prescribed 




The objectives of this study were (i) to study the impact of a liquid measurement device 
and pharmacist intervention on parent dosing accuracy and, (ii) to evaluate the effect of 





4.2.1 Setting and patient population 
Children less than 10 years of age diagnosed with pyrexia and prescribed paracetamol 
suspension by a doctor were the subjects for the study. Patients received care in the 
Srujan Hospital for Sick Children (SHSC), Sirsilla, Andhra Pradesh, India. SHSC is a 60-
bed pediatric hospital. It is the only pediatric hospital for a small town and fifteen villages 
(approximate population 100,000). SHSC contains a pharmacy where most of the patients 
will have their medications dispensed. To participate in the study, the patient’s 
prescription had to be filled at the hospital pharmacy. The study sample was collected 
during the hospital visiting hours i.e., 7.00 a.m. to 9.00 a.m., 12.00 p.m. to 4.00 p.m. and 
6 p.m. to 9.00 p.m. The researcher is a qualified pharmacist in that country. He spoke 
medical Telugu, however, all nursing assistants in the hospital were bilingual. The 
nursing assistants notified the researcher whenever the diagnosis of pyrexia was made 
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and a paracetamol suspension was prescribed. The weight for most patients was not 
available on the prescription. The researcher weighed each patient in his office in Group 
1. In Group 2, the nursing assistants weighed each patient and it was written on the 
patient notes before the pediatrician wrote the prescription. The hospital does not 
normally employ a qualified pharmacist nor nurses. 
 
 
4.2.2 Exclusion and inclusion criteria 
All outpatients prescribed a paracetamol suspension and less than 10 years of age were 
included and classified into two groups. Group 1 was studied initially and received 
standard care. Patients from Group 1 were excluded from Group 2. Since it was a time 
series study, Group 1 data were collected in week one and Group 2 data a week later 
following the intervention to the pediatricians. 
 
 
4.2.3 Data collected 
Data collected included patient details such as age, weight and sex; parent details such as 
type of carer, level of education, number of children and order of the child in the family; 
prescription details such as drug name, dose prescribed and number of doses prescribed; 
measurement details such as volume of paracetamol suspension prescribed, volume 
measured, difference and the device used for measurement.  
 
 
4.2.3.1 Data collection methodology 
In Group 1 participants received the prescription, paracetamol suspension and verbal 
instructions from the hospital staff. This was the usual care practiced at SHSC. Data were 
collected directly from the patient’s prescription. The parents were asked to give the first 
dose of paracetamol suspension to the patient in the presence of the researcher. The 
researcher had a range of measuring devices available including household teaspoons, 
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dosing spoons, droppers, measuring cups and syringes. The parent was asked to select 
and use the item most similar to what they usually used for the measurement of the dose. 
The researcher then measured that dose volume to the nearest 0.5 ml, using a calibrated 
syringe to suck up the dose to determine the reading of the dose and confirmed the 
volume by expulsion into a measuring cylinder calibrated to 0.1 ml to validate the 
syringe. If the parent measured an incorrect dose, the researcher reinforced the verbal 
instructions previously given and the dose measurement was corrected and demonstrated 
how to measure the dose. Parents were counseled on the advantages of oral dosing 
syringes and asked if they wanted to use the syringe to administer the medicine. If they 
were interested, the syringe was labeled at the prescribed dose with a “⊥”. The inverted 
“⊥” was marked from the inlet of the syringe with the line showing the mark for the 
prescribed dose. This gave a clear instruction to the parent from the point of drawing up 
to the suspension to the point which was the dose volume. Use of dosing cups available 
attached to the medication where selected was discouraged.  
 
 
In Group 2, participants received the prescription for paracetamol suspension, and the 
intervention included the marked syringe as previously described, verbal instructions and 
a demonstration by a qualified pharmacist, who was the researcher. The pediatricians also 
received feedback of Group 1 results for paracetamol dosages. A dosing chart was 
provided to the prescribers describing according to weight, the appropriate dose in 
millilitres of paracetamol suspension. Similar data were collected as in Group 1. In Group 
2, each patient was weighed and data were provided to the pediatrician before prescribing 
the dose. The researcher explained to parents the advantages of using the oral dosing 
syringe. If they were prepared to volunteer, they were asked to measure the dose. As in 




4.2.4 Pharmacy survey 
A survey of 16 pharmacies located in that area was conducted to identify the type of 
devices general practitioners (GP) were recommending to measure the dose. The 
researcher visited all the pharmacies and introduced himself, and asked the question what 
devices they provided with pediatric suspensions. Every pharmacy was located near to a 
GPs clinic. Most patients’ visited a GP, and got their medicines dispensed at any of the 
16 pharmacies located nearby. 
 
 
4.2.5 Definitions  
In this study an appropriate volume measurement was classified as a volume within ± 0.5 
ml of the recommended volume. An appropriate dose was classified as one prescribed 
within ± 25% of the recommended dose. An educated person was defined as one who 
could read, write and speak any of the 18 languages listed in the constitution of India. A 
person without formal education was defined as one who cannot read or write but can 
speak any of the 18 languages listed in the constitution of India.  
 
 
4.2.6 Data analysis 
Physicians’ prescribing of antipyretic dosages was evaluated against Australian National 
Therapeutic Guidelines (ANTG) for paracetamol.[41] The stated dosage is: paracetamol - 
15 mg/kg/dose orally, every 4 to 6 hours, to a maximum of 90 mg/kg/day. Paracetamol 
dosage was calculated according to the product of the weight of the patient and the 
recommended dose per kilogram.  
 
 
4.2.7 Statistical Evaluations 
Using Students’ t-test tested data for age differences and other population data were 
differentiated using χ2 analysis. Difference in choice of device used, number of children, 
 168
order of the child, and level of education status of the parent for the appropriate 
measurement of liquid medication and physician prescribing were evaluated by χ2 
analysis. Other parametric data differences were tested using Student’s t-test. Outcomes 
of the study were communicated to the pharmacy and relevant units at SHSC. Based on 
α=0.05 and β=0.2 and a 20% change in prescribing and dose measurement outcomes 




4.2.8 Ethical issues 
As this study involved an analysis of patient’s prescription data, ethical issues arise in 
relation to confidentiality and release of data. A unique non-patient identifiable code was 
allocated to each prescription to enable re-identification if necessary since the hospital 
holds a duplicate copy of the prescription. The coded data was kept secure in accord with 
National Health and Medical Research Council {Grandis JR, 1992 #40} guidelines and only 
group data released from the research. Informed consent of parents was not obtained, 
because the study was a quality assurance audit to determine the number of patients using 
measuring devices correctly. The treatment was within the standard of care for 




The study population consisted of 337 children of which 220 parents had no formal 
education and 117 were educated (Table 4.1). They were chosen consecutively by having 
received a prescription for paracetamol suspension for pyrexia. The number of parents in 






Table 4. 1 Parent educational status comparison statistics 




Group 1 Group 2 
Total 
No education 117 103 220 
Education 58 59 117 





Out of 337 patients, eighty-eight (50.3%) were females and eighty-seven (49.7%) were 
males in Group 1 and sixty-eight (42%) were females and ninety-four (58%) were males 
in Group 2. There was no significant gender difference between the two groups (p = 
0.190). Patients were grouped according to their age for convenience and summarised in 
the Table 4.2.  
 
 
Table 4. 2 Patient group statistics 
Group 1 Group 2 P value Group 
Male Female Total Male Female Total 
Neonate 2 2 4 3 2 5 
Infant 23 32 55 42 27 69 
Toddler 17 21 38 11 10 21 
Children 45 33 78 38 29 67 






The mean age of patients in Group 1 is 3.45 years and in Group 2 3.44 years with no 
significant difference (p=0.756) between them. The parents in Group 2 were all mothers, 
whereas in Group 1, mothers attended for 157 children and fathers for five (p=0.017). 
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Although a significant difference is evident this only arises from the zero in one of the 
Group 2 field. 
 
 
Of the educated parents 19 were educated to primary, 32 to secondary and seven were 
educated to tertiary levels. In Group 2, 27 were at primary, 29 secondary and three 
parents at tertiary levels(Table 4.3). 
 
 
Table 4. 3 Parents level of education 
Level of education Group 1 Group 2 Total 
No education 117 103 220 
Primary 19 27 46 
Secondary 32 29 61 
Tertiary 7 3 10 
Total 175 162 337 
 
 
Group 1 consisted of 63 parents with one child, 80 with two, 31 three, and one parent had 
five children. In Group 2, 57 parents had one child, 75 two, 23 had three and seven had 
five children. There was no significant difference in these data between Groups 1 and 2 










Table 4. 4 Number of children to the parent comparison statistics 
Number of parents P value Number of 
children Group 1 
Group 2 
Total 
One 63 57 120 
Two 80 75 155 
Three 31 23 54 
Other 1 7 8 






One hundred and thirteen (>64%) children were the first child in their family, 47 (27%) 
were the second child, and 15 (<9%) other children were the third child in Group 1. In 
Group 2, 106 (>65%) children were the first child, 42 (26%) were the second, 14 (9%) 
other children were the third child. There was no significant difference in these data 
between Group 1 and Group 2 (p = 0.981) (Table 4.5). 
 
 
Table 4. 5 Order of the child in the family comparison statistics 





First 113 106 219 
Second 47 42 89 
Other 15 14 29 






The device initially selected by all parents to measure the paracetamol suspension in 
Group 1 was the measuring cup. This device was often attached to the closure of the 
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4.3.1 Parents dosing 
The detailed overall outcomes of parent dosing are listed in Table 4.6. In Group 1, 85 
measured the dose accurately (±0.5ml), 58 measured 0.6 to 1ml above or below the 
recommended dose, 7 measured 1.1 to 1.5ml above or below the recommended dose, 10 
measured 1.6 to 2ml above or below the recommended dose and 15 other measured 
inappropriately. In Group 2, 160 parents measured the dose appropriately and two 




Table 4. 6 Parents measurement appropriateness 
Number of patients 
Dose appropriateness description in ml 
Group 1 Group 2 
0 to 0.5 above the recommended dose 65 (appropriate) 136 (appropriate) 
0 to 0.5 below the recommended dose 20 (appropriate) 24 (appropriate) 
0.6 to 1 above the recommended dose 37 1 
0.6 to 1 below the recommended dose 21  
1.1 to 1.5 above the recommended dose 3 1 
1.1 to 1.5 below the recommended dose 4  
1.6 to 2 above the recommended dose 6  
1.6 to 2 below the recommended dose 4  
2.1 to 2.5 below the recommended dose 14  
2.6 to 3 above the recommended dose 1  




4.3.2 Pediatrician prescribing 
Pediatricians prescribed appropriate doses for 67 patients, 26-50% above or below the 
recommended dose for 31, 51-75% above or below the recommended dose for 34, 76-
100% above the recommended dose for 19, 101-150% above the recommended dose for 
13, 151-200% above the recommended dose for 5 children. It is notable that 6 children 
received doses, which were more than double to five-fold that of the recommended 
dosages in Group 1. In Group 2, 2 patients were prescribed 26-50% below the 
recommended dose and 160 were prescribed an appropriate dose with a significance 




Table 4. 7 Pediatricians prescribing appropriateness 
No of patients (sum of doses) Dose appropriateness description 
Group 1 Group 2 
26-50% below the recommended dose 13 (159) 2 (24) 
51-75% below the recommended dose 1 (12)  
Appropriate dose 67 (807) 160 (1923) 
26-50% above the recommended dose 18 (216)  
51-75% above the recommended dose 33 (399)  
76-100% above the recommended dose 19 (240)  
101-150% above the recommended dose 13 (162)  
151-200% above the recommended dose 5 (69)  
201-250% above the recommended dose 2 (27)  
251-300% above the recommended dose 1 (12)  
301-350% above the recommended dose 1 (12)  
451-500% above the recommended dose 2 (27)  
Total 175 (2142) 162 (1947) 
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4.3.3 Overall appropriateness 
In evaluating the overall appropriateness of the dose administered (combination of 
pediatrician prescribing and parents measurement), 76 patients received an appropriate 
dose in Group 1 and 160 in Group 2 with a statistically significant improvement (p < 
0.001) (Table 4.8). Some additional appropriate doses were fortuitously achieved as a 
result of incorrect measurements of inappropriate doses (Table 4.9). Hence irrespective of 
the parent’s educational status, order of the child in their family, and number of children 




Table 4. 8 Overall appropriateness 
Number of patients (Sum of doses) Dose appropriateness description 
Group 1 Group 2 
26-50% below the recommended dose 10 (123) 2 (24) 
51-75% below the recommended dose 4 (48)  
Appropriate dose 76 (921) 160 (1923) 
26-50% above the recommended dose 14 (171)  
51-75% above the recommended dose 30 (372)  
76-100% above the recommended dose 20 (240)  
101-150% above the recommended dose 12 (150)  
151-200% above the recommended dose 2 (27)  
201-250% above the recommended dose 3 (39)  
251-300% above the recommended dose 1 (12)  
401-450% above the recommended dose 1 (12)  
451-500% above the recommended dose 2 (27)  










Group 1 Group 2 Group 1 Group 2 
Volume measured 
correctly 
31 158 54 2 
Volume measured 
incorrectly 
29 2 61 - 
 
 
Table 4. 10 Level of education Vs Appropriate measurement of dose 
Number of parents Percentage Level of 
education Group 1 Group 2 Group 1 Group 2 
No education 58 102 49.5% (58/117) 99% (102/103) 
Primary 9 27 47.4% (9/19) 100% (27/27) 
Secondary 13 29 40.6% (13/32) 100% (29/29) 
Tertiary 5 2 71.4% (5/7) 66.7% (2/3) 












Table 4. 11 Order of the child Vs Appropriate measurement of dose 
Number of patients Percentage Order of the child 
in the family Group 1 Group 2 Group 1 Group 2 
First 60 105 53% (60/113) 99% (105/106) 
Second 19 41 40.4% (19/47) 97.6% (41/42) 
Third 6 13 40% (6/15) 100% (13/13) 
Fourth - 1 - 100% (1/1) 
Total 85 160   
 
 
Table 4. 12 Number of children to the parent Vs Appropriate measurement of dose 
Number of parents Percentage Number of children 
to the parent Group 1 Group 2 Group 1 Group 2 
One 30 57 47.6% (30/63) 100% (57/57) 
Two 41 73 51.2% (41/80) 97.4% (73/75) 
Three 13 23 42% (13/31) 100% (23/23) 
Four - 6 - 100% (6/6) 
Five 1 1 100% (1/1) 100% (1/1) 
Total 85 160   
 
 
4.3.4 Pharmacy survey results 
A survey of 16 pharmacies located in this rural area found that none of them supplied or 
had for sale an oral dosing syringe. The eight physicians practicing in this area appeared 
not to be aware of this device, hence did not make any recommendations for its use. All 





The overall inappropriateness of the medication, was a combination of the following 
factors: (i) the parent measured the dose inappropriately or (ii) the physician prescribed 
an inappropriate dose of paracetamol suspension and (iii) the overall combination of dose 
measurement and prescribed dose lead to an inappropriate dose being administered. 
There was in a small number of fortuitous situations where an inappropriate dose was 
incorrectly measured to overall result in an appropriate dose being administered. These 




In this study ±0.5ml was deemed an acceptable measurement error as the suspension is 
viscous. This is a high percentage error at low dosages (e.g. 2ml) but is acceptable at 
common dose volumes of 5 to 10ml. The designated dosage error of ±25% was based on 
the common variability allowed in dosage forms and bioequivalency studies. In India 
national guidelines are not available to prescribers. It is noted however the dosage errors 
do not relate to the use of a different dosage standard since the results show wide 
variability presumably arising from not knowing the weight.  
 
 
Several very high dosages (150mgkg-1day-1 to 250mgkg-1day-1) were prescribed. Penna & 
Buchanan[43] reported in 1991 7 deaths and 11 cases of hepatotoxicity associated with 
paracetamol. Survival was usually seen in those children suffering hepatotoxicity due to 
paracetamol greater than 150mgkg-1day-1 for two to eight days.[43] However, toxicity has 
been reported rarely with therapeutic doses when administered over several days in 
children who have concurrent illnesses such as fever, vomiting, and diarrhoea.[44] 
 
 
In this study 54% of the children in Group 1 received doses above that recommended. Of 
particular concern were 6 children being prescribed more than double to five-fold of the 
recommended dose. In addition to the immediate concern, medically prescribed dosages 
 178
of medicines that are easily purchased such as paracetamol may lead to these dosages 




This study has found that irrespective of educational status or previous experience with 
other children that an appropriate intervention by a pharmacist can markedly improve the 
accuracy of measurement (Table 1). Pharmacist intervention involving parental and 
targeted physician education can be very effective in markedly improving the 
appropriateness of medication dosing and prescribing in a developing country. This study 
has demonstrated that the overall improvement is very substantial from 43.4% to 98.7%. 
With regard to providing parents’ with verbal instructions, and a syringe marked for the 
prescribed dose and a demonstration by a qualified pharmacist caused a significant 
improvement from 48.5% to 98.7% able to achieve an acceptable accuracy. This study 
shows results similar to a recent study by McMohan and colleagues of 90 English-
speaking and Spanish-speaking families, 100% of them dosed medication correctly when 
given instructions and a syringe with a line marked at the prescribed dose.[35]  
 
 
A study conducted by Mattar, Markello and Yaffe (1975) found that difficulties with 
administration of liquid medications occurred with 28-40% of children.[29, 45] Because 
traditional oral liquid medication delivery devices may cause problems with drug 
administration, these devices may adversely affect compliance.[45] It is harder to feed the 
child with the dispensing cup than with the syringe. There is a greater chance of spillage 
of the liquid during administration compared with the oral dosing syringe. 
 
 
This method of drug administration requires correct placement of the liquid in the cheek 
pouch of the patient’s mouth for the medication to be correctly swallowed. If the liquid is 
placed too close to the front of the mouth, the medication can be expelled. If the liquid is 
administered too close to the back of the throat or too rapidly, the patient may choke or 
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aspirate.[27, 46] None of the patients in this study choked or aspirated during the trial 
administration. This shows that pharmacist involvement as counsellor and demonstrator 
of oral dosing syringes and practical reinforcer of the dosing instructions has worked 
well. Good communication and verbal skills are important and is a vital role of the 
pharmacist’s activities in hospital settings.  
 
 
Matter et al[29, 45] found that when no dispensing device was given, 71% of parents used a 
teaspoon. In this study, everybody normally used dispensing cups for measuring the 
suspension. This practice can be eliminated through better parent education and by 
providing labeled measuring devices.  
 
 
Even though oral dosing syringes have been available in developed countries since 1975, 
none of the pharmacies in the survey conducted in this study, were supplying nor the 
physicians appeared to knew about this device. This reflects that there is a great need for 
pharmacist intervention and greater involvement in practice. 
 
 
Herman & Rodowskas[47] have suggested that programs meant to improve the quality of 
patient care and thus drug use, can succeed only if practitioners adopt a positive attitude 
towards such programs. It has also been reported that attitude was the strongest predictor 
of whether or not pharmacists performed some clinical pharmacy activities.[48] The 
attitudes of pharmacists and physicians to policies is likely to be one of the important 
factors that may affect their compliance with, and hence the ultimate effectiveness of 
such policies.[49]  
 
 
Although several studies have evaluated the accuracy of measuring medicines in various 
devices in several countries, this study has also linked this with the prescribing of 
appropriate doses. It is only with this combination that the administration of an 
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appropriate dose can be ensured. In addition, doses commenced in a hospital setting are 
likely to be continued when paracetamol is used or obtained in other circumstances, 
perpetuating the findings of Group 1 patients. The current situation can often lead to 
either drug toxicity or treatment failure dependent upon the combination of dosages 




In this study we found that dosing by parents from rural areas of a developing country 
can be improved by a targeted pharmacist intervention. Health care professionals should 
ensure that parents understand liquid medication dosing procedures. Treatment failure 
from underdosage or adverse effects can potentially arise from overdosage. A syringe 
provides an appropriate device for dosage administration: it is easy to control, causes 
minimal spillage, and is useful for pediatrics because it initiates sucking compared with 
use of a dosing spoon. Irrespective of parents education status, number of children and 
order of the child, pharmacist intervention through patient education significantly 
improved parents accurate dosing and physicians prescribing of an antipyretic suspension 
in a country like India where pharmacist involvement thus far is minimal. This study 
strongly supports the roles that pharmacists can perform in developing countries in 
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Chapter five 
Evaluation of Pharmacist Intervention for Drug Treatment of Severe Community-
Acquired Pneumonia at a Rural Indian Pediatric Hospital 
 
5.1 Introduction 
Lower respiratory tract infections (LRTI) are a common cause of mortality in developing 
countries and represent a major source of morbidity among children worldwide [1]. 
Although the overall incidence of acute respiratory infections is similar in developed and 
developing countries, there are marked differences in the proportions of patients with 
specific infections [2]. The incidence of pneumonia in the developing world is up to 10 
times higher than in developed countries such as the United States. Pneumonia can be 
associated with severe morbidity, and place an enormous burden, both economically and 
as a public health issue, on the entire health care system [3, 4]. 
 
 
Children under the age of five years are most commonly affected by LRTI. Children in 
the developing world have a high incidence of bacterial pneumonia, have risk factors that 
predispose to more severe infections, and often have a limited access to effective medical 
care. The risk factors include large family size with overcrowding, lateness in birth order, 
low birth weight, lack of breast feeding, malnutrition, vitamin A deficiency and exposure 
to smoke from cooking on open stoves with biomass fuels.[5, 6] 
 
 
Pneumonia remains the most common infectious cause of death in the United States and 
incurs substantial morbidity-related costs to society and the health care system [7-9]. It is 
the sixth leading cause of death and the number one cause of death due to infections [10]. 
Pneumonia-associated mortality has declined over the decades since penicillin was 




It is estimated that the cost of treatment of community-acquired pneumonia (CAP), 
including direct patient-care costs and lost wages, is more than US$20 billion per year 
[13]. In the UK the cost of treatment is estimated to be ₤440.7 million per year, and 32% 
of CAP patients need hospital treatment, which accounts for 96% of this cost [14]. CAP is 
thought to account for 10 million physician visits per year in Unites States [15]. Despite 
the introduction of newer antimicrobial agents, vaccines and more sophisticated intensive 
care facilities, the mortality rate associated with pneumonia as reported between 1982-
1990 appears to be increasing, after remaining steady during the 1950-60’s [10, 16-19].  
 
 
The risk factors predisposing to more severe disease can possibly be prevented in 
developing countries also, if the initial infection was identified and treated. This is 
important in the light of the knowledge that current therapeutic approaches are over time 
likely to be become less effective in reducing mortality, though they represent the 
standard approach at present.[20] 
 
 
5.1.1 Classification of pneumonia 
Pneumonia refers specifically to an inflammatory disease process involving the lung 
parenchyma rather than disease of the conducting airways, although both may occur at 
the same time [21]. CAP refers to pneumonia caused by a pathogen acquired in the 
community [10]. The classification of pneumonia can be categorized based on the source 
of infection (Table 1), the infectious agent (Table 2) or the major site of the pathological 








Table 5. 1 Classification of pneumonia by source of infection 
Classification of pneumonia by source of infection [21] 
Classification Features 
Community-acquired Pneumococcal pneumonia – most common 
in adults 
 Haemophilus pneumoniae pneumonia – 
common in children 
 Mycoplasma pneumoniae pneumonia – 
common in both 
Hospital acquired Increased incidence of Gram-negative 
infections 
 Higher mortality 
Aspiration pneumonia More common in infancy and childhood 
 May cause chemical pneumonitis 
 Anaerobic bacteria likely 
 May be ‘silent’ in the elderly 
Immunocompromised Wide range of organisms 
 May rapidly become life threatening 













Table 5. 2 Classification of pneumonia by infectious agent 
Classification of pneumonia by infectious agent [21] 
Classification Features 
Bacterial pneumonia Common in all ages 
 Many organisms can cause pneumonia in 
healthy people 
 Most are curable by appropriate medication
Atypical pneumonia Due to Mycoplasma, Legionella, 
Chlamydia, Rickettsiae 
 The older child and young adult are most 
commonly affected 
 Requires a macrolide or tetracycline and 
does not respond to β-lactam antibiotics 
Viral pneumonia More common in infants and children 
 More likely to be serious in patients with 
weakened resistance 
















Table 5. 3 Classification of pneumonia by site of infection 
Classification of pneumonia by site of infection [21] 
Classification Features 
Lobar pneumonia More common in bacterial pneumonia 
 Less common in infancy and elderly 
 May be secondary to bronchial obstruction 
Bronchopneumonia Patchy and widespread 
 Due to bacteria or viruses 
 Common in infancy and elderly 
 Unlikely to be associated with bronchial 
obstruction 
Interstitial pneumonia Typical of opportunistic infection 
 Typical of non-infective pneumonias 
 
 
5.1.2 Etiology of pneumonia 
Identifying the etiologic agent(s) responsible for pneumonia remains a challenge, 
primarily because of difficulty in obtaining adequate samples for culture and in 
differentiating infection from colonisation and lack of reliable diagnostic methods [22, 23]. 
Although several factors such as age, underlying disease and environment have a 
substantial influence on the microbial etiology of pneumonia, Streptococcus pneumonia 
continues to be an important bacterial cause of pneumonia, especially in infants and 
young children [24, 25]. More recently Chlamydia pneumoniae and Mycoplasma 
pneumoniae have been recognised as pathogens responsible for mild to severe 
pneumonia, particularly in children older than 4 to 5 years [25]. In younger patient’s, 
pneumonia is mostly caused by respiratory viruses [26]. Bacterial pneumoniae are 
commonly caused by Streptococcus pneumoniae, Haemophilus influenzae, and 




5.1.3 Causative agents 
Most of our knowledge on the etiological agents of pneumonia in children is derived 
from observations in developed countries where viral infections represent a considerable 
proportion. However, the finding of a viral pathogen does not rule out a bacterial 
causative agent, since viruses may predispose to secondary bacterial infection by several 
mechanisms including local and systemic immunodeficiency, acute malnutrition, and 
nosocomial infections [29].  
 
 
Evidence is accumulating that bacterial pathogens play a greater role as a primary or 
secondary cause of pneumonia in developing than in developed countries [30]. Lung 
aspiration performed in children with pneumonia who had not received previous 




It is difficult to draw consistent conclusions from such studies since they differ in many 
aspects such as their design, location, type of patients and patient’s age. In addition, there 
is no evidence that in the developed world the bacterial causative agents are similar to 
those in the developing world. Furthermore, most of these studies were performed many 
years ago, and epidemiology tends to change, at least in part, with time [29]. 
 
 
Current microbiology methods are cumbersome, time consuming, and costly and the 
majority of patients treated parenterally are discharged without the causative agent being 
identified. Traditional lung aspiration could be informative in cases of pneumonia, but it 




5.1.4 Medical Practices in India 
India is a country of over one billion population with a vast diversity in cultures, 
traditions and religion. From North to South & East to West, the people are different. 
India is not only vast but is also has the distinction of being the second most populous 
nation in the world.  
 
 
5.1.4.1 Public Hospitals 
Health-care is free in India. Public hospitals are located in every town and city. Full time 
working medical practitioners are available 24 hours and seven days a week. Most of the 
hospitals contain specialists. Public hospitals located in the district headquarters have 
proper facilities with doctors specialized in various areas and with a capacity of 500-1000 
beds. They perform all procedures free of charge. Even though health-care is free, due to 
a lack of proper funding, patients sometimes may need to buy drugs from the pharmacy. 
Each town contains only one public hospital for a population over 50,000. The number of 
public hospitals does not meet the public requirements. Most people belonging to the 
lower socio-economic class will visit public hospitals. The hospitals are not always 
properly maintained.  
 
 
5.1.4.2 Private hospitals 
The level of care in private hospitals is better than public hospitals. But most of the 
hospitals contain one or two doctors working full time. Each hospital is specialized in a 
particular area. Most of the private hospitals are located in the densely populated areas. 
People living in villages do not have access to private hospital services.  
 
 
Some private hospitals located in the cities are very well equipped with modern 
equipment. They have a wide variety of specialists. Their quality of patient care meets the 
western standards. Similarly their charges are very high. Only wealthy people can afford 
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treatment in these hospitals. Most of the public and private hospitals do not perform 
routine pathological and diagnostic testing. Some doctors who perform tests have 
business links with diagnostic services. 
 
 
On the other hand, doubtful medical practices are widespread at the village level. This 
arises from “so called” rural medical practitioners; who have no qualification, and title 
themselves as doctors. They are not allowed to prescribe any drug and to treat any patient 
but they do without holding any medical qualifications. The government does not 
recognise rural medical practitioners but also does not institute any restraint. Rural 
medical practitioners (RMP) are persons who have experience working under a qualified 
medical practitioner (QMP) for some time and gain some drug knowledge and then start 
their own clinic as a RMP. They usually charge less than QMPs. Their main goals are to 
prescribe as many drugs as possible and administer intravenous fluids to most of the 
patients as a method of achieving patient confidence. Generally, people from villages and 
small towns where 74% of India’s population lives will visit RMPs. The public doesn’t 
know the difference between a QMP and RMP. Even if they do, most cannot afford or 
have access to a QMP, who are not located in villages.  
 
 
RMP's will use stethoscopes and blood pressure apparatus for every patient. Whether 
they know how to use it is not questioned. For most patients, they will prescribe 
parenteral drugs. They can then charge for the drug and the administration procedure. If 
the patient looks weak, they will administer intravenous fluids. Most of the patients feel 
very satisfied once the RMP's have administered fluids. Neither the RMP nor the patients 
understand the role of intravenous fluids. Some RMP’s have facilities like a rudimentary 
operating theatre. They are performing procedures like cesarean, and delivery. If the 
RMP cannot manage, he/she will recommend the patient to the nearest QMP located in 
towns who is in favour to him. So, that he/she can collect commission for each patient 
from the QMP. If the patient is lucky enough, the QMP treats; otherwise the patient dies. 
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Since both are dependent on each other for their businesses, even though the patient died 
because of RMP’s inappropriate treatment, the QMP does not lodge a compliant.  
 
 
Almost all the present knowledge on prescribing trends is derived from studies conducted 
in prosperous societies and these may not be relevant for developing countries in view of 
differing health problems and priorities. Lack of adequate information about prescribing 
patterns in less developed countries promoted the present investigators to study drug use 
in severe community-acquired pneumonia (SCAP) in a rural pediatric hospital, Sirsilla, 




5.2.1 Setting and patient groups 
A prospective study was conducted at Srujan Hospital for Sick Children (SHSC), Sirsilla, 
Andhra Pradesh, India, a 60-bed rural pediatric hospital. This study was categorised into 
two groups; Group 1 a pre-intervention cohort studied for three weeks and Group 2 a 
post-intervention group, studied for a similar period following the intervention.  
 
 
5.2.2 Exclusion and inclusion criteria 
All outpatients under 18 years of age diagnosed with SCAP were included in the study. If 
the patient was admitted as an in-patient, they were excluded from the study. Group 1 




5.2.3 Data collected 
Data collected were patient demographic details such as age, weight, sex; and 
prescription related details such as drug name, dose, frequency, route and number of 
doses prescribed. The weight of most patients was not available on the prescription. The 
investigator weighed each patient in his office in Group 1. In Group 2, the weight was 
taken and written on the empty prescription form by nursing assistants before the patient 
visited the pediatrician. The nursing assistants notified the investigator whenever the 
diagnosis of SCAP was recorded. The hospital does not have a qualified pharmacist or 
qualified nursing staff. All prescribing was by medically qualified pediatricians. 
 
 
5.2.4 Data collection methodology 
The researcher collected the data from the prescription while the patients were paying the 
fees at the counter after visiting the pediatrician. SHSC contains a pharmacy where most 
of the patients will have their medications dispensed. The patients however, have no 
insurance or fee-for-service coverage. The study sample was collected during the hospital 
visiting hours i.e., 7.00 a.m. to 9.00 a.m., 12.00 p.m. to 4.00 p.m. and 6 p.m. to 9.00 p.m 
by the investigator who was a qualified pharmacist in that country.  
 
 
5.2.5 Data analysis 
The prescribing data were analysed for appropriateness against Australian National 
Therapeutic Guidelines for Respiratory Tract Infections [33] and Analgesics [34]. 
 
 
Australian National Therapeutic Guidelines (ANTG) for severe community acquired-
pneumonia (2000 edition) 
For children older than 10 years of age, erythromycin 10mg/kg up to 0.5 to 1g 
intravenously, 6-hourly PLUS benzylpenicillin 30 to 60mg/kg up to 1.2g intravenously, 
4- to 6-hourly PLUS gentamicin 6mg/kg intravenously, daily. For patients hypersensitive 
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to penicillin, substitute for benzylpenicillin and gentamicin, ceftriaxone 50mg/kg up to 1g 
intravenously, daily or cefotaxime 50mg/kg up to 1g intravenously, 8-hourly. For 
children under 10 years of age, cefotaxime 50mg/kg up to 1g intravenously, 8-hourly or 
ceftriaxone 50mg/kg up to 1g intravenously, daily PLUS di(flu)cloxacillin 50mg/kg up to 
2g intravenously, 4-hourly. The standard recommended dose for paracetamol - 15 
mg/kg/dose orally, every 4 to 6 hours, to a maximum of 90 mg/kg/day 
 
 
5.2.6 Statistical Evaluations 
Populations were matched for demographics and the influence of the intervention by χ2 
analysis. Differences in parametric data were tested using Student’s t-test. Based on 
α=0.05 and β=0.2 and a 20% change in drug prescribing and dose prescribing required a 
minimum sample of 80 patients in each group to achieve statistical significance. 
 
 
5.2.7 Intervention  
An intervention strategy involved a verbal presentation on appropriate drug treatment and 
provision of written drug information to the prescribers in the hospital. The weight of 
each patient was also provided. The results of the pre-intervention study were discussed 
with the pediatricians and specific guidelines were provided regarding appropriate 
choices and doses. A dosing chart was provided to the prescribers with dosing schedules 




According to this study, an appropriate dose was classified as one prescribed within 
±25% of the recommended dose. The designated dosage error of ±25% was based on the 
common variability allowed in dosage forms and bio-equivalency studies. An 
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inappropriate choice of the drugs / combination of drugs were those prescribed other than 
those recommended in the guidelines. 
 
 
5.2.9 Ethical Issues 
As this study involved an analysis of patient’s prescription data, ethical issues relate to 
confidentiality and release of data. A unique non-patient identifiable code was allocated 
to each prescription to enable re-identification if necessary since the hospital holds a 
duplicate copy of the prescription. Any coded data to leave the hospital was kept secure 
in accord with National Health and Medical Research Council {Grandis JR, 1992 #148} 
guidelines and only group data released from the research. Informed consent was not 
required, because the study was classified as a quality control audit and the treatment was 
within standard of care for SCAP and prescribed independently of the study. The Curtin 




The diagnosis of SCAP was made by the pediatrician and indicated on the prescription. 
Although hospitalisation is common with SCAP, it is not affordable for many in rural 
populations in India. It is therefore common to receive treatment as an outpatient.  
 
 
The total study population was 301 patients of which 146 were in Group 1 and 155 in 
Group 2 (Table 5.4). There was no significant difference between genders (p value = 
0.841) of the patients who participated in the study. The mean age of patients in Group 1 
was 2.4 years and in Group 2 was 3.6 years with a statistically significant difference 




The prescribing of the drugs for the groups is summarized in the Table 5.6. 
Dexamethasone was prescribed (200-500 µg/kg/per day) for each patient given 
ceftriaxone and cefotaxime in Group 1 and none of the prescriptions in the Group 2 
ordered dexamethasone following the intervention, showing a significant improvement (p 
< 0.001).  
 
 
Table 5. 4 Profile of patient groups 
Group 1 Group 2 Group 
Male Female Total Male Female Total 
Neonate 1 - 1 3 2 5 
Infant 25 21 46 40 25 65 
Toddler 17 19 36 10 11 21 
Children 41 21 62 31 24 55 
Teenager 1 - 1 8 1 9 
Total 84 61 146 92 63 155 
 
 
Table 5. 5 Influence of pharmacist intervention (Group 2) compared with usual care 
(Group 1) for rural pediatricians drug prescribing 
Category Group 1 Group 2 P value 
Number 146 155 0.372 
Gender 61F, 84M 63F, 92M 0.841 
Mean age (years) 2.4 3.6 <0.001 
Appropriate dose prescribed (ceftriaxone) 3/144 17/155 0.180 
Appropriate dose prescribed (paracetamol) 61/135 137/152 <0.001 




Table 5. 6 Drug prescribing pattern for SCAP 
Drugs prescribed Number of patients 
Group 1 
Ceftriaxone with dexamethasone and 
paracetamol 
134 
Ceftriaxone with dexamethasone 10 
Cefotaxime with dexamethasone and 
paracetamol 
1 
Cefotaxime with dexamethasone 1 
Total 146 
Group 2 
Ceftriaxone and paracetamol 152 




Of the total 144 patients on ceftriaxone in Group 1; 3 were prescribed an appropriate 
dose, 136 were 26-50% below the recommended dose, and 5 were on 51-75% below the 
recommended dose. In Group 2, 155 patients were prescribed ceftriaxone, of these 17 
were on an appropriate dose and 14 were on a dose 26-50% below the recommended 
dose, 121 on 51-75% below the recommended dose and 3 on 76-100% below the 
recommended dose. There was no significant improvement in appropriate dosage 
prescribing in Group 2 compared to Group 1 (p = 0.180). Cefotaxime was prescribed only 
in Group 1. Of these, one patient was on an appropriate dose and the other on 26-50% 
below the recommended dose.  
 
 
Of 137 patients on paracetamol for pyrexia in Group 1, 61 were on an appropriate dose, 9 
were on 26-50% below the recommended dose, one on 51-75% below the recommended 
dose and the remaining 66 were on doses ranging from 26-50% to 126-150% above the 
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recommended dose. In Group 2, 137 patients were on an appropriate dose, 14 were on 
26-50% below the recommended dose and one patient was on 51-75% above the 




This study has shown that there was an improvement in the treatment regimen and 
antipyretic dosages prescribed in SCAP patients following an educational intervention in 
a rural pediatric hospital in India. Even though there was a significant difference in the 
mean age of patients between the two groups, it is small and unlikely to have exerted any 
impact on the prescribing and data analysis. There was a slight increase in the number of 
appropriate doses of ceftriaxone in Group 2 compared to Group 1, but the improvement 
was not statistically significant. Sub-optimal dosing of antibiotics has two potential 
consequences: therapy failure and the possible emergence of resistance. In the western 
world antibiotic use is often strictly controlled, but on the whole a more judicious use of 
antibiotics has preserved the value of many of the traditional agents. In developing 
countries the widespread misuse of antibiotics, in combination with the spread of 
antibiotic resistance, has rendered several conventional antibiotics virtually useless.[36] 
 
 
Most of the patients diagnosed as SCAP were treated as outpatients. The reason is that 
most parents cannot afford in-patient treatment due to high hospital costs and most of the 
parents have to work on a daily basis. If one/both of the parents stays with their child for 
in-patient treatment they will lose income and they usually cannot afford to pay the 
hospital bill. Most parents are from small villages surrounding the hospital, and visit for a 
consultation and medicines only. The hospital cannot accommodate every sick child due 




In Group 1 98% of the patients and 89% in Group 2 on antibiotics were prescribed 
dosages below the recommended dose. The clinician has the responsibility to optimise 
the delivery of an appropriate antimicrobial agent to the site of an infection in 
concentrations that exceed those needed to inhibit the growth of the pathogen involved. 
An adequate level of a chemotherapeutic agent is particularly important for curing a 
infection in pediatric patients.[37] 
 
 
Possible reasons for inappropriate dosage prescribing include (i) high antibiotic costs (ii) 
low monthly incomes of rural population (iii) poverty (iv) no medical insurance (vii) no 
government subsidised medications. For example, the cost of antibiotic treatment for a 
patient weighing 25kg and less than 10 years of age, diagnosed with SCAP would be as 
follows: cost of 1g dose of ceftriaxone is Rs 165 ($AUD 6.60) (the prices are drawn from 
the CIMS of India, 2000 edition). The mean duration of treatment for SCAP is 7-10 days. 
It therefore costs Rs 1155 ($AUD 46.20) – Rs 1650 ($AUD 66) per course for antibiotic 
treatment. In comparison to the antibiotic costs, the prescriber consultation fees, cost of 
paracetamol and other indirect costs are very low. 
 
 
According to the recent survey by the National Sample Survey Organization{Grandis JR, 
1992 #149}, there was 11.05% of the rural population below the poverty line. The per 
captia annual consumption expenditure was Rs 6606.36 ($AUD 264.25) in the state of 
Andhra Pradesh. Most patients cannot afford the total treatment costs; they buy 
medications for a reduced number of days than the prescribed number. In order to 
enhance patient compliance over the total duration of the course, pediatricians are 
prescribing low antibiotic dosages. This provides reasons for no improvement in the 
prescribing of appropriate dosages of ceftriaxone following the intervention. This was not 
the case with paracetamol, since paracetamol is affordable; prescribing dosages are not 
based on cost. Since, the prescribers did not know the weight of the patient, they guessed 
the weight and prescribe a dose as occurred in Group 1. Once a dosing chart and the 
weights of the patients were provided, there was a significant improvement in the 
 201
appropriate dosage prescribing of paracetamol in Group 2. Although the intervention 
period was relatively short it still demonstrates that pharmacists can have a positive 
impact on prescribing. 
 
 
In India, health care is subsidised by the government and free medical care including 
medicines is available in government-sponsored hospitals. According to the annual report 
in 1998-1999 from the Govt. of India, there were 14,000 full-fledged hospitals, 810,538 
hospital beds, 22,243 primary health care centers and 131,471 sub-primary health centers 
of which all are government owned in which 503,900 doctors are providing services to 
patients.{Grandis JR, 1992 #150;Grandis JR, 1992 #151} These numbers are low when 
the size of the population is considered and is below WHO recommendations.  
 
 
India produces 20,000 diploma and 11,000 degree and 1000 postgraduates in pharmacy 
each year, which is more than any other developing country in the world. In most 
hospitals, the hospital pharmacy section is often consigned to a mediocre location and 
facilities are often outdated, antiquated and nonfunctional. Unlike the west, the role of the 
pharmacist in hospitals in India has until now not been fully utilized. Several training 
courses in hospital and clinical pharmacy have occurred since 1999 in India with the help 




Ceftriaxone is a 3rd-generation cephalosporin with a prolonged half-life, a broad 
spectrum, and excellent bioavailability when administered intramuscularly, allowing 
effective once daily intramuscular treatment for pneumonia and many other severe 




In a study by Dagan et al[45], children and infants with community-acquired serious 
infections were safely and effectively treated as outpatients using a regimen of once daily 
ceftriaxone given intramuscularly. A retrospective study by Powell & Mawhorter[46], 
showed that ceftriaxone was efficacious for the completion of therapy on an outpatient 




Dagan et al[45] have also shown that there was a saving of 376 days of hospitalisation for 
the 72 successfully treated patients. The only cost during their treatment was for 
ceftriaxone and the daily clinic visits. This represents a considerable financial saving 
compared with the cost of inpatient management for those conditions. Furthermore all 
successfully treated patients and their parents resumed normal activity within 3 days after 
initiation of treatment. 
 
 
In SHSC, dexamethasone was prescribed with every dose of parenteral antibiotic to 
prevent any anaphylactic reaction due to antibiotic administration. ANTG does not 
recommend any steroid administration with the parenteral antibiotic. Steroids in 
pharmacological doses depress cell-mediated immunity more than humoral immunity, 
leading to an impairment of monocyte/macrophage killing, antigen processing, and 
cytokine release. They may potentiate infection with intracellular pathogens due to 
suppression of release of γ-interferon, interleukin-1, and interleukin-2 from T-
lymphocytes.[47] Stuck et al reported that, the overall rate of infection in patients 
receiving systemic corticosteroids was 13%.[48] It is noted that dexamethasone was 
prescribed in all patients in Group 1 and none in Group 2 following the intervention. It 
was found that none of the patients were readmitted to the hospital due to any 




Children pose unique challenges to the system for ordering, dispensing, administering, 
and monitoring medications. For instance, since weight-based dosing is needed for most 
drugs in pediatrics, ordering medications typically involves calculations and therefore 
more potential errors than for adults.[49] 
 
 
Paracetamol is an antipyretic, widely used in children, which does not induce nausea and 
vomiting. It has a good reputation for safety within the recommended dosage range. The 
antipyretic effect of paracetamol is directly related to its plasma concentration.[50] Patients 
on low anti-pyretic dosage suffer high temperatures, severe complications, longer 
duration of hospital stay and increased costs and patients on high dosage may suffer from 
hepatotoxicity. However, toxicity has been reported rarely with therapeutic doses when 
administered over several days in children who have concurrent illnesses such as fever, 
vomiting, and diarrhoea.[51] 
 
 
In this study 55% of the children in Group 1 received doses above that recommended. Of 
particular concern were 8 children being prescribed more than 100% of the recommended 
dose. In addition to the immediate concern, medically prescribed dosages of medicines 
that are easily purchased subsequently such as paracetamol may lead to these dosages 




Severe community-acquired pneumonia presents challenges in the management of 
children, since its morbidity is significant, its diagnosis is intangible and the treatment 
choices are not always clear. Following the intervention there was no significant impact 
on the level of appropriate dosage prescribing of ceftriaxone and pediatricians have 
continued prescribing low doses of antibiotics to enhance patient compliance. Cost 
considerations were found to be a major contributing factor to the above problem. 
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Significant improvement was achieved in the level of appropriate dosage prescribing of 
paracetamol and following the intervention none of the patients were prescribed 
dexamethasone. There are social and economic factors influencing the prescribing of 
expensive drugs in the rural India. 
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Evaluation of antibiotic and analgesic prescribing in Adenoidectomy, Tonsillectomy 
and Adenotonsillectomy procedures in pediatric patients 
 
6.1 Introduction 
Tonsillectomy (TON), adenoidectomy (ADD) and adenotonsillectomy (ADT) are the 
most common major surgical procedures performed by otolaryngologists in children 
younger than 15 years of age [1-3]. Although the frequency of those procedures has 
decreased from the peak levels of the 1960s, an estimated 140,000 US children 
underwent ADD, and 286,000 underwent ADT procedures in 1994 [2, 4, 5]. 
 
 
Times have changed dramatically since Cornelius Celsus performed the first known 
tonsillectomy almost 2000 years ago[5]. As surgical techniques have improved through 
the years, complications associated with TON have decreased. However, many patients 
experience pain and nausea postoperatively. These effects may limit their activity level 
and oral fluid intake, leading to dehydration and a prolonged hospital stay. Many 
otolaryngologists prescribe antibiotics for patients who undergo TON [6]. 
 
 
Prolonged adenoidal upper airway obstruction may result in obstructive sleep apnea or 
cardiorespiratory syndrome requiring prompt surgical intervention. Adenoidal 
hypertrophy which obstructs the nasal airway in children is associated with multiple 
symptoms, including snoring, nasal congestion and chronic mouth breathing [7]. Chronic 
sinusitis, recurrent otitis media associated with pediatric adenoidal hypertrophy are the 




The purpose of this study was to evaluate the prescribing pattern of antibiotics and 
analgesics in ADD, TON and ADT procedures in children at a pediatric teaching hospital 




6.2.1 Setting and patient population 
A retrospective study was conducted at Princess Margaret Hospital for Children, Subiaco, 
Western Australia, a 250-bed pediatric teaching hospital. All patients admitted for ADT, 
ADD and TON surgery were eligible to be included in this study. Drug prescribing for 
the above procedures was obtained retrospectively for all cases coded for each procedure 
over the period June to November 1999. The records were obtained from the Patient 
Information Management Services Department. Patient consent and ethics approval was 
not required since it was classified as a quality assurance audit. 
 
 
Data was collected on the prescribing of antibiotics and analgesics for both prophylaxis 
and treatment and entered from the medical records onto a coded form. Patient details 
included age, weight, sex, date of admission, date of discharge, clinical details such as 
principal diagnosis and principal procedure and medication details including drug name, 
dose, frequency, route and number of doses administered. Prophylactic antibiotics 
prescribed were sourced from the operation drug sheet; drugs prescribed in the ward were 
obtained from the inpatient medication sheet and discharge medications from discharge 
medication sheet. The collected data were evaluated against the Australian Therapeutic 




6.2.2 Australian Therapeutic Guidelines for Antibiotics and Analgesics 
Pre-operative prophylaxis: According to the guidelines, prophylaxis should be considered 
for clean contaminated head and neck procedures that involve an incision through the 
oral, nasal, pharyngeal or oesophageal regions. The preferred regimen is cephalothin 25 
mg/kg up to 2g or cephazolin 25 mg/kg up to 1g intravenously, at the time of induction.  
Post-operative antibiotics: For post-operative treatment, amoxicillin 15mg/kg up to 
500mg, PO q8h or cefaclor 10mg/kg up to 250mg PO q8h for seven days.  
Post-operative analgesics: The standard recommended dose for paracetamol is 20 
mg/kg/6hrly or 15 mg/kg/4hrly when required to a maximum of 100 mg/kg/24hrs. 
Ibuprofen, an alternative, should be given as a 5-10 mg/kg/dose, 6-8 hourly. 
 
 
For this study, an appropriate dose was classified as one prescribed within ±25% of the 
recommended dose and an appropriate choice of the drugs / combination of drugs were 
those recommended in the guidelines. The designated dosage error of ±25% was based on 
the common variability allowed in dosage forms and bio-equivalency studies. Statistical  
evaluations were performed using χ2 analysis for non-parametric and differences in 
parametric data were tested using Student’s t-test. 
 
 
6.3 Results  
A total of 221 patients’ medical records comprising 115 males and 106 females were 
analysed. Of these patients, one infant (1 month to 1 year), 10 toddlers (1-2 years), 187 
children (3-12 years) and 23 teenagers (13-17 years). Of 221 patients, 170 underwent 
ADT, 42 ADD, and 9 TON.  
 
 
The mean age of the patients was 6.63 years. No significant difference occurred between 
the mean of age of patients for the procedures ADT & ADD but a statistically significant 
difference was found between ADT & TON and ADD & TON (Table 1).  
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In ADT, 6 different types of drug regimens and 2 in ADD were considered appropriate 
perioperative antibiotics (Tables 6.2 and 6.3). In TON procedures, 2 of 5 drug regimens 
were considered appropriate antibiotic choices (Table 6.4). All the discharge antibiotic 
regimens used in ADT, ADD and TON were considered appropriate (Tables 6.5-6.7). 110 
out of 170 in ADT, 6 of 42 in ADD and 8 of 9 patients in TON were on peri-operative 
antibiotics and 112 of 170 in ADT, 7 of 42 in ADD and 7 of 9 in TON were on discharge 
antibiotics. 
 
Table 6. 1 Comparison of mean age (years) between procedures 
Type of surgery Number of patients Mean age Standard deviation P value
Adenotonsillectomy 170 6.33 3.13 
Adenoidectomy 42 6.35 3.83 
0.966 
Adenotonsillectomy 170 6.33 3.13 
Tonsillectomy 9 13.6 3.3 
0.000 
Adenoidectomy 42 6.35 3.83 




Table 6. 2 Profile of antibiotic/s prescribed post-operatively in adenotonsillectomy 
Drug/s prescribed Number of patients 
Amoxycillin 104 
Amoxycillin + ceftriaxone 1 
Augmentin 1 
Cefaclor 2 
Amoxycillin + cefotaxime 1 
Cefaclor + gentamicin 1 





Table 6. 3 Profile of antibiotics prescribed post-operatively in adenoidectomy 
Drug/s prescribed Number of patients 
Amoxycillin 5 
Augmentin 1 




Table 6. 4 Profile of antibiotics prescribed in tonsillectomy 
Drug/s prescribed Number of patients 
Amoxycillin 4 
Benzyl penicillin + metronidazole 1 
Benzyl penicillin 1 
Flucloxacillin 1 
Cefaclor 1 




Table 6. 5 Profile of discharge antibiotics prescribed in adenotonsillectomy 









Table 6. 6 Profile of discharge antibiotics prescribed in adenoidectomy 








Table 6. 7 Profile of discharge antibiotics prescribed tonsillectomy 








32 of 116 on amoxycillin prescribed peri-operatively and 30 of 121 on amoxicillin and 1 
of 3 on cefaclor prescribed as discharge antibiotics are on appropriate dosages. 147 of 
201 on Liquigesic, 101 of 123 on paracetamol, 7 of 7 on Panadeine, 21 of 27 on 







Table 6. 8 Profile of drug dosage prescribing in adenotonsillectomy 
No of patients (doses) 
below the recommended 
dose 

















Total no of 
patients 
(doses) 
Amoxycillin 66 (121) 14 (28)  26 (65) 106 (214) 
Augmentin 1 (1)    1 (1) 
Cefaclor  1 (2) 2 (18)  3 (20) 
Cefotaxime    1 (12) 1 (12) 
Ceftriaxone    1 (1) 1 (10 
Gentamicin    1 (1) 1 (1) 
Ibuprofen    8 (15) 8 (15) 
Liquigesic 44 (119) 2 (2)  125 (281) 171 (402) 
Paracetamol 13 (22) 1 (2) 4 (8) 78 (119) 96 (120) 
Panadeine    4 (5) 4 (5) 
Panadeine 
forte 












Table 6. 9 Profile of drug dosage prescribing in adenoidectomy 
No of patients (doses) 
below the recommended 
dose 

















Total no of 
patients 
(doses) 
Amoxycillin 2 (2) 1 (1)  2 (3) 5 (6) 
Augmentin  1 (2)   1 (2) 
Ibuprofen    1 (1) 1 (1) 
Liquigesic 8 (12)   19 (23) 27 (35) 
Paracetamol 2 (2)  2 (2) 17 (20) 21 (24) 
Panadeine    2 (5) 2 (5) 
Panadeine 
forte 
















Table 6. 10 Profile of drug dosage prescribing in tonsillectomy 





No of patients 
(doses) on 
appropriate doses 
Total no of 
patients 
(doses) 
Amoxycillin  4 (8) 4 (8) 
Benzyl penicillin 2 (4) 1 (7) 3 (11) 
Cefaclor  1 (1) 1 (1) 
Flucloxacillin 1 (2)  1 (2) 
Metronidazole  1 (4) 1 (4) 
Ibuprofen  1 (1) 1 (1) 
Liquigesic  3 (7) 3 (7) 
Paracetamol  6 (6) 6 (6) 
Panadeine  1 (2) 1 (2) 

















Table 6. 11 Profile of discharge drug dosage prescribing 
No of patients (doses) 
below the recommended 
dose 




















Amoxycillin 74 (1554) 12 (252)  25 (525) 111 (2331) 
Augmentin® 1 (7)    1 (7) 
Cefaclor   1 (7)  1 (7) 
Liquigesic®    1 (5) 1 (5) 
Adenoidectomy 
Amoxycillin 4 (84)   1 (21) 5 (105) 
Augmentin® 1 (21)    1 (21) 
Cefaclor    1 (21) 1 (21) 
Tonsillectomy 
Amoxycillin 1 (21)   4 (84) 5 (105) 
Augmentin 1 (21)    1 (21) 
Cefaclor  1 (21)   1 (21) 
 
 
All the patients having TON & ADT procedures were prescribed one or more than one 
analgesic peri-operatively but in ADD 40 of 42 were only on analgesics. Paracetamol has 
been prescribed for 10%, paracetamol/codeine preparations for 52%, paracetamol and 
paracetamol/codeine preparations together prescribed for 33%, ibuprofen and 
paracetamol for 1.4%, paracetamol, paracetamol/codeine and ibuprofen for 0.9% and 





Table 6. 12 Profile of analgesics usage 
Analgesics prescribed Adenotonsillectomy Adenoidectomy Tonsillectomy
Paracetamol alone 9 12 1 
Paracetamol/codeine 
preparations only 




64 5 4 
Ibuprofen + paracetamol 3 - - 
Paracetamol/codeine + 
ibuprofen 




2 - - 
Total number of patients on 
analgesics in the total 
170/170 40/42 9/9 
 
 
The total mean length of stay was 1.98 days. There was an increase in the mean length of 
stay in ADT and TON compared to total mean length of stay. Significant differences in 
the mean length of stay between ADT & ADD and ADD & TON but not between ADT 
& TON was found (Table 6.13).  
 
 
No significant difference in the mean length of stay between patients received and not 
received antibiotics post-operatively in ADT and TON (Table 6.14). There was an 
increase in the mean length of stay between patients received antibiotics to patients not 




Table 6. 13 Comparison of mean length of stay between procedures 
Type of surgery Number of 
patients 
Mean length of 




Adenotonsillectomy 170 2.12 0.82 
Adenoidectomy 42 1.35 0.48 
0.000 
Adenotonsillectomy 170 2.12 0.82 
Tonsillectomy 9 2.22 0.66 
0.724 
Adenoidectomy 42 1.35 0.48 




Table 6. 14 Comparison of mean length of stay between patients received and not 
received antibiotics 








Antibiotics 109 2.14 0.95 
No antibiotics 60 2.08 0.52 
0.624 
Adenoidectomy 
Antibiotics 4 2.0 0.000 
No antibiotics 36 1.26 0.44 
0.002 
Tonsillectomy 
Antibiotics 8 2.25 0.70 





Table 6. 15 Comparison of mean length of stay of patients received and not received 
antibiotics 
Category Number of 
patients 





Antibiotics 124 2.14 0.91 




There was no significant difference in the mean length of stay found between patients 
received antibiotics between ADT & ADD, ADT & TON and ADD & TON and patients 
received appropriate and inappropriate antibiotic dosages in ADT &ADD (Table 6.16 to 
6.17). And a statistically significant difference found between patients not received 
antibiotics between ADT & ADD (Table 6.18). 
 
 
Table 6. 16 Comparison of mean length of stay between patients received antibiotics 
Type of surgery Number of 
patients 
Mean length of 




Adenotonsillectomy 109 2.14 0.95 
Adenoidectomy 4 2.0 0.000 
0.759 
Adenotonsillectomy 109 2.14 0.95 
Tonsillectomy 8 2.25 0.70 
0.764 
Adenoidectomy 4 2.0 0.000 









Table 6. 17 Comparison of mean length of stay between patients received 
appropriate and inappropriate antibiotic dosages 
Type of surgery Number of 
patients 








28 2.4 1.1 
Inappropriate 
(ADT) 





2 2.0 0.000 
Inappropriate 
(ADD) 





7 2.5 0.97 
Inappropriate 
(TON) 





Table 6. 18 Comparison of mean length of stay in days between patients not received 
antibiotics between ADT & ADD 
Category Number of 
patients 





ADT 60 2.08 0.52 





Tonsillectomy, adenoidectomy and adenotonsillectomy are still common procedures 
performed in the pediatric age group and are reportedly associated with significant 
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morbidity [11]. More than 200 patients underwent ADT, ADD and TON procedures at 
PMH in approximately six months. Most patients underwent an ADT procedure. 
 
 
Streptococcus pyogenes was the pathogen responsible in 90% of cases of chronic 
tonsillitis in the 1990’s, however there is increasing evidence that Haemophilus 
influenzae and Staphylococcus aureus may now play significant roles. Both of these 
organisms are β-lactamase producers and are characterised by multi-resistance to 
antibiotics. In the Colreavy study, patients were treated post-tonsillectomy with an 
antibiotic which provided cover against these organisms who were identified as chronic 
carriers [5]. Antibiotics administered intra-operatively and for 7 days after surgery 




In 1956, Orzac noted the use of pre-operative and post-operative antibiotics to relieve 
pain [5]. In 1980’s Telian et al [13] demonstrated that the use of pre-operative antibiotics 
decreased post-operative fever and pain, leading to improved oral intake of liquids. None 
of the patients in this study received any antibiotics pre-operatively. 
 
 
Morbidity that children experience subsequent to surgery includes intermittent fever, 
throat pain, odynophagia with poor oral intake, weight loss, and a foul odour from the 
mouth following adenotonsillectomy procedures. Many surgeons attempt to prevent or 
minimise these symptoms by treatment with antibiotics in the postoperative period [13]. 
In this study, 121 of 218 (55%) patients were prescribed post-operative antibiotics and 
analgesics and the remaining patients were only given analgesics. 
 
 
Grandis et al found a statistically significant improvement in postoperative morbidity in 
adult patients who received amoxycillin and clavulanic acid after tonsillectomy[14]. This 
 224
study identified 115 patients prescribed amoxycillin and two patients given 
amoxycillin/clavulanic acid as post-operative antibiotics.  
 
 
The mean length of stay of patients who received antibiotics was higher than those on no 
antibiotics. A possible explanation is that patients whose procedure had warranted 
antibiotics may have been considered a greater risk so there was an increased length of 
stay. In general this only amounted to a few hours. 
 
 
According to Jones et al, there was no significant difference between cefaclor and 
amoxycillin treated groups post-operatively for a period of seven days. They concluded 
that cefaclor should be reserved for the child who demonstrates a protracted or difficult 
recovery following the surgery [15]. In this study, 58% (127 of 218) of the patients 
received post-operative antibiotics for a period of seven days. Of these, 1% (3) patients 
received cefaclor and the remainder received amoxycillin as a discharge medication. 
 
 
Underdosing in relation to the guidelines was identified in this study with 68% (83/121) 
of the patients on antibiotics and 22% (82/368) of prescriptions for analgesics having 
doses considered to be below the recommended minimum dose. Examples were: (i) 
68/114 patients on amoxycillin (ward) and (ii) 79/121 patients on amoxycillin (discharge) 
were on 26-50% below the recommended dose. Suboptimal dosing of antibiotics has two 
potential consequences: those of therapy failure and the possible emergence of antibiotic 
resistance [8].  
 
 
The ideal postoperative pain medication should provide adequate analgesia while 
minimizing side effects. Two of the most commonly used pain medications after pediatric 




Paracetamol is an analgesic widely used in children and does not induce nausea and 
vomiting. It has a good reputation for safety within the recommended dosage. The 
analgesic effect of paracetamol is directly related to its plasma concentration [17]. In this 
study, 73/359 prescriptions for paracetamol/paracetamol with codeine products were 
prescribed at 26-50% below the recommended dose, hence their full analgesic 
effectiveness may not be achieved. Low dosages of paracetamol might lead to 
preventable suffering of pain and a longer length of stay in the hospital.  
 
 
The addition of codeine gives the theoretical advantage of two analgesics with different 
mechanisms of action combined to enhance analgesia [16]. In a meta-analysis of 19 trials, 
De Craen et al [18] found that the addition of codeine to paracetamol produced a 5% 
increase in analgesic effect. According to Harley and Dattolo [19] paracetamol with 
codeine appeared to be a more efficacious agent in the treatment of early post-
tonsillectomy/adenotonsillectomy pain in children. They found that children treated with 
paracetamol with codeine appeared to resume normal night time sleeping patterns and 
return to a regular diet earlier than those treated with paracetamol alone. 
 
 
NSAIDs are an attractive option for the relief of post tonsillectomy/adenotonsillectomy 
pain because of the neutralization of prostaglandin-induced inflammation and oedema. In 
children with severe airway obstruction, the potential for central nervous system 
depression, as would be seen with opiates, is averted [19]. Forbes et al. noted ibuprofen 
and ketorolac to be more effective analgesics, with fewer side effects than paracetamol 
with codeine. Ibuprofen was as effective as paracetamol with codeine in postoperative 
analgesia. Ibuprofen and paracetamol with codeine were equal in their effect on 
postoperative temperature control and bleeding. Furthermore, ibuprofen patients had 
much less nausea than paracetamol with codeine patients. Therefore ibuprofen appears to 




Besides evaluating antibiotic and analgesic usage in TON, ADT and ADD procedures in 
children, this study has in addition evaluated the dosage prescribing appropriateness in 
the same subjects. With respect to the latter it has identified dosages that warrant further 
review by clinicians.  
 
 
Review is an essential element of drug policies in hospitals, but as far as antibiotic agents 
are concerned such a review should include a reconciliation of the guidelines and usage 
with antibiotic resistance and cost. The application of antibiotic policies will resulted in 
improved practices and reduced costs [20]. 
 
 
Providing feedback to clinicians regarding their own prescribing practices has been a 
successful technique for achieving behaviour change. Feedback can entail comparisons 
with peers or with a standard. As with practice guidelines, feedback may be most 
effective when the system is developed with local input, where clinicians accept the 
measures as important, fair, and relevant to their own practices [21]. 
 
 
Ideally, the pharmacist should be involved in pursuing the above objectives through 
continually monitoring prescribing, providing information to new doctors and nurses and 




In the study subjects, the major finding was that the dosages prescribed for post-operative 
and discharge antibiotic and analgesics were somewhat lower than those recommended in 
the current guidelines. None of the patients received prophylactic antibiotics and many 
patients did not receive post-operative and discharge antibiotics. When prescribed most 
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of the patients received a recommended post-operative antibiotic regimen and a small 
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This thesis has considered major areas of drug usage in pediatric settings. It has identified 
that the interventions used can have an impact on prescribing including the dosage levels. 
Different intervention strategies were used in each study to alter the prescribing 
behaviour. Different studies have shown varied levels of change in the prescribing 
behaviour according to the type of intervention implemented. 
 
 
This thesis has investigated quality use of medicines in a range of pediatric settings 
including some limited but important studies in developing countries. In terms of the 
evaluations in pediatric hospitals an overall approach to understanding usage was initially 
studied. Drilling down from that broad evaluation then occurred to investigate in depth 
specific treatments in selected disease states. These were selected based on usage patterns 
e.g. ceftriaxone where there was potential for the usage to be modified where other 
antibiotics were recommended in Australian or local guidelines. In the pediatric setting 
dosage is a much greater factor since it varies with respect to age, weight or surface area. 
Dosage being less variable in adults except in a small number of drugs with a narrow 
therapeutic range is often less important. In previous studies in pediatric settings 
involving rational drug usage dosages have received a low priority. 
 
 
To have any influence on drug usage there has to be the ability to communicate and 
achieve a consensus. The availability or development of national or local policies against 





A range of methodologies has been employed in these studies. The random controlled 
trial (RCT) is considered the gold standard for providing a high level of scientific 
validity. The normal methodology for a RCT is not directly applicable to drug usage 
studies involving interventions since the intervention cannot usually be contained or 
blinded to one group of prescribers. Hence the pre-post design is the most common 
approach adopted. The weakness in this design is that change may have occurred as a 
result of external factors (e.g. a recently published paper). This design is strengthened by 
the use of a control group and time series analyses with respect to the intervention. 
 
 
The above methodology was adopted for these studies as the most appropriate for this 
type of investigation. Data collection can be retrospective or prospective. In this study 
both were used but in the main study retrospective collections were performed. The 
advantages of retrospective studies are the lack of influences on prescribers. It is 
advantageous to adopt standard methodologies to eliminate bias in data collection. The 
major issue in retrospective collections is insufficient or deficient data recorded. This was 
not a significant factor in these studies. 
 
 
Several studies have evaluated drug usage in children[2-7], and in pediatric 
appendectomy[8-10], but none of the studies considered dosage prescribing appropriateness 
in children. Our study has identified that pharmacist intervention influences drug dosage-
prescribing appropriateness of pediatricians in pediatric settings. 
 
 
In this study the term appropriateness related to the prescribing of dosage or drug or both 
in accordance with the guidelines used in this study. The term appropriateness has been 
defined differently in different studies. In a French study by Talon et al.[11] which 
evaluated surgical antimicrobial prophylaxis, used the terms acceptable and unacceptable 
in their study. A multi-centre study by Bailly et al.[12] on surgical antibiotic prophylaxis in 
eighteen hospitals used the terms justified and not-justified. Tunger et al.[7] used the terms 
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rational and irrational use for antibiotics. The terms defined in other studies have a 
similar meaning to this study where we have used appropriate and inappropriate.  
 
 
7.2 Practice guidelines 
Practice guidelines have been developed in many countries and become well 
recognized[13]. The value of using guidelines as the underlying arbiter in this study is the 
view that they are independent, involve multidisciplinary groups either local national or 
international in their development and the information is clearly defined[14]. 
 
 
Often guidelines provide recommendations based on cost-effectiveness as part of their 
decision-making, although the main aim is to reduce inappropriate practices. The 
literature includes methodological approaches for the development of guidelines[13, 14]. 
 
 
This study has commonly employed the Australian Therapeutic Guidelines. Initial studies 
have shown that despite popularity there was only limited antibiotic prescribing that 
complied with the recommendations[15]. Many studies have identified the value of 
guidelines as an acceptable basis for clinical practice[16]. Poor acceptance usually arises 
from a lack of ownership or where there is difficulty in application at the clinical 
interface[16, 17]. This study had built on the general acceptance of national and local 
guidelines being accepted bases for quality prescribing. This has not been questioned in 
areas of the studies carried out. 
 
 
7.3 Therapeutic guidelines and studies on surgical prophylaxis and antibiotic usage 
The Therapeutic Guidelines indicated that for abdominal surgery adequate concentrations 
of antimicrobial must be present prior to surgery. A single dose is usually sufficient 
unless the procedure is longer than 3 hours. Several alternatives are available however 
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cefetotan is recommended as a single agent at the time of anaesthetic indication{Grandis 
JR, 1992 #54}. 
 
 
This recommendation was adopted within the hospital following appropriate consultation. 
The second-generation cephalosporins are used widely in surgical prophylaxis and are a 
current recommendation for appendectomy procedures[19-21]. In a review, which has 
evaluated the literature, cefotetan (n = 389) had a low rate in infection failure at 8.4%, 
lower than most other commonly used regimes. The adverse event rate for cefotetan was 
slightly higher than some other regimes however the range is less marked. An overall 
assessment of cefotetan selected for this study was as good or better than combination 
therapy with respect to overall efficacy[22]. The major advantage was the simplicity of a 
single dose. This allows it to be used in a similar way to ceftriaxone, as this is an 
inappropriate choice because of its potential for producing resistance. 
 
 
Emil et al.[23] evaluated the current therapeutic recommendations for appendicitis in 
children in pediatric surgery department. In their study, gentamicin (2mg/kg) and 
clindamycin (10mg/kg) were given as prophylactic antibiotics to all the patients. For 




In this appendectomy study, for routine prophylaxis including patients with ‘non-
anaphylactic’ penicillin allergy, cefotetan 50mg/kg IV (maximum dose of 1g) as a single 
dose was given at the time of induction of anaesthesia. Patients with a history of 
penicillin allergy, clindamycin 10mg/kg IV (maximum dose 600mg) and gentamicin 
7mg/kg IV, was given as a single dose at the time of induction. To determine whether the 
appendix was normal or not, was based on the pathology report irrespective of the 
surgeons diagnosis. Generally the pathology report was sent to the surgeon two days after 
the surgery. In the mean time, surgeons might have given antibiotics post-operatively. In 
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this study, patients with a normal appendix also received post-operative antibiotics. Even 
though different prophylactic regimens were used in the Emil et al. study, they worked 
effectively. But the outcomes were different from our study. Their infection rate was 
higher 88/648 (13.6%) than ours 2/207 (0.9%), length of stay was lower, and the number 
of patients that did not receive prophylactic antibiotics was 21/648 (3.2%) lower than our 




In the study by Bailly et al. 112/117 (95.7%) patients received an antibiotic with a 
broader spectrum of activity than that recommended; mostly third generation 
cephalosporins or quinolones instead of first or second-generation cephalosporins or co-
amoxiclav. In a study in Thailand[24], second or third generation cephalosporins were 
given when cefazolin would have been equally effective, which was classified as an 
inappropriate choice of antibiotics for surgical prophylaxis. In their study, they concluded 
that third-generation cephalosporins should not be prescribed for surgical prophylaxis, as 
the use of these broad-spectrum agents leads to unacceptable increases in hospital costs 
and the emergence of resistant bacteria and superinfections. In our study, 58% (59/102) 
of the patients were on third generation cephalosporins in the pre-intervention study, 
which was decreased to 6% (6/105) following the implementation of multi-faceted 
educational intervention program. Knowledge of diagnostics and therapeutics is believed 
to play a role in inappropriate prescribing of antibiotics. Doctors in their desire to use 
‘potent’ medicines, tend to use newer, broad-spectrum, more expensive agents, as 




Van Houten et al.[6] analysed the utilisation of antibiotics in a pediatric hospital over three 
consecutive years, with special regard to antibiotic prescription attitudes and patterns. 
They found that children admitted to intensive care units and young children are 
especially at risk of receiving multiple courses of antibiotics. A total of 1120 patients 
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were admitted during the study period in their study, of which a mean of 36% received at 
least one course of antibiotics during their hospitalisation. During the study period a shift 
to the use of more expensive and broader spectrum antibiotics was noticed for all groups. 
In the initial broad study of drug usage reported in this thesis 25.5% of patients were 
prescribed antibiotics.  
 
 
7.4 Intervention studies 
In our study, 0% of patients were on an appropriate prophylactic antibiotic regimen, 
which was increased to 68% and appropriateness of total antibiotic dosages from 0% to 
57% following the implementation of treatment guidelines developed by the pharmacy 
department in conjunction with microbiology and surgical services divisions through a 
multifaceted educational intervention program. In community-acquired pneumonia where 
data was collected for two weeks before and after the implementation of the intervention 
by giving feedback of the pre-intervention study results. An educational intervention 
program carried out in Thailand[24] has a similar methodology as the community-
acquired pneumonia study and guideline development in the appendectomy study. They 
found that a 22% reduction in the prevalence of antibiotic use for in-patients, and a 23% 
for out-patients occurred after the intervention. The cost of antibiotics was decreased by 
20%. In a pediatric department, the prevalence of antibiotic use in in-patients decreased 
from 59% to 50% and 54% to 36% in the out-patient setting. In their study, the guidelines 
for the appropriate use of antibiotics was developed by an antibiotic use committee with 
support from clinical, pharmacology, microbiology and finally approved by the medical 
department. The intervention was implemented by providing training sessions for 
individual groups of prescribers separately. Feedback was given two weeks following the 
intervention and the impact was then evaluated for a week after the intervention. 
However the intervention was a single workshop and followed for only one week. Its 




Gorecki et al[26] compared the efficacy of Surgical Infection Society (SIS) guidelines 
versus common practice for antibiotic usage in pediatric surgery patients. They defined 
appropriate prophylactic administration, which was adopted from SIS guidelines but 
failed to define the acceptable dosage error in the study. There was no pre-intervention 
study to compare the impact of the guidelines. 
 
 
The study was divided into two groups, Group A prescribers were SIS guideline 
supporters and Group B common practice supporters. The mean duration of antibiotic 
treatment was 3.9 days in Group A and 7.1 days in Group B, antibiotic usage 
appropriateness was 77% and 36% and excessive duration of treatment received was in 
31% and 54% of patients. Their effort to follow the SIS guidelines resulted in 
significantly better antibiotic usage than in the comparative group B.  
 
 
They stated that the inability of the clinician to distinguish between inflammation, 
contamination, and infection and the failure to stratify its severity were the main reasons 
for the excessive administration of antibiotics. Consequently, courses of treatment were 
continued for periods much longer than needed. The current pediatric surgery 
environment demands the provision of quality health care at an affordable cost. Both 
payers and regulators are committed to lowering cost through initiation of best practice 
strategies that include practice guidelines, clinical pathways, and standards of care[26]. 
 
 
In our study, we evaluated the dosage of inappropriately administered antibiotics to 
evaluate the ability of surgeons to prescribe recommended antibiotic dosages 
appropriately. This gives information about surgeon’s ability to prescribe other drug 
treatments also. The definition of dosage and acceptable dosage error was clearly defined 
in our study. In a study by Talon et al.[11] both indication and choice of antibiotic were 
considered inappropriate, dosage was not evaluated. How was the dosage evaluated and 
the definition for the appropriate dosage was not mentioned in their study. The 
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percentage of patients on appropriate dosage of antibiotic was higher than in our study 
since adults were given fixed dosage units, the chances of prescribing an inappropriate 
dosage is therefore lower.  
 
 
Emil et al. in their study on appendicitis in children, dosage appropriateness was not 
defined and also not evaluated[23]. In a multi-centre study by Bailly et al., dosage 
evaluation was considered but not defined what was the acceptable appropriate dosage 
error in the study[12]. Tunger et al. collected data related to dosage of antibiotics, but 
never considered their appropriateness[7]. 
 
 
A recent French study[11] in adult patients in four surgical departments evaluated the 
surgical antimicrobial prophylaxis in various procedures before and after the 
implementation of local guidelines, found that 75/101 (74%) of patients were on 
appropriate antibiotic choice which changed to 124/129 (96%) following the intervention. 
The number of patients on appropriate dosage was 72/77 (96%) improved to 123/124 
(99%). The total appropriateness in their study was 45/145 (31%), which increased to 
114/139 (82%) following the intervention with a significant difference. The success of 
their intervention was due to the development of guidelines by anaesthetists in 
collaboration with surgeons, who are the main antibiotic prescribers in the theatre and 
surgical department. In our study, clinical pharmacists in conjunction with clinical 
microbiologists and the division of surgical services developed the guidelines. We also 
achieved a statistically significant improvement in the total appropriateness of antibiotic 




Dean et al.[27] evaluated the impact of their intervention following the implemented 
treatment guidelines for community-acquired pneumonia. In their study, they 
implemented the guidelines by giving formal presentations, academic detailing, letters, 
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reminders by pharmaceutical representatives, pre-printed outpatient and admission order 
sheets, and reporting of outcome data to providers[26]. This is similar to our multi-
faceted educational intervention program implemented in appendectomy study. In our 
study, we released a newsletter, gave presentations, held formal discussions, posted 
guideline posters in ward and theatre and reminded by clinical pharmacists in the wards. 
 
 
The limitations of their study were data related to specific antibiotic use and severity of 
the pneumonia patients were not evaluated. However, among all patients admitted to the 
Intermountain Health Care hospitals during the study period, the percentage that were 
treated with a guidelines-recommended antibiotic regimen increased from 677/2350 
(28.1%) to 1386/2462 (56.3%) before and after the implementation of the guidelines[27]. 
Although a significant improvement, the extensive nature of the intervention has had only 
a moderate effect. 
 
 
Berbatis et al.[28] evaluated the effect of drug bulletin on prescribing of oral analgesics 
before and after the release of drug bulletin. They found a marked improvement in 
prescribing but the effect was short-lived. Drug bulletins can be used to create an 




Dobrzanski et al.[29] evaluated the impact of guideline introduction on peri-operative 
antibiotic prescribing of surgeons in a district general hospital. They found a decrease in 
the number of antibiotic doses, total cost per patient, and increase in the number of 
patients on appropriate therapy. In their study they did not mentioned how the 
intervention was implemented or guidelines developed. A major financial impact was 
shown with the mean antibiotic cost per patient. The pharmacist interaction program with 
verbal consultation between pharmacists and physicians was effective in improving 




Davis et al.[31] reviewed 50 randomised controlled trials to assess the impact of diverse 
continuing medical education interventions on physician performance and health 
outcomes and they showed that the methods of continuing medication education were 
very important in changing the behaviour of clinicians. The method of disseminating 
information alone produced mostly negative or inconclusive results whereas the methods 
of dissemination of information plus the measure facilitating the desired change in the 
practice site or reinforcing via reminders or feedback consistently improved physician 
performance and in some instances, health outcomes. In the area of prescribing 
antibiotics, it has been shown that antibiotic guidelines or mailed brochures alone were 
unlikely to be effective[32, 33], although some of the studies found a minimal effect[29]. 
However, when other interventions such as problem-oriented training sessions, face-to-
face information via pharmacist or physician visits, reminders, or information campaigns 
were used or combined in the educational program, they were likely to be effective in 
improving antibiotic use[34, 35]. 
 
 
In this drug utilisation evaluation study, a change of appropriateness of dosage 
prescribing of ceftriaxone from 58% to 89% (p<0.001), flucloxacillin from 68% to 90% 
(p<0.001) and Liquigesic Co® from 73.8% to 73.9% (p>0.05) was noticed following the 
release of dosage guidelines in the form of a newsletter and given formal presentation by 
chief pharmacist. The intervention had an impact on the dosage prescribing of ceftriaxone 
and flucloxacillin. Liquigesic Co® dosage appropriateness did not show any significant 
improvement following the intervention. This shows that the intervention, which was the 
same methodology as for antibiotics, showed success for antibiotics and had no effect on 
analgesic prescribing. On further investigation it was found that prescribers were using a 
monograph, which is not endorsed by the hospital and also did not match the current 
guidelines for dosages of analgesics. When newsletters were used alone, without clinical 
pharmacist involvement they are not capable of affecting a large-scale change in the 
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short-term particularly if the motivation to change is low. If the degree of resistance is 
high, this intervention program should begin well in advance of the change.  
 
 
The percentage of patients on total antibiotic dosage in the appendectomy study was 
31%, 75% in drug utilisation evaluation study, 7% in community-acquired pneumonia 
study and 17% in tonsillectomy study and 67% of anti-pyretic dosage in liquid 
medication dosing errors study were identified as appropriate. Using antibiotics at an 
inappropriate dosage can led to resistant strains. Guillemot et al[36]. found that children 
treated with low daily doses of oral β-lactams had an increased risk of penicillin resistant 
streptococcus pneumococci carriage compared with children who did not. Patients on low 
anti-pyretic dosages suffer high temperatures, severe complications, longer duration of 
hospital stay and increased costs and patients on high dosage may suffer from 
hepatotoxicity. Following the implementation of the educational intervention program 
and introducing guidelines in appendectomy, providing feedback of the pre-intervention 
study results compared against national guidelines along with the treatment guidelines 
reinforced in all studies except in tonsillectomy, achieved a statistically significant 
improvement. 
 







Ceftriaxone 50/86 (58%) 68/76 (89%) <0.001 DUE 
Flucloxacillin 108/157 (68%) 87/96 (90%) <0.001 
Total antibiotic 0/102 60/105 (57%) <0.001 APP 
Total analgesic 159/222 (71%) 244 /260 (94%) <0.001 
LMDE Paracetamol (overall) 76/175 (43%) 160/162 (99%) <0.001 
CAP Ceftriaxone 3/144 (2%) 17/155 (4.5%) 0.180 
TON Total antibiotic (post-
operative) 




Different studies in this thesis have shown varied levels of inappropriateness in the 
prescribing of medications by pediatricians. But, the common basis of inappropriateness 
was the dosage prescribing. Prescribing inappropriate dosages was evident in both 
Australian and Indian studies reported in this thesis. Pharmacist educational intervention 
both initially and reminders had significantly improved appropriate dosage prescribing in 
the Australian studies. In Indian studies, the improvement was only seen in low cost 
drugs due to lower income patients who cannot afford expensive antibiotics. Hence the 
social context was clearly important in achieving change. In the Indian setting a more 
appropriate antibiotic, which would provide a similar outcome to ceftriaxone but is 
cheaper and at the first or second generation level needs to be identified. 
 
 
7.5 Pneumonia studies 
In community-acquired pneumonia study, the impact of intervention was seen in areas 
where there is no increase in cost of drug treatment to the patient. High antibiotic costs, 
low monthly incomes, poverty, no medical insurance and finally no government subsidies 
for prescription medications are the reasons led to the inappropriate dosage prescribing of 
antibiotics by pediatricians in that settings. Even though prescribers were aware of the 
appropriate dosage, intentionally they are prescribing low dosage to enhance patient 
compliance of taking medicines by reducing the cost of drug treatment. In this type of 
situation, if the pediatrician was to prescribe appropriate dosages, the patient cannot 
afford to buy the medicines, and the patient might shop around to find a cheaper drug 
treatment for their condition. Henceforth, the government should take an initiative to 
provide subsidies for essential drugs for at least people below poverty in India.  
 
 
In SHSC, dexamethasone was prescribed with every dose of parenteral antibiotic to 
prevent any drug reaction. Since there exits no system for reporting a suspected reaction, 
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and there is no official mechanism for alerting doctors of possible adverse reactions, the 
doctors are taking precautions to avoid any adverse events. Drugs are prescribed based on 
their familiarity rather than their efficacy and safety in pediatric patients in India. 
Following the intervention, the dexamethasone prescribing was stopped and no patient 
was re-admitted due to any adverse event. 
 
 
In developing nations bacterial infectious diseases are among the major clinical problems 
that the medical practitioner should be expected to manage with a high degree of skill and 
expertise. Therefore, the medical education system is obligated to prepare physicians to 
understand the key elements of medical microbiology and the fundamentals of 
pathogenesis, diagnosis, natural history, immunization, and chemotherapy of infectious 
diseases. It should be emphasised in the curriculum that the ultimate objective of this 
training is the welfare of the patient and that effective therapy can be accomplished best 




7.6 Parental education studies 
In our liquid medication dosing errors study, we evaluated the ability of parents to 
measure the liquid medication correctly pre-post educational intervention by 
demonstrating how to measure a dose along with a marked syringe by a pharmacist. A 
significant improvement in the measurement of liquid medication by parents was 
achieved irrespective of their educational status with a simple educational intervention 
program implemented by a qualified pharmacist in India. This finding is similar to a 
study by Taylor et al.[38] conducted a randomised controlled trial to determine whether 
“Your Child and Antibiotics”, accompanied by a short videotape message reinforcing the 
key points in the pamphlet, would be effective in improving parental attitudes about the 
judicious use of antibiotics. The effect of the intervention was similar in parents of 




Parents in the intervention group had significantly different attitude scores about 
antibiotic use in their children from those in the control group. Parents who received the 
antibiotic education materials were statistically less likely to agree that antibiotics are 
necessary when a child’s nasal discharge turns to green in colour, that it is worth trying 
an antibiotic in their children when upper respiratory infections (URI) symptoms persist 
for 5 days, that antibiotics are useful in treating colds, that giving antibiotics to a child 
with a URI can prevent a bacterial infection, and that antibiotics help URI symptoms 
clear up more quickly than parents who did not receive these materials[38].  
 
 
Trepka et al.[39] assessed the impact of a multifaceted community-wide effort to reduce 
the inappropriate use of antibiotics. The intervention consisted of distribution of the 
pamphlet “Your Child and Antibiotics” and presentations to groups of parents and 
providers. Parents of young children who resided in the intervention and a control 
community were surveyed before and after the educational effort. Parents who lived in 
the exposed community had a significantly greater increase in awareness about antibiotic 
resistance than those in the control community. In addition, the reduction in the number 
of viral respiratory illness diagnoses for which parents thought antibiotics were indicated 
was greater in the intervention community. 
 
 
In a study of similar design to Taylor et al., Bauchner et al conducted a randomised 
controlled trial of the effectiveness of an educational 20-minute videotape and 
accompanying brochure in modifying parental knowledge and attitudes about antibiotics. 
Parents who were randomised to the intervention group received the educational 
materials, whereas those in the control group did not get any materials. After responses 
on the initial questionnaires were compared with the pre-intervention group, there were 





In our study on liquid medication dosing errors following the implementation of 
pharmacist educational intervention to the prescriber on appropriate dosage prescribing 
and to parents on measuring a correct liquid medication dosage, shown a significant 
improvement from 76/175 (43%) to 160/162 (99%). Pharmacists also could be involved 
in developing education programs and drug therapy protocols. Limited published data are 
available regarding the role of the clinical pharmacist in reducing medication errors in 
children. Fortescue et al.[41] found that a clinical pharmacist’s monitoring ordering 
might have prevented 58% of all medication errors and 72% of potentially harmful errors 
related to dosing. Pharmacists monitoring transcribing might have prevented an 
additional 20% of all errors and 13% of potentially harmful errors. Pharmacist 
intervention involving parental and pediatrician education can be very effective in 
improving the administration of medication and prescribing of appropriate dosage to the 
pediatric patient.  
 
 
Since cost is not a factor in paracetamol prescribing, the pediatricians are willing to 
prescribe appropriate dosage according to the recommended guidelines provided and 
parents are administering correct liquid medication dosage according to the 




After the release of a report by Institute of Medicine entitled “ To Err Is Human[42]” by 
the committee on quality of health care in America in 1999, many studies have assessed 
medication errors in children and adults in USA. None of the studies evaluated the 
combined effect of prescribing and administration error to a pediatric patient. In this 
study, we evaluated the affect of pharmacist intervention on parents’ measurement and 
pediatrician prescribing appropriateness and also evaluated the combination error, which 
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led to inappropriate dose, was incorrectly measured to overall result in appropriate dose 
in pediatric settings. This study of its kind is first to be carried out in India or elsewhere.  
 
 
In our studies, we demonstrated that establishing a formal policy to govern antibiotic use 
and giving feedback of the prescribing to physicians might help to rationalise 
questionable prescribing and with improved patient care. The most immediately apparent 
impact of the guidelines was that fewer doses of antibiotics and unnecessary antibiotics 
and appropriate prophylactic antibiotics were given in appendectomy study, reduced 
inappropriate antibiotic dosage prescribing in drug utilisation study, increased adherence 
to guidelines on the choice of drugs and non-prescription of dexamethasone following the 
intervention in community-acquired pneumonia, improvement in the prescribing of anti-
pyretic doses and measurement of correct liquid medication doses in liquid medication 
dosing errors and identification of errors in prescribing doses and omission of 
prophylactic antibiotics in tonsillectomy study was reported. It might be argued that 
patients in our studies gained benefit in not receiving unnecessary drugs, and there was, 
in turn, a reduced workload for medical and nursing staff in terms of drug administration. 
The reduction in the inappropriate antibiotic and analgesic dosage was achieved in our 
studies was therefore a reduced likelihood of the emergence of bacterial antibiotic 
resistance and unnecessary patient sufferings.  
 
 
Drug utilisation studies need to perform regularly by pharmacists in order to improve 
physicians prescribing and implement policies and procedures in the hospitals in 
conjunction with other departments. While doing so increased patient care can be 
achieved and probably reduced financial burden on the government. More studies needs 
to be performed on children since they pose unique challenges to the system for ordering, 





The study has achieved through pharmacist educational interventions implemented in this 
thesis: 
• Improvement in the prescribing of appropriate dosages of ceftriaxone and 
flucloxacillin across the hospital 
• The choice and dosage of pre-and post-operative antibiotics and analgesics were 
significantly improved in appendectomy patients 
• Improvement in the prescribing and measurement of correct liquid medication 
dosages were achieved in out-patients in a rural hospital setting in India 
• Prescribing of dexamethasone along with every antibiotic was ceased in 
community acquired pneumonia in a rural hospital in India 
 
 
The following outcomes were identified in studies carried out in this thesis 
• Evaluation of drug usage and implementation of local guidelines along with 
feedback of the pre-intervention results has resulted in improved practices 
• Locally developed guidelines are more likely to be accepted and followed than 
those developed nationally without local input and promotion 
• Ability of parents from rural areas of a developing country to measure a correct 
liquid medication dosage can be improved by pharmacist intervention 
• Cost considerations were found to be a major contributing factor to the 
prescription of low dosage of ceftriaxone in India 
• None of the patients received prophylactic antibiotics and many patients did not 
receive post-operative or discharge antibiotics in tonsillectomy procedures 
• The dosages prescribed for post-operative and discharge antibiotics and 
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Appendix 8. 1 Publications and Presentations 
Publications 
Publication 1 
Liquid Medication Dosing Errors: a pre-post time series in India 
Mallik V Angalakuditi, V Bruce Sunderland 
School of Pharmacy, Curtin University of Technology, Bentley, WA, Australia 
International Journal of Pharmacy Practice. 2003, 11; 105-110 
 
Abstract 
Objective To evaluate the influence of pharmacist intervention on the level of parental 
dosing measurement errors and pediatrician dosage prescribing in a clinic in India. 
Design and setting The study was conducted at Srujan Hospital for Sick Children, India. 
The design involved 175 children prescribed paracetamol and assigned to a standard 
treatment (Group 1). Following an educational intervention including feedback on 
dosages prescribed for Group 1 and promotion of a dosing chart for prescribers and 
individual dosing education for parents, 162 patients were admitted to the intervention 
group (Group 2). Patients in Group 1 received paracetamol suspension and verbal 
instructions from hospital staff (standard care). Parents in Group 2 were provided with a 
syringe with a line marking the prescribed dose and its use demonstrated to them by the 
pharmacist. Data on the dosages prescribed and measurement accuracy by parents were 
obtained for both groups. 
Main outcome measures (i) improvement in the measurement of correct dosages by 
parents (ii) improvement in the prescribing of appropriate dosages by prescribers 
Results In Group 1 85 of 175 (48.9%) correctly measured (±0.5ml) doses and 
pediatricians prescribed 67 of 175 (38.2%) appropriate dosages. In Group 2, 160 of 162 
(98.7%) parents measured the correct dose and physicians prescribed 160 of 162 (98.7%) 
appropriate dosages showing statistically significant improvements in both indicators 
(p<0.001). When the impact of prescribing and dosing correctness was combined on an 
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individual patient basis, 76 of 175 (43.4%) were appropriate in Group 1, whereas 160 of 
162 (98.7%) were appropriate in Group 2. There was a statistically significant 
improvement (p<0.001) in appropriate dosing outcome between the two groups. 
Conclusion Pharmacist intervention through patient education including the use of a 
syringe significantly improved parents dosing accuracy and physicians prescribing errors 






























Treatment of Community-Acquired Pneumonia at a Rural Indian Pediatric 
Hospital 
Mallik AV, Sunderland VB 
School of Pharmacy, Curtin University of Technology, Bentley, Western Australia 
 
This study is presented at the following conferences: 
American Society of Health System of Pharmacists, Baltimore, USA, 2002 
The Mark Liveris Health Sciences Research Student Seminar, Perth, Australia, 2002 
Australasian Pharmaceutical Science Association, Melbourne, Australia 2001 
Pharmaceutical International Federation, Singapore, 2001 
 
 
Objective. This study was to evaluated drug therapy provided to pediatric patients 
diagnosed with community-acquired pneumonia (CAP) at a pediatric hospital, India in 
order to compare prescribed drug therapy in relation to Australian National Therapeutic 
Guidelines (ANTG) and evaluate the impact of an intervention on prescribing trends in 
drug management.  
Method. Prescribing data of pediatric patients with CAP treatment were collected 
prospectively for four weeks from outpatients in Group 1. Patient details included age, 
weight, sex, and medication details including drug name, dose, frequency, and number of 
doses administered were documented on a standardised form. These data were analysed 
according to the ANTG. An intervention strategy involved, presentation of results and 
provision of drug information to the prescriber. A post-intervention study in Group 2 was 
conducted after an intervention to evaluate the impact.  
Result. The study evaluated 171 patients, of which 146 were diagnosed as severe CAP 
and 25 as mild CAP in Group 1. For severe CAP, a combination of ceftriaxone, 
dexamethasone and paracetamol was prescribed for most patients and for mild CAP, 
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ciprofloxacin and paracetamol. Of these 98% (1005/1021) of ceftriaxone, 16% (36/215) 
of ciprofloxacin, 54% (861/1597) of paracetamol doses were classified as inappropriate 
according to ANTG. The major factors influencing these data were low and high dosages 
and inappropriate drug choice. In Group 2, 155 patients were diagnosed as severe CAP. 
Of these, 152 were on ceftriaxone and paracetamol and 3 other. Inappropriate prescribing 
of paracetamol and ceftriaxone doses has been reduced to 9% (186/1992) and 89% 
(1208/1354) and none of the patients received dexamethasone in Group 2. The 
intervention had a statistically significant (p value=0.000) in the reduction of 
inappropriate prescribing of paracetamol and dexamethasone in this setting.  
Conclusion. This study reveals that (i) there was an improvement in the prescribing of 
drugs for CAP (ii) there were social, culture and economic factors playing a role in the 
decision of prescribing of drugs (iii) pediatricians were prescribing less antimicrobial 





















Liquid Medication Dosing Errors: A pre-post time series in India 
Mallik AV, Sunderland VB 
School of Pharmacy, Curtin University of Technology, Bentley, Western Australia 
 
This study is presented at American Society of Health System of Pharmacists, Baltimore, 




Objective. To determine whether parental errors in dosing liquid medication and 
prescribing behaviour of a pediatrician can be improved through the pharmacist 
intervention by education.  
Design and setting. A controlled trial was conducted at Srujan Hospital for Sick 
Children, India. Children of 220 uneducated and 117 educated parents treated with an 
analgesic suspension were assigned to standard treatment or an intervention. Group 1 
patients received the prescription, analgesic suspension and verbal instructions from the 
hospital staff and Group 2 patients received the prescription, analgesic suspension, a 
syringe and a line was marked at the correct dose and was demonstrated how to measure 
the dose by a qualified pharmacist. The pediatrician received a dosing chart for patient 
Group 2.  
Main outcome measure. (i) percent of patients who administer the correct dose (ii) 
improvement in the prescribing of appropriate dose by the pediatrician.  
Result. Group 1 parents administer (±0.5 ml) 85 of 175 (48%) and physician prescribed 
(±25% recommended dose) 60 of 175 (30%)) of the appropriate dose. In Group 2, 160 of 
162 (98%) parents administered the correct dose and physician prescribed appropriate 
dose (p value 0.000). When physician’s prescribing and parents dosing administration 
combined, 31 of 175 were appropriate in Group 1, whereas 158 of 162 were appropriate 
in Group 2. There is a statistically significant difference (p value 0.000) between the two 
groups.  
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Conclusion. Pharmacist intervention through patient education significantly improved 
parents dosing and physicians prescribing errors even in a country where currently 



























Impact on surgeons prescribing following the implementation of treatment 
guidelines in pediatric appendectomy procedures 
Mallik AV1, Sunderland VB1, Roberts MJ2, Turner SC2, Wojnar-Horton R3, Lilley BJ4  
1School of Pharmacy, Curtin University of Technology, Bentley, WA; 2Department of 
Pharmacy, King Edward Memorial and Princess Margaret Hospital, Subiaco, WA; 
3Department of Pharmacy, Fremantle Hospital, Fremantle, WA; 4Department of 
Pharmacy, Royal Women’s and Royal Children Hospital, Melbourne, VIC 
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Pharmaceutical International Federation, Sydney, Australia 2003 
Society of Hospital Pharmacists of Australia, Perth, 2002 
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Objective To evaluate the appropriateness of antibiotic therapy for appendectomy 
surgery in patients at a West Australian pediatric teaching hospital pre and post an 
educational intervention programme. 
Method Demographic, clinical and prescribing data of patients who had undergone 
appendectomies were reviewed retrospectively from April 2000 to August 2001 (Group 
1). In the absence of in-house prescribing guidelines, prescribing data for antibiotic 
prophylaxis and treatment was analysed against the antibiotics for abdominal surgery as 
outlined in the Antibiotic Therapeutic Guidelines Version 11 2000. A multi-faceted 
intervention strategy was designed and undertaken and a post-intervention study was 
conducted from December 2001 to April 2002 (Group 2) to evaluate the impact. Group 
comparisons involved χ2 and Student’s t-test statistics. 
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Results The study evaluated 102 patients in Group 1 and 105 in Group 2. There was no 
significance difference between the patient populations of the two groups (p > 0.05). In 
Group 1 82% of patients were documented as receiving prophylactic antibiotics however 
none of these complied with the recommended standard regimen. Following the 
intervention programme 66% of patients received prophylactic antibiotics in accordance 
with the recommended regimen (p<0.001). The appropriateness of the prescribed dosage 
of prophylactic antibiotics improved from 50% of patients in Group 1 to 94% of patients 
in Group 2. In patients prescribed post-operative antibiotics, 48% of Group 1 patients 
received antibiotics in accordance with the recommended regimen. Following the 
intervention this increased to 85% of patients. The appropriateness of the prescribed 
dosage of post-operative antibiotics increased from 32% of patients in Group 1 to 87% of 
patients in Group 2. 
Conclusion Significant improvements can be achieved in both the selection and use of 




















Antibiotic and analgesic usage review in pediatric appendectomy and 
adenotonsillectomy procedures 
Mallik.A.V1, Sunderland VB1, Roberts MJ2, Tenni PC1 
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Objective To review antibiotics and analgesic prescribed for appendectomy (APP) and 
adenotonsillectomy (ADT) procedures in pediatric patients at Princess Margaret Hospital 
for Children, a 250-bed pediatric teaching hospital. 
Method A retrospective review of the medical records for consecutive patients who had 
undergone APP and ADT between April 1999 to Feb 2000 for APP and June to Nov 
1999 for ADT was performed. A range of demographic, clinical and medication details 
were recorded in a standardised form and analysed for prescribing with respect to 
hospital and national policies and guidelines. 
Results An 174 patients for APP and 229 patients for ADT were included in this study. 
For the APP procedure, metronidazole was prescribed alone for 16%, ceftriaxone alone 
4.4%, a combination of metronidazole and ceftriaxone was prescribed for 52%, and 
metronidazole in combination with other drugs was prescribed 26% of patients. Of these 
85% of metronidazole, 71% of ceftriaxone and 44% of paracetamol doses administered 
were classified as inappropriate. For ADT, amoxycillin was prescribed 141 times as in-
patient medication and 149 times as discharge medication. Of these, 19% of in-patient 
medication and 20% of discharge medications were inappropriate. The dosages 
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prescribed were frequently well below those stated in the guidelines. For analgesia, 
paracetamol was prescribed 135 times and Liquigesic®(paracetamol/codeine) 191 times 
for the ADT procedure. Approximately half of the doses prescribed were outside of the 
guidelines for Liquigesic® and 27% for paracetamol. 
Conclusion This study has identified problems related to the prescribing of antibiotic and 
analgesic for APP and ADT procedures in this hospital. The next step in the strategy is to 
reduce the level of inappropriate prescribing of antibiotic and analgesic by educating 


























Intervention studies regarding antibiotic and analgesic prescribing in a pediatric 
teaching hospital 
Mallik AV1, Sunderland VB1, Roberts MJ2 
1School of Pharmacy, Curtin University of Technology, Bentley, WA 6102 
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Objective To evaluate the level and impact of an intervention on the levels of 
inappropriate prescribing of flucloxacillin, ceftriaxone and Liquigesic Co® (paracetamol 
120 mg, codeine 5 mg/ml) in a pediatric teaching hospital 
Method Prescribing data for the above treatments were collected by retrospective review 
of 348 patient records from standard wards over five weeks. Data collected included 
dosage, frequency, duration, and sensitivity data (where available). These data were 
analysed according to hospital and national policies and guidelines. An intervention 
strategy involved a lecture and provision of drug information. A prospective study was 
carried out over five weeks evaluating all prescribing of the above treatments.  
Results The study evaluated 348 patient records of which 45% of Liquigesic Co®, 43% 
of flucloxacillin and 51% of ceftriaxone doses were administered inappropriately. The 
major factor influencing these data were the prescribing of low doses (44% Liquigesic 
Co®, 42% flucloxacillin and 46% ceftriaxone). The intervention had a major impact with 
statistically significant reductions in inappropriate prescribing of flucloxacillin (25%) and 
ceftriaxone (25%) but an increase in Liquigesic Co® to 58%. This resulted from a shift in 
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the percentage of inappropriately high doses increasing from 0.4% to 54% following the 
intervention. 
Conclusion The intervention had statistically significant effects on the prescribing of 
antibiotics and Liquigesic Co® although in the wrong direction for the latter. The levels 
of inappropriate prescribing identified warrant continued vigilance in the maintenance of 
the quality of use of medicines. 
 
 
 
 
